Document:

Exhibit
4.24

 

CERTAIN PORTIONS OF THIS
EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
UNDER RULE 24b–2 OF THE SECURITIES AND EXCHANGE COMMISSION.  SUCH PORTIONS HAVE BEEN REDACTED AND
BRACKETED IN THE REQUEST AND APPEAR AS [ 
*  ] IN THE TEXT OF THIS
EXHIBIT.  THE OMITTED CONFIDENTIAL
INFORMATION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION.

 

ASSET
PURCHASE AGREEMENT

 

 

BY
AND BETWEEN

 

VALEANT
PHARMACEUTICALS INTERNATIONAL,

 

AS BUYER

 

 

AND

 

 

AMARIN
CORPORATION PLC

 

AND

 

AMARIN
PHARMACEUTICALS COMPANY LIMITED,

 

AS SELLERS

 

 

DATED
FEBRUARY      , 2004

 

 

TABLE
OF CONTENTS

 

	
  ARTICLE 1

  	
   

  
	
   

  	
  DEFINITIONS
  AND USAGE

  	
   

  
	
  1.1

  	
  Definitions

  	
   

  
	
  1.2

  	
  Usage

  	
   

  
	
   

  	
   

  	
   

  
	
  ARTICLE 2

  	
   

  
	
   

  	
  SALE
  AND TRANSFER OF THE ACQUIRED ASSETS; CLOSING

  	
   

  
	
  2.1

  	
  Assets
  to be Sold

  	
   

  
	
  2.2

  	
  Purchase
  Price

  	
   

  
	
  2.3

  	
  Assumed
  Liabilities

  	
   

  
	
  2.4

  	
  Allocation

  	
   

  
	
  2.5

  	
  Closing

  	
   

  
	
  2.6

  	
  Closing
  Obligations

  	
   

  
	
  2.7

  	
  API Adjustment
  Amount and Payment

  	
   

  
	
   

  	
   

  	
   

  
	
  ARTICLE 3

  	
   

  
	
   

  	
  REPRESENTATIONS
  AND WARRANTIES OF SELLERS AS TO SELLERS

  	
   

  
	
  3.1

  	
  Organization and
  Good Standing

  	
   

  
	
  3.2

  	
  Enforceability;
  Authority; No Conflict

  	
   

  
	
  3.3

  	
  Title to
  Acquired Assets; Encumbrances

  	
   

  
	
  3.4

  	
  Financial
  Statements

  	
   

  
	
  3.5

  	
  Material Amarin Contracts

  	
   

  
	
  3.6

  	
  Absence of
  Certain Changes and Events

  	
   

  
	
  3.7

  	
  Intellectual Property

  	
   

  
	
  3.8

  	
  Legal Proceedings; Orders

  	
   

  
	
  3.9

  	
  Product Registrations.

  	
   

  
	
  3.10

  	
  Solvency

  	
   

  
	
  3.11

  	
  Disclosure

  	
   

  
	
  3.12

  	
  Brokers
  or Finders

  	
   

  
	
   

  	
   

  	
   

  
	
  ARTICLE 4

  	
   

  
	
   

  	
  REPRESENTATIONS
  AND WARRANTIES OF SELLERS AS TO API

  	
   

  
	
  4.1

  	
  Organization and
  Good Standing

  	
   

  
	
  4.2

  	
  Enforceability;
  Authority; No Conflict

  	
   

  
	
  4.3

  	
  Capitalization

  	
   

  
	
  4.4

  	
  Financial
  Statements

  	
   

  
	
  4.5

  	
  Books
  and Records

  	
   

  
	
  4.6

  	
  Title to Assets;
  Encumbrances

  	
   

  
	
  4.7

  	
  Condition and
  Sufficiency of Assets

  	
   

  
	
  4.8

  	
  Accounts
  Receivable

  	
   

  
	
  4.9

  	
  Inventory

  	
   

  
	
  4.10

  	
  No Undisclosed
  Liabilities

  	
   

  
	
  4.11

  	
  Taxes

  	
   

  

 

i

 

	
  4.12

  	
  No Material Adverse
  Change

  	
   

  
	
  4.13

  	
  Employee
  Benefits

  	
   

  
	
  4.14

  	
  Compliance
  with Legal Requirements; Governmental Authorizations

  	
   

  
	
  4.15

  	
  Legal Proceedings;
  Orders

  	
   

  
	
  4.16

  	
  Absence of
  Certain Changes and Events

  	
   

  
	
  4.17

  	
  Material API
  Contracts; No Defaults

  	
   

  
	
  4.18

  	
  Insurance

  	
   

  
	
  4.19

  	
  Environmental Matters

  	
   

  
	
  4.20

  	
  Employees

  	
   

  
	
  4.21

  	
  Labor Relations;
  Compliance

  	
   

  
	
  4.22

  	
  Intellectual Property
  Assets

  	
   

  
	
  4.23

  	
  Certain
  Payments

  	
   

  
	
  4.24

  	
  Relationships with
  Affiliates

  	
   

  
	
  4.25

  	
  Solvency

  	
   

  
	
   

  	
   

  	
   

  
	
  ARTICLE 5

  	
   

  
	
   

  	
  REPRESENTATIONS
  AND WARRANTIES OF BUYER

  	
   

  
	
  5.1

  	
  Organization and
  Good Standing

  	
   

  
	
  5.2

  	
  Authority; No Conflict

  	
   

  
	
  5.3

  	
  Certain
  Proceedings

  	
   

  
	
  5.4

  	
  Brokers
  or Finders

  	
   

  
	
  5.5

  	
  Investment Representation

  	
   

  
	
   

  	
   

  	
   

  
	
  ARTICLE 6

  	
   

  
	
   

  	
  COVENANTS OF
  AMARIN PRIOR TO CLOSING

  	
   

  
	
  6.1

  	
  Access and Investigation

  	
   

  
	
  6.2

  	
  Conduct of Amarin’s
  Business

  	
   

  
	
  6.3

  	
  Operation of API’s
  Business

  	
   

  
	
  6.4

  	
  Negative
  Covenant

  	
   

  
	
  6.5

  	
  Required
  Approvals

  	
   

  
	
  6.6

  	
  Notification

  	
   

  
	
  6.7

  	
  No
  Negotiation

  	
   

  
	
  6.8

  	
  Best Efforts

  	
   

  
	
  6.9

  	
  Interim Financial
  Statements

  	
   

  
	
  6.10

  	
  Payment of API
  Liabilities

  	
   

  
	
   

  	
   

  	
   

  
	
  ARTICLE 7

  	
   

  
	
   

  	
  COVENANTS OF BUYER
  PRIOR TO CLOSING

  	
   

  
	
  7.1

  	
  Required
  Approvals

  	
   

  
	
  7.2

  	
  Best Efforts

  	
   

  
	
   

  	
   

  	
   

  
	
  ARTICLE 8

  	
   

  
	
   

  	
  CONDITIONS
  PRECEDENT TO BUYER’S OBLIGATION TO CLOSE

  	
   

  
	
  8.1

  	
  Accuracy of
  Representations

  	
   

  
	
  8.2

  	
  Amarin’s
  Performance

  	
   

  
	
  8.3

  	
  Material Consents
  and Approvals

  	
   

  
	
  8.4

  	
  Exercise of Elan Option

  	
   

  

 

ii

 

	
  8.5

  	
  Elan Assignment Agreement

  	
   

  
	
  8.6

  	
  Additional
  Documents

  	
   

  
	
  8.7

  	
  No
  Proceedings

  	
   

  
	
   

  	
   

  	
   

  
	
  ARTICLE 9

  	
   

  
	
   

  	
  CONDITIONS
  PRECEDENT TO SELLERS’ OBLIGATIONS TO CLOSE

  	
   

  
	
  9.1

  	
  Accuracy of
  Representations

  	
   

  
	
  9.2

  	
  Buyer’s
  Performance

  	
   

  
	
  9.3

  	
  Material Consents
  and Approvals

  	
   

  
	
  9.4

  	
  Additional
  Documents

  	
   

  
	
  9.5

  	
  No Proceeding

  	
   

  
	
   

  	
   

  	
   

  
	
  ARTICLE 10

  	
   

  
	
   

  	
  TERMINATION

  	
   

  
	
  10.1

  	
  Termination
  Events

  	
   

  
	
  10.2

  	
  Effect of Termination

  	
   

  
	
   

  	
   

  	
   

  
	
  ARTICLE 11

  	
   

  
	
   

  	
  ADDITIONAL
  COVENANTS

  	
   

  
	
  11.1

  	
  Payment
  of Taxes Resulting From Sale of Acquired Assets

  	
   

  
	
  11.2

  	
  Regulatory
  Matters

  	
   

  
	
  11.3

  	
  REDUCTION OF PERMAX
  INVENTORY

  	
   

  
	
  11.4

  	
  Reports
  and Returns

  	
   

  
	
  11.5

  	
  Assistance in
  Proceedings

  	
   

  
	
  11.6

  	
  Noncompetition,
  Nonsolicitation and Nondisparagement

  	
   

  
	
  11.7

  	
  Customer
  and Other Business Relationships

  	
   

  
	
  11.8

  	
  Retention of
  and Access to Records

  	
   

  
	
  11.9

  	
  Further
  Assurances

  	
   

  
	
  11.10

  	
  Change
  of API Name

  	
   

  
	
   

  	
   

  	
   

  
	
  ARTICLE 12

  	
   

  
	
   

  	
  INDEMNIFICATION; REMEDIES

  	
   

  
	
  12.1

  	
  Survival

  	
   

  
	
  12.2

  	
  Indemnification
  and Reimbursement by Sellers

  	
   

  
	
  12.3

  	
  Indemnification
  and Reimbursement by Buyer

  	
   

  
	
  12.4

  	
  Limitations on
  Amount—Sellers

  	
   

  
	
  12.5

  	
  Limitations on
  Amount—Buyer

  	
   

  
	
  12.6

  	
  Time
  Limitations

  	
   

  
	
  12.7

  	
  Right of
  Setoff

  	
   

  
	
  12.8

  	
  Third-Party
  Claims

  	
   

  
	
  12.9

  	
  Other Claims

  	
   

  
	
  12.10

  	
  Indemnification
  in Case of Strict Liability or Indemnitee Negligence

  	
   

  
	
   

  	
   

  	
   

  
	
  ARTICLE 13

  	
   

  
	
   

  	
  CONFIDENTIALITY

  	
   

  
	
  13.1

  	
  Definition
  of Confidential Information

  	
   

  
	
  13.2

  	
  Restricted
  Use of Confidential Information

  	
   

  

 

iii

 

	
  13.3

  	
  Exceptions

  	
   

  
	
  13.4

  	
  Legal
  Proceedings

  	
   

  
	
  13.5

  	
  Return
  or Destruction of Confidential Information

  	
   

  
	
  13.6

  	
  Attorney-Client
  Privilege

  	
   

  
	
   

  	
   

  	
   

  
	
  ARTICLE 14

  	
   

  
	
   

  	
  GENERAL
  PROVISIONS

  	
   

  
	
  14.1

  	
  Expenses

  	
   

  
	
  14.2

  	
  Public Announcements

  	
   

  
	
  14.3

  	
  Notices

  	
   

  
	
  14.4

  	
  Jurisdiction;
  Service of Process

  	
   

  
	
  14.5

  	
  Waiver
  of jury trial

  	
   

  
	
  14.6

  	
  Enforcement of Agreement

  	
   

  
	
  14.7

  	
  Waiver; Remedies
  Cumulative

  	
   

  
	
  14.8

  	
  Entire Agreement
  and Modification

  	
   

  
	
  14.9

  	
  Disclosure Schedules

  	
   

  
	
  14.10

  	
  Assignments,
  Successors and No Third-Party Rights

  	
   

  
	
  14.11

  	
  Severability

  	
   

  
	
  14.12

  	
  Construction

  	
   

  
	
  14.13

  	
  Time
  of Essence

  	
   

  
	
  14.14

  	
  Governing
  Law

  	
   

  
	
  14.15

  	
  Execution of Agreement

  	
   

  

 

iv

 

ASSET
PURCHASE AGREEMENT

 

This Asset Purchase
Agreement (as amended from time to time, this “Agreement”) is made and entered into
this        day
of February, 2004, by and between Valeant Pharmaceuticals International, a
Delaware corporation (“Buyer”), and Amarin Corporation plc, a public limited
company incorporated in England and Wales (“Amarin”) and Amarin Pharmaceuticals Company
Limited, a limited company incorporated in England and Wales (“APCL”) (Amarin and
APCL being hereinafter from time to time referred to collectively as the “Sellers”).

 

WITNESSETH:

 

WHEREAS, Amarin is a London-based specialty
pharmaceutical company that is focused on the development and marketing of
pharmaceuticals used in the treatment of neurological diseases and disorders;

 

WHEREAS, Amarin operates in the United
States primarily through its second-tier subsidiary, Amarin Pharmaceuticals,
Inc., a Delaware corporation (“API”);

 

WHEREAS, APCL is a wholly owned subsidiary
of Amarin and is the registered holder of 100% of the issued and outstanding
capital stock of API;

 

WHEREAS, Buyer is a California-based global
pharmaceutical company that develops, manufactures and distributes a broad
range of prescription and non-prescription pharmaceuticals;

 

WHEREAS, Buyer desires to purchase (i) from
Amarin, the Amarin Products and Rights (as hereinafter defined) and (ii) from
APCL, 100% of the issued and outstanding capital stock of API, for the
consideration and on the terms set forth in this Agreement; and

 

WHEREAS, Amarin and APCL desire to sell to
Buyer the Amarin Product Rights and 100% of the issued and outstanding capital
stock of API, respectively,  for the consideration and on the terms set
forth in this Agreement;

 

NOW, THEREFORE, in consideration of the
premises, the mutual covenants herein contained, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto agree as follows:

 

ARTICLE 1

DEFINITIONS AND USAGE

 

1.1                               DEFINITIONS

 

For purposes of this
Agreement, the following terms and variations thereof have the meanings
specified or referred to in this Section 1.1:

 

“ANDA” — an abbreviated new drug application
as filed with the FDA under the Act.

 

“APCL”— as defined in the first paragraph of
this Agreement.

 

 

“API” — as defined in the third paragraph of
this Agreement.

 

“API Adjustment Amount” — as defined in
Section 2.7.

 

“API Facility” — collectively, API’s Mill
Valley Facility, API’s New Jersey Facility, and any other facility owned or
occupied by API.

 

“API Shares” — the shares representing 100% of
the issued and outstanding capital stock of API.

 

“API’s Intellectual Property Assets” — as
defined in Section 4.22(a).

 

“API’s Interim Balance Sheet” — as defined in
Section 4.4.

 

“API’s Inventory” — all finished goods
inventory of Permax® and the PCP Products owned or controlled by API.

 

“API’s Mill Valley Facility” — API’s principal
office located at Two Belvedere Place, Suite 330, Mill Valley, California
94941.

 

“API’s New Jersey Facility” — API’s office
located at 25 Independence Blvd., Suite 100, Warren, New Jersey 07059.

 

“Accounts Receivable” — (a) all trade accounts
receivable and other rights to payment from customers and the full benefit of
all security for such accounts or rights to payment, including all trade
accounts receivable representing amounts receivable in respect of goods shipped
or products sold or services rendered to customers, (b) all other accounts or
notes receivable and the full benefit of all security for such accounts or
notes and (c) any claim, remedy or other right related to any of the foregoing.

 

“Acquired Assets” — collectively, the PCP
Product Assets, Amarin Product Rights and API Shares.

 

“Act” — U.S. Federal Food, Drug and Cosmetic
Act, as amended.

 

“Affiliate” — means, with respect to any
Person, another Person that, directly or indirectly through one or more
intermediaries, controls, is controlled by or is under common control with such
Person.  “Control” and, with correlative
meanings, the terms “controlled by” and “under common control with” means the
power to direct or cause the direction of the management or policies of a
Person, whether through the ownership of voting securities, by contract or
otherwise; provided that for purposes of this Agreement, neither Elan
Corporation plc nor any of its Affiliates shall be deemed to be an Affiliate of
Amarin, APCL or API.

 

“Amarin” — as defined in the first paragraph
of this Agreement.

 

“Amarin Products” — collectively, the PCP
Products, Permax and Zelapar.

 

2

 

“Amarin  Product Rights” — collectively, the PCP Product Rights,
Permax® Rights, and Zelapar Rights.

 

“Assumed Liabilities” — as defined in
Section 2.3.

 

“Best Efforts” — the reasonable efforts that a
prudent Person desirous of achieving a result would use in similar
circumstances to achieve that result as promptly as practicable; provided,
however, that a Person required to use Best Efforts under this
Agreement will not be thereby required to take actions that would result in a
material adverse change in the benefits to such Person of this Agreement and
the Contemplated Transactions or to dispose of or make any change to its
business, expend any material funds or incur any other material burden.

 

“Breach” — any breach of, or any inaccuracy
in, any representation or warranty or any breach of, or failure to perform or
comply with, any covenant or obligation, in or of this Agreement or any other
Contract.

 

“Business Day” — any day other than (a)
Saturday or Sunday or (b) any other day on which banks in London or Costa Mesa,
California, are permitted or required to be closed.

 

“Buyer” — as defined in the first paragraph of
this Agreement.

 

“Buyer Indemnified Persons” — as defined in
Section 12.2.

 

“Closing” — as defined in Section 2.5.

 

“Closing Date” — the date on which the Closing
actually takes place.

 

“COBRA” — as defined in Section 4.13(e).

 

“Code” — the Internal Revenue Code of 1986, as
amended.

 

“Confidential Information” — as defined in
Section 13.1(a).

 

“Consent” — any approval, consent,
ratification, waiver or other authorization.

 

“Contemplated Transactions” — all of the
transactions contemplated by this Agreement.

 

“Contract” — any agreement, contract, Lease,
consensual obligation, promise or undertaking (whether written or oral and
whether express or implied), whether or not legally binding, together with all
amendments, modifications and supplements thereto.

 

“Damages” — as defined in Section 12.2.

 

“Disclosure Schedules” — the disclosure
schedules delivered by Amarin to Buyer concurrently with the execution and
delivery of this Agreement, as may be amended in accordance with
Section 6.6.

 

“ERISA” — the Employee Retirement Income
Security Act of 1974, as amended.

 

3

 

“Elan/Amarin Option Agreement” — that certain
Amended and Restated Option Agreement, dated August 4, 2003, as amended,
by and between Elan and Amarin.

 

“Elan” — Elan  Pharma International Limited, a company
incorporated in the Republic of Ireland, and a party to the Scherer/Elan
License Agreement and the Elan/Amarin Option Agreement.

 

“Elan Assignment Agreement” – as defined in
Section 8.5.

 

“Eli Lilly” — Eli Lilly and Company, an
Indiana corporation and party to the Eli Lilly/Amarin License Agreement.

 

“Eli Lilly/Amarin License Agreement” — that
certain Amended and Restated License and Supply Agreement, dated March 29,
2002, as amended, by and between Eli Lilly and Amarin.

 

“Employee Plan” — as defined in
Section 4.13(a).

 

“Encumbrance” — any charge, claim, community
or other marital property interest, condition, equitable interest, lien,
option, pledge, security interest, mortgage, right of way, easement,
encroachment, servitude, right of first option, right of first refusal or
similar restriction, including any restriction on use, voting (in the case of
any security or equity interest), transfer, receipt of income or exercise of
any other attribute of ownership, except for such imperfections of title and
other encumbrances which are not substantial in character, amount or extent and
do not materially detract from the value of the properties subject thereto.

 

“Environment” — soil, land surface or
subsurface strata, surface waters (including navigable waters and ocean
waters), groundwaters, drinking water supply, stream sediments, ambient air
(including indoor air), plant and animal life and any other environmental
medium or natural resource.

 

“Environmental Liabilities” — any cost,
damages, expense or liability arising from or under any Environmental Law,
including those consisting of or relating to:

 

(a)                                  any
environmental matter or condition (including on-site or off-site contamination,
and regulation of any chemical substance or product);

 

(b)                                 any
fine, penalty, judgment, award, settlement, legal or administrative proceeding,
damages, loss, claim, demand or response, remedial or inspection cost or expense
arising under any Environmental Law;

 

(c)                                  financial
responsibility under any Environmental Law for cleanup costs or corrective
action, including any cleanup, removal, containment or other remediation or
response actions (“Cleanup”)
required by any Environmental Law (whether or not such Cleanup has been
required or requested by any Governmental Body or any other Person) and for any
natural resource damages; or

 

4

 

(d)                                 any
other compliance, corrective or remedial measure required under any
Environmental Law.

 

The terms “removal,”
“remedial” and “response action” include the types of activities covered by the
United States Comprehensive Environmental Response, Compensation and Liability
Act of 1980 (“CERCLA”).

 

“Environmental Law” — any Legal Requirement
that requires or relates to:

 

(a)                                  advising
appropriate authorities, employees or the public of intended or actual Releases
of pollutants or hazardous substances or materials, violations of discharge
limits or other prohibitions and the commencement of activities, such as
resource extraction or construction, that could have significant impact on the
Environment;

 

(b)                                 preventing
or reducing to acceptable levels the Release of pollutants or hazardous
substances or materials into the Environment;

 

(c)                                  reducing
the quantities, preventing the Release or minimizing the hazardous
characteristics of wastes that are generated;

 

(d)                                 assuring
that products are designed, formulated, packaged and used so that they do not present
unreasonable risks to human health or the Environment when used or disposed of;

 

(e)                                  protecting
resources, species or ecological amenities;

 

(f)                                    reducing
to acceptable levels the risks inherent in the transportation of hazardous
substances, pollutants, oil or other potentially harmful substances;

 

(g)                                 cleaning
up pollutants that have been Released, preventing the Threat of Release or
paying the costs of such clean up or prevention; or

 

(h)                                 making
responsible parties pay private parties, or groups of them, for damages done to
their health or the Environment or permitting self-appointed representatives of
the public interest to recover for injuries done to public assets.

 

“Exchange Act” — the Securities Exchange Act
of 1934, as amended.

 

“FDA” 
— the U. S. Food and Drug Administration or any successor entity
thereto.

 

“Governing Documents” — with respect to any
particular entity, (a) if a corporation, the articles or certificate of
incorporation and the bylaws; (b) if a general partnership, the partnership
agreement and any statement of partnership; (c) if a limited partnership, the
limited partnership agreement and the certificate of limited partnership; (d)
if a limited liability company, the articles of organization and operating
agreement; (e) if another type of Person, any other charter or similar document
adopted or filed in connection with the creation, formation or organization of
the Person; and (f) any amendment or supplement to any of the foregoing.

 

5

 

“Governmental Authorization” — any Consent,
license, registration (including a Product Registration), or permit issued,
granted, given or otherwise made available by or under the authority of any
Governmental Body or pursuant to any Legal Requirement.

 

“Governmental Body” — any:

 

(a)                                  nation,
state, county, city, town, borough, village, district or other jurisdiction;

 

(b)                                 federal,
state, local, municipal, foreign or other government;

 

(c)                                  governmental
or quasi-governmental authority of any nature (including any agency, branch,
department, board, commission, court, tribunal or other entity exercising
governmental or quasi-governmental powers), including specifically the FDA;

 

(d)                                 body
exercising, or entitled or purporting to exercise, any administrative,
executive, judicial, legislative, police, regulatory or taxing authority or
power; or

 

(e)                                  official
of any of the foregoing.

 

“Hazardous Activity” — the distribution,
generation, handling, importing, management, manufacturing, processing,
production, refinement, Release, storage, transfer, transportation, treatment
or use (including any withdrawal or other use of groundwater) of Hazardous
Material in, on, under, about or from any of the API Facilities or any part
thereof into the Environment.

 

“Hazardous Material” — any substance, material
or waste which is regulated by any Governmental Body, including any material,
substance or waste which is defined as a “hazardous waste,” “hazardous
material,” “hazardous substance,” “extremely hazardous waste,” “restricted
hazardous waste,” “contaminant,” “toxic waste” or “toxic substance” under any
provision of Environmental Law, and including petroleum, petroleum products,
asbestos, presumed asbestos-containing material or asbestos-containing
material, urea formaldehyde and polychlorinated biphenyls.

 

“HSR Act” — the Hart-Scott-Rodino Antitrust
Improvements Act, as amended.

 

“IND” — an investigational new drug
application as filed with the FDA under the Act.

 

“IRS” — the United States Internal Revenue
Service and, to the extent relevant, the United States Department of the
Treasury.

 

“Indemnified Person” — as defined in
Section 12.8.

 

“Indemnifying Person” — as defined in
Section 12.8.

 

“Knowledge” — an individual will be deemed to
have Knowledge of a particular fact or other matter if                                    that
individual is actually aware of that fact or matter. A Person (other than an
individual) will be deemed to have Knowledge of a particular fact or other
matter if any individual who is serving as a director, executive officer,
partner, or trustee of that Person (or in any similar capacity), or who has had
active and significant involvement in the Contemplated

 

6

 

Transactions on behalf of
such Person, has Knowledge of that fact or other matter.  For the avoidance of doubt, the executive
officers of Amarin, APCL and API, and the persons having active and significant
involvement in the Contemplated Transactions on behalf of such entities, are
Richard A B Stewart, Michael Coffee, Ian Garland, Donald Joseph, Jonathan Lamb
and Darren Cunningham. For purposes of the representations and warranties
contained in Article 4 hereof, Amarin shall be deemed to have Knowledge of
all matters as to which APCL or API have Knowledge.

 

“Lease” — any real property lease or any other
lease or rental agreement, license, right to use or installment or conditional
sale agreement, or any other Contract pertaining to the leasing or use of any
real or tangible personal property.

 

“Legal Requirement” — any federal, state,
local, municipal, foreign, international, multinational or other constitution,
law, ordinance, principle of common law, code, regulation, statute or treaty.

 

“Liability” — with respect to any Person, any
liability or obligation of such Person of any kind, character or description,
whether known or unknown, absolute or contingent, accrued or unaccrued,
disputed or undisputed, liquidated or unliquidated, secured or unsecured, joint
or several, due or to become due, vested or unvested, executory, determined,
determinable or otherwise.

 

“Master Assignment and Assumption Agreement” —
as defined in Section 2.6(a)(i).

 

“Material API Contract” — any Contract (a)(i)
under which API has or may acquire any rights or benefits, (ii) under which API
has or may become subject to any obligation or liability, or (iii) by which API
or any of the assets owned or used by API is or may become bound, and in
addition, (b) which is disclosed, or required to be disclosed, on
Schedule 4.17.

 

“Material
Adverse Effect” – an event, change or effect that is
materially adverse to any of (i) the Permax Rights taken as a whole, (ii) the
Zelapar Rights taken as a whole, (iii) the PCP Product Rights taken as a whole
or (iv) the financial condition or results of operations of API.

 

“Material Amarin Contract” — any Contract (a)
under which Amarin has or may acquire any material rights or benefits with
respect to any of the Acquired Assets, (b) under which Amarin has or may become
subject to any material obligation or liability with respect to the Acquired
Assets, or (c) by which any of the Acquired Assets are or may become bound in
any material respect.

 

“Material Consents” — in the case of (a)
Amarin, collectively, those Consents identified as “Material Consents” on
Schedule 3.2, (b) API and APCL, collectively, those Consents identified as
“Material Consents” on Schedule 4.2, and (c) Buyer, collectively, those
Consents identified as “Material Consents” on Schedule 5.2.

 

“Mill Valley Lease” — as defined in
Section 11.12(a).

 

“NDA” — a new drug application as filed with
the FDA under the Act.

 

7

 

“NDA/ANDA Transfer Letter” — as defined in
Section 2.6(a)(iii).

 

“Order” — any order, injunction, judgment,
decree, ruling, assessment or arbitration award of any Governmental Body or
arbitrator.

 

“Ordinary Course of Business” — an action
taken by a Person will be deemed to have been taken in the Ordinary Course of
Business only if that action

 

(a)                                  is
consistent in nature, scope and magnitude with the past practices of such
Person and is taken in the ordinary course of the normal, day-to-day operations
of such Person; and

 

(b)                                 does
not require authorization by the board of directors or shareholders of such
Person (or by any Person or group of Persons exercising similar authority).

 

“PCP Product Assets” — collectively, the PCP
Product Know-How, PCP Product Records, PCP Product Registrations, and PCP
Product Trademarks.

 

“PCP Product Know-How” — the manufacturing
information, including formulae, processes, methods, manufacturing and testing
procedures, technical information, clinical information, regulatory
information, know-how and inventions, patentable and non-patentable, owned by
Amarin and relating specifically and solely to the PCP Products.

 

“PCP Product Records” — the books, records and
other materials held by Amarin that pertain solely to the PCP Products, whether
in electronic or tangible form.

 

“PCP Product Registrations” — the Product
Registrations disclosed on Schedule 3.9.

 

“PCP Products” — the pharmaceutical products
that comprise Amarin’s portfolio of primary care products, being those products
disclosed on Schedule 3.9.

 

“PCP Product Rights” — all of Amarin’s right,
title and interest in and to the PCP Product Assets.

 

“PCP Product Trademarks” — the trademark
registrations and applications disclosed on Schedule 3.9.

 

“Permax®” — a pharmaceutical formulation
containing pergolide mesylate currently sold by API under the product name
Permax®.

 

“Permax® Rights” — all of Amarin’s rights under the Eli Lilly/Amarin
License Agreement, including but not limited to the exclusive right to use,
promote, market, sell and distribute Permax® (excluding the Permax® Patch, a
transdermal patch potentially in development for the delivery of Permax®) in
the Territory.

 

“Permitted Encumbrances” — as defined in
Section 4.6.

 

8

 

“Person” — an individual, partnership,
corporation, business trust, limited liability company, limited liability
partnership, joint stock company, trust, unincorporated association, joint
venture or other entity or a Governmental Body.

 

“Pro Forma Balance Sheet” — the pro forma
balance sheet of API set forth in Schedule 2.7 annexed hereto.

 

“Proceeding” — any action, arbitration, audit,
hearing, investigation, litigation or suit (whether civil, criminal,
administrative, judicial or investigative, whether formal or informal, whether
public or private) commenced, brought, conducted or heard by or before, or
otherwise involving, any Governmental Body or arbitrator.

 

“Product Registrations” — all regulatory
approvals, licenses, applications, including NDAs, ANDAs, and INDs, and all
supplements thereto, whether existing, pending, withdrawn or in draft form,
together with all material correspondence to or from the FDA relative to any
pharmaceutical product.

 

“Purchase Price” — as defined in
Section 2.2.

 

“Record” — information that is inscribed on a
tangible medium or that is stored in an electronic or other medium and is
retrievable in perceivable form.

 

“Release” — any release, spill, emission,
leaking, pumping, pouring, dumping, emptying, injection, deposit, disposal,
discharge, dispersal, leaching or migration on or into the Environment or into
or out of any property.

 

“Remedial Action” — all actions, including any
capital expenditures, required or voluntarily undertaken (a) to clean up,
remove, treat or in any other way address any Hazardous Material or other
substance; (b) to prevent the Release or Threat of Release or to minimize the
further Release of any Hazardous Material or other substance so it does not
migrate or endanger or threaten to endanger public health or welfare or the
Environment; (c) to perform pre-remedial studies and investigations or
post-remedial monitoring and care; or (d) to bring all API Facilities and the
operations conducted thereon into compliance with Environmental Laws and
environmental Governmental Authorizations.

 

“Representative” — with respect to a
particular Person, any director, officer, manager, employee, agent, consultant,
advisor, accountant, financial advisor, legal counsel or other representative
of that Person.

 

“SEC” — the United States Securities and
Exchange Commission.

 

“Schedule” — a part or section of the
Disclosure Schedules.

 

“Scherer” — R. P. Scherer Corporation, a
Delaware corporation and a party to the Scherer/Elan License Agreement.

 

9

 

“Scherer/Elan License Agreement” — that
certain License and Supply Agreement, dated February 25, 1999, as amended,
by and between Scherer and Elan.

 

“Securities Act” — the Securities Act of 1933,
as amended.

 

“Sellers” — as defined in the first paragraph
of this Agreement.

 

“Software” — all computer software and
subsequent versions thereof, including source code, object, executable or
binary code, objects, comments, screens, user interfaces, report formats,
templates, menus, buttons and icons and all files, data, materials, manuals,
design notes and other items and documentation related thereto or associated
therewith.

 

“Subsidiary” — with respect to any Person (the
“Owner”), any
corporation or other Person of which securities or other interests having the
power to elect a majority of that corporation’s or other Person’s board of
directors or similar governing body, or otherwise having the power to direct
the business and policies of that corporation or other Person (other than
securities or other interests having such power only upon the happening of a
contingency that has not occurred), are held by the Owner or one or more of its
Subsidiaries.

 

“Tax” — any income, gross receipts, license,
payroll, employment, excise, severance, stamp, occupation, premium, property,
environmental, windfall profit, customs, vehicle, airplane, boat, vessel or
other title or registration, capital stock, franchise, employees’ income
withholding, foreign or domestic withholding, social security, unemployment,
disability, real property, personal property, sales, use, transfer, value
added, alternative, add-on minimum and other tax, fee, assessment, levy, tariff,
charge or duty of any kind whatsoever and any interest, penalty, addition or
additional amount thereon imposed, assessed or collected by or under the
authority of any Governmental Body or payable under any tax-sharing agreement
or any other Contract.

 

“Taxation Authority” — means any governmental
or other authority whatsoever competent to impose any Taxation, whether in the
United Kingdom, the United States or elsewhere.

 

“Tax Return” — any return (including any
information return), report, statement, schedule, notice, form, declaration,
claim for refund or other document or information filed with or submitted to,
or required to be filed with or submitted to, any Governmental Body in
connection with the determination, assessment, collection or payment of any Tax
or in connection with the administration, implementation or enforcement of or
compliance with any Legal Requirement relating to any Tax.

 

“Territory” — with respect to Permax and/or
the Permax Rights, as defined in the Eli Lilly/Amarin License Agreement, and
with respect to Zelapar and/or the Zelapar Rights shall mean the United States.

 

“Third Party” — a Person that is not a party
to this Agreement.

 

“Third-Party Claim” — any claim against any
Indemnified Person by a Third Party, whether or not involving a Proceeding.

 

10

 

“Threat of Release” — a reasonable likelihood
of a Release that may require action in order to prevent or mitigate damage to
the Environment that may result from such Release.

 

“Trademark Assignment” — as defined in
Section 2.6(a)(ii).

 

“UK  GAAP” — generally accepted accounting principles for
financial reporting in the United Kingdom, applied on a basis consistent with
the basis on which the balance sheets and the other financial statements
referred to in Section 4.4 were prepared.

 

“VAT” — means value added tax.

 

“ZelaparTM — a pharmaceutical formulation of
selegeline hydrochloride that falls within the claims of certain Zydis® patents
(as more fully described in the Scherer/Elan License Agreement).

 

“Zelapar Development Agreement” — as defined
in Section 11.2(a)(i).

 

“Zelapar R&D Studies” — the research and
development study or studies contemplated in, and to be effected pursuant to,
the Zelapar Development Agreement.

 

“Zelapar Rights” —  all of Elan’s right, title and interest in any data, information,
or know-how pertaining to, and any license or other rights in, Zelapar in the
Territory owned or controlled by Elan at the time of Amarin’s exercise of its
option under the Elan/Amarin Option Agreement, and relating to the use,
promotion, distribution and sale of Zelapar in the Territory for use in the
field of human therapeutic treatment of any disease, condition or
disorder.  The foregoing includes but is
not limited to (i) all of Elan’s and Amarin’s rights under the Scherer/Elan
License Agreement, as it pertains to the Territory, and (ii) all clinical,
preclinical and other data, protocols, inventory, work in progress, regulatory
rights or applications of any kind, contract rights, market research, patent
rights, patent applications, trademark rights, trademark applications, and any
know-how associated with Zelapar for use in the Territory.

 

1.2                               USAGE

 

(a)                                  Interpretation.  In this Agreement, unless a clear
contrary intention appears:

 

(i)                                     the
singular number includes the plural number and vice versa;

 

(ii)                                  reference
to any Person includes such Person’s successors and assigns but, if applicable,
only if such successors and assigns are not prohibited by this Agreement, and
reference to a Person in a particular capacity excludes such Person in any
other capacity or individually;

 

(iii)                               reference
to any gender includes each other gender;

 

11

 

(iv)                              reference
to any agreement, document or instrument means such agreement, document or
instrument as amended or modified and in effect from time to time in accordance
with the terms thereof;

 

(v)                                 reference
to any Legal Requirement means such Legal Requirement as amended, modified,
codified, replaced or reenacted, in whole or in part, and in effect from time
to time, including rules and regulations promulgated thereunder, and reference
to any section or other provision of any Legal Requirement means that
provision of such Legal Requirement from time to time in effect and
constituting the substantive amendment, modification, codification, replacement
or reenactment of such section or other provision;

 

(vi)                              “hereunder,”
“hereof,” “hereto,”  and words of
similar import shall be deemed references to this Agreement as a whole and not
to any particular Article, Section or other provision hereof;

 

(vii)                           “including”
(and with correlative meaning “include”) means including without limiting the
generality of any description preceding such term;

 

(viii)                        “or”
is used in the inclusive sense of “and/or”;

 

(ix)                                with
respect to the determination of any period of time, “from” means “from and
including” and “to” means “to but excluding”; and

 

(x)                                   references
to documents, instruments or agreements shall be deemed to refer as well to all
addenda, exhibits, schedules or amendments thereto.

 

(b)                                 Accounting
Terms and Determinations.  Unless
otherwise specified herein, all accounting terms used herein shall be
interpreted and all accounting determinations hereunder shall be made in
accordance with UK GAAP.

 

(c)                                  Legal
Representation of the Parties.  This
Agreement was negotiated by the parties with the benefit of legal
representation, and any rule of construction or interpretation otherwise
requiring this Agreement to be construed or interpreted against any party shall
not apply to any construction or interpretation hereof.

 

ARTICLE 2

SALE AND TRANSFER OF THE ACQUIRED
ASSETS; CLOSING

 

2.1                               ASSETS
TO BE SOLD

 

Upon the terms and
subject to the conditions set forth in this Agreement, at the Closing, and
effective as of the Closing Date, Sellers shall sell, convey, assign, transfer
and deliver to Buyer, and Buyer shall purchase and acquire from Sellers, free
and clear of any Encumbrances other than Permitted Encumbrances, all of
Sellers’ right, title and interest in and to the Acquired Assets. 
Notwithstanding the foregoing, the transfer of the
Acquired Assets pursuant to this Agreement shall not include the assumption of
any Liability except for the Assumed Liabilities.

 

12

 

2.2                               PURCHASE
PRICE

 

(a)                                  The
purchase price for the Acquired Assets (the “Purchase Price”) will consist of (i) Thirty-Eight Million U.S.
Dollars (U.S. $38,000,000), payable at Closing by the Buyer to the Sellers or
to any Third Party at the Sellers’ direction, (ii) Three Million U.S. Dollars
(U.S. $3,000,000), payable upon Successful Completion (as hereinafter defined)
of the Zelapar R&D Studies, (iii) Five Million U.S. Dollars (U.S.
$5,000,000), payable upon final FDA approval of the Zelapar NDA, and (iv) the
assumption by Buyer at Closing of the Assumed Liabilities.  For purposes hereof “Successful Completion” shall have the meaning
set forth in the Zelapar Development Agreement.

 

(b)                                 Following
Closing, the API Adjustment Amount shall be determined and paid as provided in
Section 2.7.

 

(c)                                  Amarin
shall be responsible for all transfer, sales, bulk sales, use and other related
Taxes, other than VAT, if any, arising at any time out of the sale of the
Acquired Assets to Buyer pursuant to this Agreement. Buyer shall be responsible
for all VAT arising at any time out of the sale of the Acquired Assets to Buyer
pursuant to this Agreement.

 

2.3                               ASSUMED
LIABILITIES

 

(a) On the Closing Date,
and effective as of the Closing Date, Buyer shall assume the following
Liabilities of Amarin (collectively, the “Assumed Liabilities”):

 

Zelapar Related
Liabilities. 
Buyer shall assume all obligations and liabilities of Amarin arising
under the Elan/Amarin Option Agreement (or any other documentation entered into
by Valeant at Closing under which it succeeds to Amarin’s rights and
obligations under the Elan/Amarin Option Agreement) on and after the Closing
Date, including the following:

 

(i)                                     Elan
Milestone Payment.  Buyer
shall assume Amarin’s obligation to pay a one-time milestone payment to Elan
under Section 7.1 of the Elan/Amarin Option Agreement;

 

(ii)                                  Elan Royalty
Payment.  Buyer shall assume
Amarin’s obligation to pay Elan a 12.5% royalty on “Net Sales” of Zelapar in
the Territory during the first 8 “Launch Years” under Section 7.3 of the
Elan/Amarin Option Agreement; and

 

(iii)                               Scherer/Elan
License Agreement Liabilities. 
Buyer shall assume all obligations and liabilities of Amarin (as assumed
by Amarin under Section 3.1(d) of the Elan/Amarin Option Agreement)
arising under the Scherer/Elan License Agreement after the Closing Date,
including Amarin’s obligation to pay Cardinal Health, Inc., as
successor-in-interest by merger to R. P. Scherer, a 10% royalty on “Net Sales”
of Zelapar in the Territory under Section 4.2 of the Scherer/Elan License
Agreement.

 

13

 

Permax® Related
Liabilities. 
Buyer shall assume the following obligations and liabilities of Amarin
to the extent they arise after the Closing Date:

 

(iv)                              Eli
Lilly/Amarin License Agreement Liabilities.  Buyer shall assume all of Amarin’s
obligations and liabilities under the Eli Lilly/Amarin License Agreement; and

 

(v)                                 Elan Royalty
Payment.  Buyer shall assume
Amarin’s obligation to pay Elan an adjustable royalty on “Net Sales” of Permax®
in the Territory under Section 3.10(e) of that certain Amended and
Restated Distribution, Marketing and Option Agreement, dated September 28,
2001, as amended, by and between Elan and Amarin.

 

(b)                                 API Liabilities.  For the avoidance of doubt, Sellers and
Buyer acknowledge that except as expressly provided herein, none of API’s
Liabilities are assumed by Sellers or Buyer as part of or in connection with
the Contemplated Transactions, but rather all Liabilities of API shall remain
Liabilities of API, including without limitation all Liabilities relating to
any termination or redundancy affecting employees of API or otherwise relating
to any employee of API, and including all severance obligations to employees of
API, except that Buyer shall not retain those Liabilities specifically assumed
by Amarin under Section 11.15 hereof.   In
furtherance of the foregoing, it is understood and agreed that Sellers shall
not be responsible for, and Buyer and its Affiliates hereby release Sellers
from, any and all Liabilities of API, except for liabilities as to which Sellers
are obligated to indemnify Buyer under Section 12.2 hereof.

 

(c)                                  Post-Closing
Reduction of Assumed Liabilities. 
In the event and to the extent that Buyer is able to negotiate and
secure a reduction of some or all of the Assumed Liabilities after the Closing,
any savings attributable to any such reductions shall inure exclusively to the
benefit of Buyer.

 

2.4                               ALLOCATION

 

The Purchase Price shall
be allocated in accordance with Exhibit A. 
Buyer and Sellers acknowledge that the Purchase Price allocations were
determined pursuant to arm’s length bargaining regarding the fair market values
of the Acquired Assets.  After the
Closing, the parties shall make consistent use of the allocation specified in
Exhibit A for all Tax purposes and in all filings, declarations and reports
with the IRS in respect thereof, including the reports, if any, required to be
filed under Section 1060 of the Code. 
If required under Section 1060 of the Code, Buyer shall prepare and
deliver IRS Form 8594 to Sellers within forty-five (45) days after the Closing
Date to be filed with the IRS.  In any
Proceeding related to the determination of any Tax, neither Buyer nor Sellers
shall contend or represent that such allocation is not a correct
allocation.  Notwithstanding the
foregoing, if any Taxation Authority challenges the Purchase Price allocations
contained in this Agreement in any administrative or judicial proceeding,
Sellers or Buyer, as the case may be, shall be allowed to settle or compromise
such dispute in

 

14

 

such manner as that party
determines to be practicable, irrespective of whether such settlement is
contrary to the specific terms of this Agreement regarding Purchase Price
allocations.

 

2.5                               CLOSING

 

The purchase and sale
provided for in this Agreement (the “Closing”) will take place at API’s Mill Valley
Facility.  Unless Buyer and Sellers
agree otherwise, the Closing shall take place on the date that is five (5)
Business Days following  the receipt of
all of the Material Consents duly executed by all relevant parties or the
waiver by the relevant party(ies) of the right to receive any such Material
Consents as a condition to Closing. Subject to the provisions of
ARTICLE 10, failure to consummate the purchase and sale provided for in
this Agreement on the date and time and at the place determined pursuant to
this Section 2.5 will not result in the termination of this Agreement and
will not relieve any party of any obligation under this Agreement.  In such a situation, the Closing will occur
as soon as practicable, subject to ARTICLE 10.

 

2.6                               CLOSING
OBLIGATIONS

 

In addition to any other
documents to be delivered under other provisions of this Agreement, at the
Closing:

 

(a)                                  Amarin
shall deliver to Buyer:

 

(i)                                     a
general bill of sale, assignment and assumption agreement in a form to be
mutually agreed (the “Master Assignment and Assumption Agreement”), executed
by Amarin, pursuant to which (A) Amarin shall convey the Amarin Product Rights
(except for the PCP Product Trademarks) to Buyer, and (B) Buyer shall assume
the Assumed Liabilities;

 

(ii)                                  an
assignment in a form to be mutually agreed (the “Trademark Assignment”), executed by Amarin,
pursuant to which Amarin shall assign to Buyer the PCP Product Trademarks held
by Amarin;

 

(iii)                               a
letter from Amarin to the FDA, dated as of the Closing Date, in form and
substance acceptable to Buyer (the “NDA/ANDA Transfer Letter”) pursuant to which Amarin
shall advise the FDA of its transfer of the PCP Product Registrations to Buyer
pursuant to this Agreement;

 

(iv)                              a
termination agreement, dated as of the Closing Date, by and between Amarin and
API, in form and substance acceptable to Buyer (the “Termination Agreement”), pursuant to which
Amarin and API shall terminate, effective as of the Closing Date, (A) that
certain Services Agreement, dated July 12, 2000, by and between Amarin and
API, and (B) that certain Sales Agent Agreement, dated July 12, 2000, by
and between Amarin and API;

 

(v)                                 the
Zelapar Development Agreement, executed by Amarin;

 

(vi)                              the
Elan Assignment Agreement, executed by Elan and Amarin;

 

15

 

(vii)                           letters
of resignation, dated as of the Closing Date, in form and substance reasonably
acceptable to Buyer, from each of API’s officers and directors;

 

(viii)                        evidence
reasonably satisfactory to Buyer that each of the Material Consents disclosed
on Schedules 3.2 and 4.2 has been obtained;

 

(ix)                                such
other deeds, bills of sale, assignments, certificates of title, documents and
other instruments of transfer and conveyance as may reasonably be requested by
Buyer, each in form and substance reasonably satisfactory to Buyer and its
legal counsel and executed by Amarin;

 

(x)                                   a
certificate executed by Amarin as to the accuracy of its representations and
warranties as of the date of this Agreement and as of the Closing in accordance
with Section 8.1 and as to its compliance with and performance of its
covenants and obligations to be performed or complied with at or before the
Closing in accordance with Section 8.2; 
and

 

(xi)                                a
certificate of the secretary of Amarin certifying, as complete and accurate as
of the Closing, attached copies of the Governing Documents of Amarin,
certifying and attaching all requisite resolutions or actions of Amarin’s board
of directors and shareholders (if applicable) approving the execution and
delivery of this Agreement and the consummation of the Contemplated Transactions
and certifying to the incumbency and signatures of the officers of Amarin
executing this Agreement and any other document relating to the Contemplated
Transactions.

 

(xii)                             the
Repurchase Agreements (as defined in Section 11.3), to the extent any have
been entered into as of the Closing Date.

 

(b)                                 APCL
shall deliver to Buyer:

 

(i)                                     the
original stock certificate representing the API Shares, duly endorsed by APCL
for transfer to Buyer or accompanied by a separate stock power duly endorsed by
APCL; and

 

(ii)                                  a
certificate of the secretary of APCL certifying, as complete and accurate as of
the Closing, attached copies of the Governing Documents of APCL, certifying and
attaching all requisite resolutions or actions of APCL’s board of directors and
shareholders (if applicable) approving the execution and delivery of this
Agreement and the consummation of the Contemplated Transactions and certifying
to the incumbency and signatures of the officers of APCL executing this
Agreement and any other document relating to the Contemplated Transactions.

 

(c)                                  Buyer
shall deliver to Amarin:

 

(i)                                     Thirty-Eight
Million U.S. Dollars (U.S. $38,000,000) by wire transfer to an account
specified by Amarin, a portion of which amount (consistent with Exhibit A

 

16

 

hereto) shall be
deemed to be paid to Amarin on behalf of APCL as payment for the API Shares;

 

(ii)                                  the
Master Assignment and Assumption Agreement executed by Buyer;

 

(iii)                               the
Zelapar Development Agreement, executed by Buyer;

 

(iv)                              evidence
satisfactory to Amarin that each of the Material Consents disclosed on
Schedule 5.2 has been obtained;

 

(v)                                 a
certificate executed by Buyer as to the accuracy of its representations and
warranties as of the date of this Agreement and as of the Closing in accordance
with Section 9.1 and as to its compliance with and performance of its
covenants and obligations to be performed or complied with at or before the
Closing in accordance with Section 9.2; and

 

(vi)                              a
certificate of the secretary of Buyer certifying, as complete and accurate as
of the Closing, attached copies of the Governing Documents of Buyer and
certifying and attaching all requisite resolutions or actions of Buyer’s board
of directors approving the execution and delivery of this Agreement and the
consummation of the Contemplated Transactions and certifying to the incumbency
and signatures of the officers of Buyer executing this Agreement and any other
document relating to the Contemplated Transactions.

 

(vii)                           a
Stock Purchase Agreement relating to the sale of the API Shares from APCL to
Buyer, in a form to be mutually agreed, executed by APCL and Buyer.

 

2.7                               API
ADJUSTMENT AMOUNT AND PAYMENT

 

(a)   As promptly as reasonably practicable
following the Closing, Buyer shall prepare, and Buyer and Amarin shall jointly
agree upon, a balance sheet of API (the “API Closing Balance Sheet”) as of the Closing Date on
the same basis and applying the same accounting principles, policies and
practices as were used in preparing the Pro Forma Closing Balance Sheet (as set
out in Schedule 2.7 hereto). Each of the Buyer and Amarin shall give the
other (or procure that the other has) access, through its employees, agents and
advisers (provided that each party shall be entitled, at its option, to have its
Representatives present), to all relevant files and/or working papers (with the
right to take copies) in their possession or control to the extent that they
are required in connection with the preparation and/or review of the API
Closing Balance Sheet. The Buyer shall submit the draft API Closing Balance
Sheet is submitted to Amarin for review within 14 calendar days after Closing.
Once accepted by Amarin or otherwise agreed upon by Amarin and Buyer, the API
Closing Balance Sheet shall be binding upon the parties. To avoid potential
duplication between this Section 2.7 and Section 11.3, the API
Closing Balance Sheet shall be prepared on the basis of wholesalers carrying
two months of Permax inventory and on the basis that all of the envisaged Quality
King inventory buy-back set out in the Pro-Forma Closing Balance Sheet has
actually occurred.  In addition, the API
Closing Balance Sheet shall contain the same fair value adjustments in the same
amount as contained in the Pro-Forma Closing Balance Sheet.

 

17

 

 

(b)  The “API Adjustment Amount” (which may be a positive or
negative number) will be equal to the amount determined by subtracting (i) the
Total Assets less Current Liabilities as reflected in the API Closing Balance
Sheet from (ii) the Total Assets less Current Liabilities as of
February 29, 2004 as reflected in the Pro Forma Closing Balance Sheet.

 

(c)  If the API Adjustment Amount is less than
zero, then subject to Section 2.7(e) below, the Purchase Price will be
increased by the API Adjustment Amount, and Buyer shall pay or cause to be paid
the API Adjustment Amount to Amarin by wire transfer or by other mutually
acceptable means within three (3) Business Days following the final
determination of the API Adjustment Amount.

 

(d)  If the API Adjustment Amount is greater than
zero, then subject to Section 2.7(e) below, the inter-company receivable
due to API from Amarin shall not be waived in full as provided in the Deed of
Termination between Amarin and API (as further defined in Section 9.6) ,
and in such event Amarin shall pay to API such portion of the said
inter-company receivable as is equal to the API Adjustment Amount, and only the
then-remaining portion of such inter-company receivable shall be waived under
the Deed of Termination. In the event an adjustment to such inter-company
receivable is required under this Section 2.7(d), the amount thereof shall
be settled by Amarin by wire transfer or by other mutually acceptable means
within three (3) Business Days following the final determination of the API
Adjustment Amount.

 

(e)  No adjustment shall be made to the Purchase
Price under Section 2.7(c) above or to the inter-company receivable under
Section 2.7(d) above unless the amount of the API Adjustment Amount is at
least fifty thousand dollars ($50,000)

 

(f)  The parties shall pay their own respective
costs in connection with the preparation of the API Closing Balance Sheet.

 

(g)  The draft API Closing Balance Sheet shall be
deemed to have been accepted by Amarin as the binding API Closing Balance Sheet
unless, within 20 calendar days of its receipt, Amarin delivers to the Buyer
notice to the contrary specifying with reasonable detail:

 

(i)                                     the
item or items disputed;

 

(ii)                                  the
reason(s) for disputing such item or items; and

 

(iii)                               how
the draft API Closing Balance Sheet should be adjusted.  If the Buyer and Amarin resolve the matters
raised in the notice in the 20 Business Days following receipt of the notice,
the draft API Closing Balance Sheet (adjusted, if necessary, as agreed by the
Buyer and Amarin) will be deemed to have been accepted by the parties as the
binding API Closing Balance Sheet;

 

18

 

(h)  If Amarin and the Buyer are unable to reach
agreement within 20 calendar days of the notice referred to in Clause 2.7(d),
the matter(s) in dispute shall, at the written election of Amarin or the Buyer,
be referred to the decision of a UK independent chartered accountant (the “Independent Accountant”) to be appointed
(in default of nomination by agreement between Amarin and the Buyer) by the
President for the time being of the Institute of Chartered Accountants in
England and Wales on the written application of Amarin or of the Buyer
(whichever applies first);

 

(i)  The Independent Accountant shall act as an
expert and not as an arbitrator. The Independent Accountant’s decision shall
(in the absence of manifest error) be final and binding on Amarin and the Buyer
for all the purposes of this Agreement. 
The Buyer and Amarin shall use their Best Efforts to ensure that the
Independent Accountant’s decision as to the matter in dispute is made within 30
calendar days of appointment. The draft API Closing Balance Sheet, as adjusted
(if necessary) to reflect the Independent Accountant’s final and binding
decision, will be deemed to have been accepted by the parties as the binding
API Closing Balance Sheet.

 

The costs of the
Independent Accountant shall be apportioned between the parties as the
Independent Accountant shall decide but each party shall be responsible for its
own costs of presenting its case to the Independent Accountant.

 

(b)

 

ARTICLE 3

REPRESENTATIONS AND WARRANTIES OF
SELLERS AS TO SELLERS

 

Amarin (as to itself and
APCL) and APCL (only as to itself) represent and warrant to Buyer as follows:

 

3.1                               ORGANIZATION
AND GOOD STANDING

 

Amarin and APCL each is a
corporation duly organized, validly existing and in good standing under the
laws of its jurisdiction of incorporation, with full corporate power and authority
to conduct its business as it is now being conducted, and to own or use its
properties and assets in the conduct of its business.

 

3.2                               ENFORCEABILITY;
AUTHORITY; NO CONFLICT

 

(a)                                  This
Agreement constitutes the legal, valid and binding obligation of each of Amarin
and APCL and is enforceable against each of them in accordance with its
terms.  Upon the execution and delivery
by Amarin and APCL of the Master Assignment and Assumption Agreement, the
Trademark Assignment, and each other agreement to be executed or delivered by
either or both of them at the Closing (collectively, the “Sellers’ Closing Documents”), each of
Sellers’ Closing Documents signed by Amarin will constitute the legal, valid
and binding obligation of Amarin enforceable against it in accordance with its
terms, and each of the Sellers’ Closing Documents signed by APCL will
constitute the legal, valid and binding obligation of APCL enforceable against
it in accordance with its terms.  Amarin
and APCL each has the full and unrestricted right, power and authority to
execute and deliver this Agreement and each of the Sellers’ Closing Documents
to which

 

19

 

it is a party and
to perform its obligations under this Agreement and each of the Sellers’
Closing Documents to which it is a party, and such action has been duly
authorized by all necessary action by each of Amarin’s and APCL’s shareholders
(if required) and board of directors.

 

(b)                                 Except
as set forth in Schedule 3.2, neither the execution and delivery of this
Agreement nor the consummation or performance of any of the Contemplated
Transactions will, directly or indirectly (with or without notice or lapse of
time):

 

(i)                                     Breach
any provision of any of the Governing Documents of Amarin or APCL;

 

(ii)                                  Breach
any Legal Requirement or any Order to which Amarin or APCL or any of the
Acquired Assets, may be subject;

 

(iii)                               contravene,
conflict with or result in a violation or breach of any of the terms or
requirements of, or give any Governmental Body the right to revoke, withdraw,
suspend, cancel, terminate or modify, any Governmental Authorization that is
held by Amarin or APCL and is material to the Acquired Assets;

 

(iv)                              Breach
any provision of, or give any Person the right to declare a default under, or
to accelerate the maturity or performance of, or payment under, or to cancel,
terminate or modify, any Material Amarin Contract;

 

(v)                                 result
in the imposition or creation of any Encumbrance upon or with respect to any of
the Acquired Assets; or

 

(vi)                              result
in any shareholder of Amarin having the right to exercise dissenters’ appraisal
rights or any equivalent thereof.

 

(c)                                  Except
as set forth in Schedule 3.2, neither Amarin nor APCL is required to
obtain any Consent from any Person in connection with the execution and
delivery of this Agreement or the consummation or performance of any of the
Contemplated Transactions.

 

3.3                               TITLE
TO ACQUIRED ASSETS; ENCUMBRANCES

 

(a)                                  Zelapar
Rights.  The Elan/Amarin
Option Agreement is valid and binding, and in full force and effect, and will
continue to be so as of the Closing Date. 
Amarin has the right under the Elan/Amarin Option Agreement to obtain
the Zelapar Rights from Elan, and as of the Closing Date Amarin shall have
obtained the Zelapar Rights from Elan and conveyed the Zelapar Rights to Buyer
hereunder, free and clear of any Encumbrances other than those contained in the
Scherer/Elan License Agreement; provided that any grant of rights to, or
retention of rights by, Amarin under the Zelapar Development Agreement shall
not be deemed an Encumbrance against the Zelapar Rights and shall not otherwise
be deemed a breach of the foregoing representations and warranties.

 

20

 

(b)                                 Permax® Rights.  The Eli Lilly/Amarin License Agreement is
valid and binding, and in full force and effect, and will continue to be so as
of the Closing Date.  Amarin owns, and
as of the Closing Date Amarin shall convey to Buyer hereunder, the Permax Rights,
free and clear of any Encumbrances other than those contained in the Eli
Lilly/Amarin License Agreement..  Amarin
specifically represents and warrants to Buyer that (i) neither Eli Lilly nor
Elan has assigned to Amarin, and Amarin does not currently own, the “Elan
Retained Rights” (as defined and contemplated in the Eli Lilly/Amarin License
Agreement), and (ii) Eli Lilly has not granted Amarin, and Amarin does not
currently own, a license to manufacture Permax® in the Territory as
contemplated in [Section 14.5] of the Eli Lilly/Amarin License Agreement.

 

(c)                                  PCP Product
Assets and PCP Product Rights. 
Amarin owns, and as of the Closing Date Amarin shall convey to Buyer
hereunder, the PCP Product Assets and PCP Product Rights, free and clear of any
Encumbrances.

 

(d)                                 API Shares.  APCL owns, and as of the Closing Date APCL
shall convey to Buyer hereunder, the API Shares, free and clear of any
Encumbrances.

 

3.4                               FINANCIAL
STATEMENTS

 

Amarin has delivered to
Buyer: (a) audited balance sheets of Amarin as at December 31 in each of
the fiscal years 2000 through 2002, and the related audited statements of
income, changes in shareholders’ equity and cash flows for each of the fiscal
years then ended, including in each case the notes thereto together with the
report thereon of PricewaterhouseCoopers LLP, independent certified public
accountants; and (b) unaudited quarterly selected financial data of Amarin as
submitted to the Securities and Exchange Commission under cover of Forms 6-K.

 

3.5                               MATERIAL
AMARIN CONTRACTS

 

(a)                                  Schedule 3.5
contains an accurate and complete list of, and Amarin has delivered to Buyer
current and complete copies of, all of the Material Amarin Contracts.

 

(b)                                 All
of the Material Amarin Contracts are valid, binding and in full force and
effect, and neither Amarin nor, to Amarin’s Knowledge, any other party to any
Material Amarin Contract, is in breach of or in default under (nor has any
event occurred that with the notice or lapse of time or both would constitute a
default, result in a material loss of benefits or rights, or result in the
creation of an Encumbrance, under or pursuant to) any Material Amarin Contract.

 

(c)                                  Schedule 3.5(c)
identifies each Material Amarin Contract with respect to which any third party
has notified Amarin (whether orally or in writing) of its intention to
terminate, cancel or modify such Material Amarin Contract or otherwise to
reduce or change its activity thereunder such that it would adversely affect
the benefits derived, or currently expected to be derived, thereunder by
Amarin.

 

21

 

3.6                               ABSENCE
OF CERTAIN CHANGES AND EVENTS

 

Except as set forth in
Schedule 3.6, since January 1, 2003, Amarin has not (i) amended
or changed in any material respect its distribution practices or terms with
respect to any of the Amarin Products, (ii) caused or effected any
increase outside of the Ordinary Course of Business in API’s Inventory at the
wholesale, chain, institutional or retail levels, (iii) engaged in or
implemented, either directly or through API, any special pricing, rebate
allowance, promotional or marketing program or activities, special returns
policy or special restocking program outside the Ordinary Course of Business
that would materially impact the normal course or level of expected returns
with respect to Zelapar, Permax or the PCP products, or (iv) entered into
or amended any Contract with the intent of effecting any of the foregoing
matters.

 

3.7                               INTELLECTUAL
PROPERTY

 

Except as disclosed in
Schedule 3.7:

 

(a)                                  Since
January 1, 2003, Amarin has not received any notice of or does not
otherwise have any Knowledge of any claim that any of the Amarin Products and
Rights infringe on any property right of any other third party, and there is no
claim, action, suit or proceeding pending or, to Amarin’s Knowledge, threatened
alleging the ownership or use by Amarin or by API of any of the Amarin Products
and Rights infringes any patent or other intellectual property rights of any
third parties.

 

(b)                                 Other
than the licenses and rights granted under the Amarin Material Contracts,
Amarin has not granted any licenses, or authorized or permitted any other
person or entity, other than Amarin and API, to use any of the Amarin Product
Rights in the Territory.

 

(c)                                  To
Amarin’s Knowledge, there are not any intellectual property rights, including
without limitation any patents, trade secrets, know-how, or trademarks, that
are either owned by or licensed to Amarin, and that are not included in the
Amarin Product Rights, that would be infringed by Buyer’s ownership and use of
the Amarin Product Rights in the Territory.

 

3.8                               LEGAL
PROCEEDINGS; ORDERS

 

(a)                                  Except
as set forth in Schedule 3.8, there is no pending or, to Amarin’s
Knowledge, threatened Proceeding:

 

(i)                                     by
or against Amarin or APCL that relates to any Material Amarin Contract or any
of the Acquired Assets; or

 

(ii)                                  that
would reasonably be expected to have the effect of prohibiting the consummation
of any of the Contemplated Transactions.

 

To the Knowledge of
Amarin, no event has occurred or circumstance exists that is reasonably likely
to give rise to or serve as a basis for the commencement of any such
Proceeding.  Amarin has delivered to
Buyer copies of all pleadings, correspondence and other documents relating to
each Proceeding listed in Schedule 3.8

 

22

 

(b)                                 Except
as set forth in Schedule 3.8, there is no Order to which Amarin or any of
the Acquired Assets are subject that would be likely to affect any of the
Acquired Assets or that would reasonably be expected to have the effect of
prohibiting the consummation of the Contemplated Transactions.

 

3.9                               PRODUCT
REGISTRATIONS.

 

Schedule 3.9
contains an accurate and complete list, and Amarin has delivered to Buyer
current and complete copies, of all Product Registrations owned by Amarin or in
Amarin’s possession relative to the ownership, use, sale or distribution of
Zelapar, Permax® and the PCP Products in the Territory.

 

3.10                        BROKERS
OR FINDERS

 

Except as set forth on
Schedule 3.10, Amarin has not incurred any obligation or liability,
contingent or otherwise, for brokerage or finders’ fees or agents’ commissions
or other similar payments in connection with the sale of the Acquired Assets or
the Contemplated Transactions.  Amarin
shall be solely responsible for the obligations and liabilities disclosed on
Schedule 3.10.

 

ARTICLE 4

REPRESENTATIONS AND WARRANTIES OF SELLERS AS TO
API

 

Amarin and APCL represent
and warrant to Buyer as follows:

 

4.1                               ORGANIZATION
AND GOOD STANDING

 

(a)                                  Schedule 4.1
contains a complete and accurate list of API’s jurisdiction of incorporation
and any other jurisdictions in which it is qualified to do business as a
foreign corporation. API is a corporation duly organized, validly existing and
in good standing under the laws of its jurisdiction of incorporation, with full
corporate power and authority to conduct its business as it is now being
conducted, to own the properties and assets that it owns, and to perform all
its obligations under the Material API Contracts. API is duly qualified to do
business as a foreign corporation and is in good standing under the laws of
each state or other jurisdiction in which either the ownership or use of the
properties owned or used by it, or the nature of the activities conducted by
it, requires such qualification, or if API is not so qualified in any
jurisdiction, it can become so qualified without any Material Adverse Effect on
API.

 

(b)                                 Complete
and accurate copies of the Governing Documents of API, as currently in effect,
have been previously provided to Buyer.

 

(c)                                  API
has no Subsidiary and, except as disclosed in Schedule 4.1, does not own
any shares of capital stock or other securities of any other Person.

 

23

 

4.2                               ENFORCEABILITY;
AUTHORITY; NO CONFLICT

 

(a)                                  Except
as set forth in Schedule 4.2, neither the execution and delivery of this
Agreement nor the consummation or performance of any of the Contemplated
Transactions will, directly or indirectly (with or without notice or lapse of
time):

 

(i)                                     Breach
any provision of any of the Governing Documents of API;

 

(ii)                                  Breach
any Legal Requirement or any Order to which API may be subject;

 

(iii)                               contravene,
conflict with or result in a violation or breach of any of the terms or
requirements of, or give any Governmental Body the right to revoke, withdraw,
suspend, cancel, terminate or modify, any Governmental Authorization that is
held by API and is material to the business of API; or

 

(iv)                              Breach
any provision of, or give any Person the right to declare a default under, or
to accelerate the maturity or performance of, or payment under, or to cancel,
terminate or modify, any Material API Contract;

 

(b)                                 Except
as set forth in Schedule 4.2, API is not required to obtain any Consent
from any Person in connection with the consummation or performance of any of
the Contemplated Transactions.

 

4.3                               CAPITALIZATION

 

The authorized capital
stock of API consists of one thousand (1,000) shares of common stock, par value
$0.001 per share, of which ten (10) shares are issued and outstanding. APCL is
and on the Closing Date will be the record and beneficial owner of the API
Shares.  There are no Contracts that
would obligate Amarin, APCL or API to issue, sell or transfer any equity
securities or other securities of API. 
None of the API Shares was issued in violation of the Securities Act or
any other Legal Requirement.

 

4.4                               FINANCIAL
STATEMENTS

 

Amarin has delivered to
Buyer: (a) unaudited balance sheets of API as at December 31 in each of
the fiscal years 2000 through 2002, and the related unaudited statements of
income for each of the fiscal years then ended; and (b) an unaudited balance
sheet of API as at December 31, 2003, attached as Schedule 4.4 hereto
(“API’s Interim Balance Sheet”),
and the related unaudited statement of income for the fiscal year then
ended.  Such financial statements
accurately reflect in all material respects the financial condition and the
results of operations, changes in shareholders’ equity and cash flows of API as
at the respective dates of and for the periods referred to in such financial
statements, all in accordance with UK GAAP. 
The financial statements referred to in this Section 4.4 reflect
the consistent application of such accounting principles throughout the periods
involved.  The financial statements have
been prepared from and are in accordance with the accounting Records of
API.  Amarin has also delivered to Buyer
copies of all letters from Amarin’s auditors to API’s board of directors or the
audit committee thereof during the twelve (12) months preceding the execution
of this Agreement.

 

24

 

4.5                               BOOKS
AND RECORDS

 

The books of account and
other financial Records of API, all of which have been made available to Buyer,
are complete and correct in all material respects and represent actual, bona
fide transactions and have been maintained in accordance with sound business
practices, including the maintenance of an adequate system of internal
controls.  The minute books of API, all
of which have been made available to Buyer, contain accurate and complete
Records of all meetings held of, and corporate action taken by, the
shareholders, the board of directors and committees of the board of directors
of API, and no meeting of any such shareholders, board of directors or
committee has been held for which minutes have not been prepared or are not
contained in such minute books.

 

4.6                               TITLE
TO ASSETS; ENCUMBRANCES

 

Except for API’s Mill
Valley Facility, for which Amarin holds the leasehold estate, API (a) owns, or
holds a valid leasehold interest in, all of the tangible properties and assets
(whether real, personal, or mixed) that it uses in the conduct of its business,
and (b) owns or possesses licenses or other rights to use all intangible
properties that it uses in the conduct of its business, including all of the
properties and assets reflected in API’s Interim Balance Sheet (except for
assets sold since the date of API’s Interim Balance Sheet).  All material properties and assets reflected
in API’s Interim Balance Sheet are free and clear of all Encumbrances, except
for those reflected on API’s Interim Balance Sheet and those otherwise
specified in Schedule 4.6 (the “Permitted Encumbrances”).

 

4.7                               CONDITION
AND SUFFICIENCY OF ASSETS

 

Except as set forth in
Schedule 4.7, all of the material tangible assets owned or used by API in
the conduct of its business, including those assets reflected on API’s Interim
Balance Sheet, are structurally sound, are in good operating condition and
repair subject to ordinary wear and tear, and are adequate for the uses to
which they are being put.  None of such
assets is in need of maintenance or repairs except for ordinary, routine
maintenance and repairs that are not material in nature or cost.

 

4.8                               ACCOUNTS
RECEIVABLE

 

All Accounts Receivable
that are reflected on API’s Interim Balance Sheet or on the accounting Records
of API as of the Closing Date represent or will represent valid obligations
arising from sales actually made or services actually performed by API in the
Ordinary Course of Business. Except as set forth in Schedule 4.8, to
Amarin’s Knowledge, there is no contest, claim, defense or right of setoff,
other than returns, rebates, and chargebacks in the Ordinary Course of Business
of API, under any Contract with any account debtor of an Account Receivable
relating to the amount or validity of such Account Receivable.  Schedule 4.8 contains a complete and
accurate list of all Accounts Receivable as of the date of the Interim Balance
Sheet, which list sets forth the aging of each such Account Receivable.

 

25

 

4.9                               INVENTORY

 

Schedule 4.9
contains an accurate and complete list of API’s Inventory as of
December 31, 2003.  Taking into
account the reserves for inventory on the books of API, all items of API’s
Inventory set forth on Schedule 4.9 are of a quality and quantity usable
and, with respect to finished goods, saleable, in the Ordinary Course of
Business. API is not in possession of any inventory not owned by API, including
goods already sold.

 

4.10                        NO
UNDISCLOSED LIABILITIES

 

Except as set forth in
Schedule 4.10, API has no Knowledge of any Liabilities required to be
disclosed under UK GAAP except for Liabilities reflected or reserved against in
API’s Interim Balance Sheet and current liabilities incurred in the Ordinary
Course of Business since the date of API’s Interim Balance Sheet.

 

4.11                        TAXES

 

(a)                                  Tax Returns
Filed and Taxes Paid.  API
has filed or caused to be filed on a timely basis all Tax Returns and all
reports with respect to Taxes that are or were required to be filed pursuant to
applicable Legal Requirements.  All Tax
Returns and reports filed by API are true, correct and complete.  API has paid, or made provision for the
payment of, all Taxes that have or may have become due for all periods covered
by the Tax Returns or otherwise, or pursuant to any assessment received by API,
except such Taxes, if any, as are listed in Schedule 4.11 and are being
contested in good faith and as to which adequate reserves (determined in
accordance with UK GAAP) have been provided in API’s Interim Balance
Sheet.  Except as provided in
Schedule 4.11, API currently is not the beneficiary of any extension of
time within which to file any Tax Return. 
No claim has ever been made, nor does Amarin have Knowledge of any state
of facts which could result in a claim, that API is subject to taxation in that
jurisdiction, by any Governmental Body in a jurisdiction where API does not
file Tax Returns.  There are no
Encumbrances on any of API’s assets that arose in connection with any failure
(or alleged failure) to pay any Tax, and Amarin has no Knowledge of any basis
for assertion of any claims attributable to Taxes which, if adversely
determined, would result in any such Encumbrance.

 

(b)                                 Delivery of
Tax Returns and Information Regarding Audits and Potential Audits.
Amarin has delivered or made available to Buyer copies of, and
Schedule 4.11 contains a complete and accurate list of, all Tax Returns
filed by or on behalf of API since January 1, 1999.  Schedule 4.11 contains a complete and
accurate list of all Tax Returns of API that have been audited or are currently
under audit and accurately describes any deficiencies or other amounts that
were paid or are currently being contested. 
To the Knowledge of Amarin, no undisclosed deficiencies are expected to
be asserted with respect to any such audits. 
All deficiencies proposed as a result of such audits have been paid,
reserved against, settled or are being contested in good faith by appropriate
proceedings as described in Schedule 4.11. Amarin has delivered, or made
available to Buyer, copies of any examination reports, statements or
deficiencies or similar items with respect to such audits.  Except as provided in Schedule 4.11,
Amarin has no Knowledge of any reasonable basis pursuant to which any
Governmental Body may assert a claim or

 

26

 

assess any
additional taxes for any period for which Tax Returns have been filed.  There is no dispute or claim concerning any
Taxes of API either (i) claimed or raised by any Governmental Body in writing
or (ii) as to which Amarin has Knowledge. 
Except as described in Schedule 4.11, API has not given or been
requested to give waivers or extensions of any statute of limitations relating
to the payment of Taxes of API or for which API may be liable.

 

(c)                                  Proper
Accrual.  The charges,
accruals and reserves with respect to Taxes on the Records of API are adequate
(determined in accordance with UK GAAP) and are at least equal to API’s
liability for Taxes.  There exists no
proposed tax assessment or deficiency against API except as disclosed in API’s
Interim Balance Sheet or in Schedule 4.11.

 

(d)                                 Specific
Potential Tax Liabilities and Tax Situations.

 

(i)                                     Withholding.  All Taxes that API is or was required by
Legal Requirements to withhold, deduct or collect have been duly withheld,
deducted and collected and have been paid to the proper Governmental Body or
other Person.

 

(ii)                                  Tax Sharing
or Similar Agreements.  There
is no tax sharing agreement, tax allocation agreement, tax indemnity obligation
or similar written or unwritten agreement, arrangement, understanding or
practice with respect to Taxes (including any advance pricing agreement,
closing agreement or other arrangement relating to Taxes) that will require any
payment by API.

 

(iii)                               Consolidated
Group.  API (A) has not been
a member of an affiliated group within the meaning of Code Section 1504(a)
(or any similar group defined under a similar provision of state, local or
foreign law) and (B) has no liability for Taxes of any person (other than API
and its Subsidiaries) under Treas. Reg. sect. 1.1502-6 (or any similar
provision of state, local or foreign law), as a transferee or successor by
contract or otherwise.

 

(iv)                              Excessive
Employee Remuneration.  The
disallowance of a deduction under Code Section 162(m) for employee
remuneration will not apply to any amount paid or payable by API under any
contractual arrangement currently in effect.

 

(v)                                 Golden
Parachute Payments.  API has
not made any payments, is not obligated to make any payments, and is not a
party to any agreement that, under certain circumstances, could obligate it to
make any payments that will not be deductible under Code Section 280G.

 

(vi)                              FIRPTA.  API is not and has not been a “U.S. real
property holding corporation” (within the meaning of Code
Section 897(c)(2)) during the applicable period specified in Code
Section 897(c)(1)(A)(ii).

 

(vii)                           Other Taxes.  No sales or use tax will be payable by API
as a result of the transactions contemplated by this Agreement, and there will
be no documentary

 

27

 

stamp tax, or
other excise tax (or comparable tax imposed by a governmental entity) as a
result of the transactions contemplated by this Agreement.

 

(viii)                        S
Corporation Status.  API has
never been an “S Corporation” as defined in Code Section 1361(a).

 

(ix)                                Tax
Attributes.  API shall make
available to the Buyer upon request: 
(a) the basis of each asset of API; (b) the amount of any net
operating loss, net capital loss, unused investment tax credit or other tax
credit, unused foreign tax or tax credit, or excess charitable contribution;
and (c) with respect to the preceding clause (b) any limitations on use of
any such attributes other than by reason of the transactions contemplated by
this Agreement, in each case as at the date of API’s last federal Tax Return.

 

(x)                                   Partnerships.  API does not have any ownership interest in
any entity formed as a limited partnership or general partnership under the
applicable laws of any State.

 

4.12                        NO
MATERIAL ADVERSE CHANGE

 

Since January 1,
2003, except as set forth in Schedule 4.12 there has not been any material
adverse change in the business, operations, assets, results of operations or
condition (financial or other) of API, and no event has occurred or
circumstance exists that would reasonably be expected to result in such a
material adverse change; provided, however, that in no event shall
any of the following constitute a material adverse change in the business,
operations, assets, results of operations or condition of API: (i) any change
resulting from the announcement or pendency of any of the transactions
contemplated by this Agreement; (ii) any change resulting from compliance by
API or Amarin with the terms of, or the taking of any action contemplated or
permitted by, this Agreement; (iii) any change resulting from changes in
general economic conditions, the financial markets or the pharmaceuticals
industry generally including, without limitation, the entry of generic or other
competitors into the market; or (iv) any change related to the commencement of
war or other hostilities, acts of terrorism, or any national or international
calamity affecting the United States.

 

4.13                        EMPLOYEE
BENEFITS

 

(a)                                  Set
forth in Schedule 4.13 is a complete and correct list of all “employee
benefit plans” as defined by Section 3(3) of ERISA, all specified fringe
benefit plans as defined in Section 6039D of the Code, and all other
bonus, incentive-compensation, deferred-compensation, profit-sharing,
stock-option, stock-appreciation-right, stock-bonus, stock-purchase,
employee-stock-ownership, savings, severance, change-in-control,
supplemental-unemployment, layoff, salary-continuation, retirement, pension,
health, life-insurance, disability, accident, group-insurance, vacation,
holiday, sick-leave, fringe-benefit or welfare plan, and any other employee
compensation or benefit plan, agreement, policy, practice, commitment, contract
or understanding (whether qualified or nonqualified, currently effective or
terminated, written or unwritten) and any trust, escrow or other

 

28

 

agreement related
thereto that (i) is maintained or contributed to by API or has been maintained
or contributed to in the last six (6) years by API, or with respect to which
API has or may have any liability, and (ii) provides benefits, or describes
policies or procedures applicable to any current or former director, officer,
employee or service provider of API, or the dependents of any thereof,
regardless of how (or whether) liabilities for the provision of benefits are
accrued or assets are acquired or dedicated with respect to the funding thereof
(each an “Employee
Plan” and, collectively,
the “Employee Plans”).  Schedule 4.13 identifies as such any
Employee Plan that is a plan intended to meet the requirements of
Section 401(a) of the Code.

 

(b)                                 API does not sponsor, participate in,
or contribute to any Employee Plan that is (x) a “Defined Benefit Plan” (as defined in
Section 414(l) of the Code);   (y) a “Multiemployer
Plan” (as defined in Section 3(37) of ERISA); or (z) a plan
subject to Title IV of ERISA, other than a Multiemployer Plan.

 

(c)                                  Amarin
has delivered to Buyer true, accurate and complete copies of (i) the documents
comprising each Employee Plan (or, with respect to any Employee Plan which is
unwritten, a detailed written description of eligibility, participation,
benefits, funding arrangements, assets and any other matters which relate to
the obligations of API); (ii) all trust agreements, insurance contracts or any
other funding instruments related to the Employee Plans; (iii) all rulings,
determination letters, no-action letters or advisory opinions from the IRS, the
U.S. Department of Labor, the Pension Benefit Guaranty Corporation (the “PBGC”) or any other
Governmental Body that pertain to each Employee Plan and any open requests
therefor; (iv) the most recent actuarial and financial reports (audited and/or
unaudited) and the annual reports filed with any Government Body with respect
to the Employee Plans during the current year and each of the three preceding
years; (v) all collective bargaining agreements pursuant to which contributions
to any Employee Plan(s) have been made or obligations incurred (including both
pension and welfare benefits) by API, and all collective bargaining agreements
pursuant to which contributions are being made or obligations are owed by such
entities; (vi) all securities registration statements filed with respect to any
Employee Plan; (vii) all contracts with third-party administrators, actuaries,
investment managers, consultants and other independent contractors that relate
to any Employee Plan, (viii) all summary plan descriptions, summaries of
material modifications and memoranda, employee handbooks and other written
communications regarding the Employee Plans.

 

(d)                                 Except
as disclosed in Schedule 4.13, full payment has been made of all amounts
that are required under the terms of each Employee Plan to be paid as
contributions with respect to all periods prior to and including the last day
of the most recent fiscal year of such Employee Plan ended on or before the
date of this Agreement and all periods thereafter prior to the Closing Date.  API has paid in full all required insurance
premiums, subject only to normal retrospective adjustments in the ordinary
course, with regard to the Employee Plans for all policy years or other
applicable policy periods ending on or before the Closing Date.

 

(e)                                  API
has, at all times, complied, and currently complies, in all material respects
with the applicable continuation requirements for its welfare benefit plans,
including (1) Section 4980B of the Code (as well as its predecessor
provision, Section 162(k) of the Code) and Sections 601 through 608,
inclusive, of ERISA, which provisions are hereinafter referred to collectively
as

 

29

 

“COBRA” and (2) any applicable state statutes
mandating health insurance continuation coverage for employees.

 

(f)                                    The
form of all Employee Plans is in compliance with the applicable terms of ERISA,
the Code, and any other applicable laws, including the Americans with
Disabilities Act of 1990, the Family Medical Leave Act of 1993 and the Health
Insurance Portability and Accountability Act of 1996, and such plans have been
operated in compliance with such laws and the written Employee Plan
documents.  Neither API nor any
fiduciary of an Employee Plan has violated the requirements of Section 404
of ERISA.  All required reports and
descriptions of the Employee Plans (including Internal Revenue Service Form
5500 Annual Reports, Summary Annual Reports and Summary Plan Descriptions and
Summaries of Material Modifications) have been (when required) timely filed
with the IRS, the U.S. Department of Labor or other Governmental Body and
distributed as required, and all notices required by ERISA or the Code or any
other Legal Requirement with respect to the Employee Plans have been appropriately
given.

 

(g)                                 Each
Employee Plan that is intended to be qualified under Section 401(a) of the
Code has received a favorable determination letter from the IRS, and Amarin has
no Knowledge of any circumstances that will or could result in revocation of
any such favorable determination letter. 
Each trust created under any Employee Plan has been determined to be
exempt from taxation under Section 501(a) of the Code, and API is not
aware of any circumstance that will or could result in a revocation of such exemption.  Each Employee Welfare Benefit Plan (as
defined in Section 3(1) of ERISA) that utilizes a funding vehicle
described in Section 501(c)(9) of the Code or is subject to the provisions
of Section 505 of the Code has been the subject of a notification by the
IRS that such funding vehicle qualifies for tax-exempt status under
Section 501(c)(9) of the Code or that the plan complies with
Section 505 of the Code, unless the IRS does not, as a matter of policy,
issue such notification with respect to the particular type of plan.  With respect to each Employee Plan, no event
has occurred or condition exists that will or could give rise to a loss of any
intended tax consequence or to any Tax under Section 511 of the Code.

 

(h)                                 There
is no material pending or threatened Proceeding relating to any Employee Plan,
nor is there any basis for any such Proceeding.  Neither API nor any fiduciary of an Employee Plan has engaged in
a transaction with respect to any Employee Plan that, assuming the taxable
period of such transaction expired as of the date hereof, could subject API or
Buyer to a Tax or penalty imposed by either Section 4975 of the Code or
Section 502(l) of ERISA or a violation of Section 406 of ERISA.  The Contemplated Transactions will not
result in the potential assessment of a Tax or penalty under Section 4975
of the Code or Section 502(l) of ERISA nor result in a violation of
Section 406 of ERISA.

 

(i)                                     API
has maintained workers’ compensation coverage as required by applicable state
law through purchase of insurance and not by self-insurance or otherwise except
as disclosed to Buyer on Schedule 4.13.

 

(j)                                     Except
as required by Legal Requirements, the consummation of the Contemplated
Transactions will not accelerate the time of vesting or the time of payment, or
increase the amount, of compensation due to any director, employee, officer,
former employee or former officer of API. 
There are no contracts or arrangements providing for payments that could
subject any person to liability for tax under Section 4999 of the Code.

 

30

 

(k)                                  Except
for the severance
plans and agreements set forth in Schedule 4.13 and
continuation coverage requirements of COBRA, API has no obligations or
potential liability for benefits to employees, former employees or their
respective dependents following termination of employment or retirement under
any of the Employee Plans that are Employee Welfare Benefit Plans.

 

(l)                                     None
of the Contemplated Transactions will result in an amendment, modification or
termination of any of the Employee Plans. 
No written or oral representations have been made to any employee or
former employee of API promising or guaranteeing any employer payment or
funding for the continuation of medical, dental, life or disability coverage
for any period of time beyond the end of the current plan year (except to the
extent of coverage required under COBRA). 
No written or oral representations have been made to any employee or
former employee of API concerning the employee benefits of Buyer.

 

(m)                               Each
Employee Welfare Benefit Plan which is a “group health plan” as defined in
Section 607(l) of ERISA has been operated in material compliance with Part
7 of Title I, Subtitle B of ERISA and sections 9801-9803, 9811, 9812 and
9831-9833 of the Code at all times.

 

(n)                                 Each
Employee Welfare Benefit Plan that is a “health plan” within the meaning of 45
C.F.R. Parts 160 and 164, but not a “small health plan” within the meaning of
45 C.F.R. Parts 160 and 164, is in compliance with the privacy requirements
described in the Regulations issued under sections 262 and 264 of the Health
Insurance Portability and Accountability Act of 1996.

 

(o)                                 API
has complied in all material respects with all aspects and requirements of the
Sarbanes-Oxley Act of 2002 and the Regulations promulgated pursuant thereto
applicable to any Employee Plans maintained by API.

 

4.14                        COMPLIANCE
WITH LEGAL REQUIREMENTS; GOVERNMENTAL AUTHORIZATIONS

 

(a)                                  Except
as set forth in Schedule 4.14:

 

(i)                                     API
is, and at all times since January 1, 2003, has been, in full compliance
with each Legal Requirement that is or was applicable to it or to the conduct
or operation of its business or the ownership or use of any of its assets;

 

(ii)                                  no
event has occurred or circumstance exists that (with or without notice or lapse
of time) would be reasonably likely to constitute or result in a violation by
API of, or a failure on the part of API to comply with, any Legal Requirement;
and

 

(iii)                               API
has not received, at any time since January 1, 2003, any notice or other
communication (whether oral or written) from any Governmental Body regarding
any actual, alleged, possible or potential violation of, or failure to comply
with, any Legal Requirement.

 

31

 

(b)                                 Schedule 4.14
contains a complete and accurate list of each Governmental Authorization that
is held by API.  Each Governmental
Authorization listed or required to be listed in Schedule 4.14 is valid
and in full force and effect.   Except
as set forth in Schedule 4.14:

 

(i)                                     API
is, and at all times since January 1, 2003, has been, in full compliance
with all of the terms and requirements of each Governmental Authorization
identified or required to be identified in Schedule 4.14;

 

(ii)                                  no
event has occurred or circumstance exists that would be reasonably likely (with
or without notice or lapse of time) to (A) constitute or result directly or
indirectly in a violation of or a failure to comply with any term or
requirement of any Governmental Authorization listed or required to be listed
in Schedule 4.14 or (B) result directly or indirectly in the revocation,
withdrawal, suspension, cancellation or termination of, or any modification to,
any Governmental Authorization listed or required to be listed in
Schedule 4.14;

 

(iii)                               API
has not received, at any time since January 1, 2003, any notice or other
communication (whether oral or written) from any Governmental Body or any other
Person regarding (A) any actual, alleged, possible or potential violation of or
failure to comply with any term or requirement of any Governmental
Authorization listed in Schedule 4.14 or (B) any actual, proposed,
possible or potential revocation, withdrawal, suspension, cancellation,
termination of or modification to any Governmental Authorization listed in
Schedule 4.14;  and

 

(iv)                              all
applications required to have been filed for the renewal of the Governmental
Authorizations listed or required to be listed in Schedule 4.14 ,other
than such Governmental Authorizations the non-renewal of which would not have a
Material Adverse Effect, have been duly filed on a timely basis with the
appropriate Governmental Bodies, and all other filings required to have been
made to maintain in full force and effect such Governmental Authorizations have
been duly made on a timely basis with the appropriate Governmental Bodies.

 

The Governmental
Authorizations listed in Schedule 4.14 collectively constitute all of the
Governmental Authorizations necessary to permit API to lawfully conduct and
operate its business substantially in the manner in which it currently conducts
and operates such business and to permit API to own and use its assets in the
manner in which it currently owns and uses such assets.

 

4.15                        LEGAL
PROCEEDINGS; ORDERS

 

(a)                                  Except
as set forth in Schedule 4.15, there is no pending or, to Amarin’s
Knowledge, threatened Proceeding

 

(i)                                     by
or against API or that relates to the business of, or any of the assets owned
or used by, API.

 

To the Knowledge of
Amarin, no event has occurred or circumstance exists that is reasonably likely
to give rise to or serve as a basis for the commencement of any such

 

32

 

Proceeding.  API has delivered to Buyer copies of all
pleadings, correspondence and other documents relating to each Proceeding
listed in Schedule 4.15.

 

(b)                                 Except
as set forth in 4.15:

 

(i)                                     there
is no Order to which API, its business or any of its assets is subject or that
would be reasonably expected to have the effect of prohibiting the consummation
of any of the Contemplated Transactions; or

 

(ii)                                  no
officer or director of API is subject to any Order that prohibits such officer
or director from engaging in or continuing any conduct, activity or practice
relating to the business of API.

 

4.16                        ABSENCE
OF CERTAIN CHANGES AND EVENTS

 

Except as set forth in
Schedules 4.16 and 4.17, from January 1, 2003 through December 31,
2003, API has conducted its business only in the Ordinary Course of Business,
and since January 1, 2003 there has not been any:

 

(a)                                  change
in API’s authorized or issued capital stock, grant of any stock option or right
to purchase shares of capital stock of API or issuance of any security
convertible into such capital stock;

 

(b)                                 amendment
to the Governing Documents of API;

 

(c)                                  payment
or increase (except in the Ordinary Course of Business) by API of any bonuses,
salaries or other compensation to any director, officer or employee or entry
into any employment, severance or similar Contract with any director, officer
or employee;

 

(d)                                 adoption
of, amendment to or material increase in the payments to or benefits under, any
Employee Plan;

 

(e)                                  damage
to or destruction or loss of any material asset, whether or not covered by
insurance;

 

(f)                                    entry
into, termination of or receipt of notice of termination of any material
license, distributorship, dealer, sales representative, joint venture, credit
or similar Contract to which API is a party and which is material to API;

 

(g)                                 sale
(other than sales of Inventories in the Ordinary Course of Business), lease or
other disposition of any material asset or property of API or the creation of
any Encumbrance on any material asset;

 

(h)                                 cancellation
or waiver of any material claims or rights with a value to API;

 

(i)                                     indication
by any customer or supplier of an intention to discontinue or materially
adversely change the terms of any material relationship with API;

 

33

 

(j)                                     material
change in the accounting methods used by API; or

 

(k)                                  contract
entered into by API to do any of the foregoing.

 

4.17                        MATERIAL
API CONTRACTS; NO DEFAULTS

 

(a)                                  Schedule 4.17
contains an accurate and complete list, and Amarin has delivered to Buyer
accurate and complete copies, of:

 

(i)                                     each
Contract that involves performance of services or delivery of goods or
materials by API of an amount or value in excess of Twenty-Five Thousand U.S.
Dollars (U.S. $25,000);

 

(ii)                                  each
Contract that involves performance of services or delivery of goods or
materials to API of an amount or value in excess of Twenty-Five Thousand U.S.
Dollars (U.S. $25,000);

 

(iii)                               each
Contract that involves expenditures or receipts by API in excess of Twenty-Five
Thousand U.S. Dollars (U.S. $25,000);

 

(iv)                              each
Contract with API that affects the ownership of, leasing of, title to, use of
or any leasehold or other interest in any real or personal property (except
personal property leases and installment and conditional sales agreements
having a value per item or aggregate payments of less than Twenty-Five Thousand
U.S. Dollars (U.S. $25,000) and with a term of less than one year);

 

(v)                                 each
Contract between API and any labor union or other employee representative of a
group of employees relating to wages, hours and other conditions of employment;

 

(vi)                              each
Contract (however named) involving a sharing of profits, losses, costs or
liabilities by API with any other Person;

 

(vii)                           each
Contract containing covenants that in any material respect purport to restrict
API’s business activity or limit the freedom of API to engage in any line of
business or to compete with any Person;

 

(viii)                        each
Contract with API that provides for payments to or by any Person in excess of
$25,000 based on sales, purchases or profits, other than direct payments for
goods;

 

(ix)                                each
power of attorney of API that is currently effective and outstanding;

 

(x)                                   each
Contract that contains or provides for an express undertaking by API to be
responsible for consequential damages; provided that the failure to disclaim
consequential damages does not constitute such an express undertaking;

 

34

 

(xi)                                each
Contract with API involving capital expenditures in excess of Twenty-Five
Thousand U.S. Dollars (U.S. $25,000);

 

(xii)                             each
written warranty, guaranty and/or other similar undertaking with respect to
contractual performance that obligates, or would be reasonably expected to
obligate, API to make one or more payments which in the aggregate exceed
Twenty-Five Thousand U.S. Dollars (U.S. $25,000); and

 

(xiii)                          each
amendment, supplement and modification (whether oral or written) in respect of
any of the foregoing.

 

(b)                                 Except
as set forth in Schedule 4.17:

 

(i)                                     each
Material API Contract identified or required to be identified in
Schedule 4.17 is in full force and effect and is valid and enforceable in
accordance with its terms; and

 

(ii)                                  no
Material API Contract identified or required to be identified in
Schedule 4.17 provides for the acceleration of the benefits and
obligations thereunder, or the automatic or optional termination thereof, or
the payment of a penalty or other extraordinary payment thereunder, as a result
of the purchase of the API Shares by Buyer.

 

(c)                                  Except
as set forth in Schedule 4.17:

 

(i)                                     API
is in compliance with all applicable terms and requirements of each Material
API Contract;

 

(ii)                                  to
Amarin’s Knowledge, each other Person that has or had any obligation or
liability under any Material API Contract is in compliance with all applicable
terms and requirements of such Contract;

 

(iii)                               to
Amarin’s Knowledge, no event has occurred or circumstance exists that (with or
without notice or lapse of time) is reasonably likely to contravene, conflict
with or result in a Breach of, or give API or other Person the right to declare
a default under, or to accelerate the maturity or performance of, or payment
under, or to cancel, terminate or modify, any Material API Contract;

 

(iv)                              to
Amarin’s Knowledge, no event has occurred or circumstance exists under or by
virtue of any Material API Contract that (with or without notice or lapse of
time) would cause the creation of any Encumbrance affecting any of API’s
assets; and

 

(v)                                 API
has not given to or received from any other Person, at any time since
January 1, 2003, any notice or other communication (whether oral or
written) regarding any actual, alleged, possible or potential violation or
Breach of, or default under, any Material API Contract.

 

35

 

(d)                                 There
are no renegotiations of, attempts to renegotiate or outstanding rights to
renegotiate any material amounts paid or payable to API under current or
completed Material API Contracts with any Person having the express contractual
or statutory right to demand or require such renegotiation and no such Person has
made written demand for such renegotiation.

 

(e)                                  Each
Material API Contract relating to the sale, design, manufacture or provision of
products or services by API has been entered into without the commission of any
act alone or in concert with any other Person, or any consideration having been
paid or promised, that is in violation of any Legal Requirement.

 

4.18                        INSURANCE

 

(a)                                  Amarin
has delivered to Buyer:

 

(i)                                     accurate
and complete copies of all policies of insurance (and correspondence relating
to coverage thereunder) to which API is a party or under which API is or has
been covered at any time since January 1, 2003; and

 

(ii)                                  accurate
and complete copies of all pending applications by API for policies of
insurance.

 

(b)                                 Schedule 4.18
describes:

 

(i)                                     any
self-insurance arrangement by or affecting API, including any reserves
established thereunder, but excluding any deductibles set forth in the
insurance policies provided to Buyer; and

 

(ii)                                  all
obligations of API to provide insurance coverage to Third Parties on an
additional insured basis (for example, under Leases or service agreements) and
identifies the policy under which such coverage is provided.

 

(c)                                  Amarin
has provided to Buyer, for the current policy year and each of the two (2)
preceding policy years:

 

(i)                                     a
summary of the loss experience under each policy of insurance;

 

(ii)                                  a
statement describing each claim under a policy of insurance for an amount in
excess of Twenty-Five Thousand U.S. Dollars (U.S. $25,000), which sets forth:

 

(A)                              the
name of the claimant;

 

(B)                                a
description of the policy by insurer, type of insurance and period of coverage;
and

 

(C)                                the
amount and a brief description of the claim;

 

36

 

(iii)                               a
statement describing the loss experience for all claims that were self-insured,
including the number and aggregate cost of such claims.

 

(d)                                 Except
as set forth in Schedule 4.18:

 

(i)                                     all
policies of insurance to which API is a party or that provide coverage to API:

 

(A)                              are
valid, outstanding and enforceable;

 

(B)                                are
issued by an insurer that is financially sound and reputable;

 

(C)                                taken
together, provide adequate insurance coverage for API’s assets and operations
for all risks normally insured against by a Person carrying on the same business
or businesses as API in the same or a similar location for all risks to which
API is normally exposed; and

 

(D)                               are
sufficient for compliance with all Legal Requirements and Material API
Contracts;

 

(ii)                                  API
has not received (A) any refusal of coverage or any notice that a defense will
be afforded with reservation of rights or (B) any notice of cancellation or any
other indication that any policy of insurance is no longer in full force or
effect or that the issuer of any policy of insurance is not willing or able to
perform its obligations thereunder;

 

(iii)                               API
has paid all premiums due, and has otherwise performed all of its obligations,
under each policy of insurance to which it is a party or that provides coverage
to API; and

 

(iv)                              API
has given notice to the insurer of all claims that may be insured thereby.

 

4.19                        ENVIRONMENTAL
MATTERS

 

Except as disclosed in
Schedule 4.19:

 

(a)                                  API
is in compliance with, and is not in violation of or liable under, any
Environmental Law. API has not received any actual or threatened order, notice
or other communication from (i) any Governmental Body or private citizen acting
in the public interest or (ii) the current or prior owner or operator of any
API Facility, of any actual or potential violation or failure to comply with
any Environmental Law, or of any actual or threatened obligation to undertake
or bear the cost of any Environmental Liabilities with respect to any API
Facility or other property or asset (whether real, personal or mixed) in which
API has or had an interest, or with respect to any property or API Facility at
or to which Hazardous Materials were generated, manufactured, refined,
transferred, imported, used or processed by API or any other Person for whose
conduct it is or may be held responsible, or from which Hazardous Materials
have been transported, treated, stored, handled, transferred, disposed,
recycled or received.

 

37

 

(b)                                 There
are no pending or, to the Knowledge of Amarin, threatened claims, Encumbrances,
or other restrictions of any nature, resulting from any Environmental
Liabilities or arising under or pursuant to any Environmental Law with respect
to or affecting any API Facility or any other property or asset (whether real,
personal or mixed) in which API has or had an interest.

 

(c)                                  Amarin
does not have any Knowledge of, nor has API received, any citation, directive,
inquiry, notice, Order, summons, warning or other communication that relates to
Hazardous Activity, Hazardous Materials or any alleged, actual, or potential
violation or failure to comply with any Environmental Law, or of any alleged,
actual, or potential obligation to undertake or bear the cost of any
Environmental Liabilities with respect to any API Facility or property or asset
(whether real, personal or mixed) in which API has or had an interest, or with
respect to any property or API Facility to which Hazardous Materials generated,
manufactured, refined, transferred, imported, used or processed by API or any
other Person for whose conduct it is or may be held responsible, have been
transported, treated, stored, handled, transferred, disposed, recycled or
received.

 

(d)                                 API
does not have any Environmental Liabilities with respect to any API Facility
or, to the Knowledge of Amarin, with respect to any other property or asset
(whether real, personal or mixed) in which API (or any predecessor) has or had
an interest or at any property geologically or hydrologically adjoining any API
Facility or any such other property or asset.

 

(e)                                  To
the Knowledge of Amarin, there are no Hazardous Materials present on or in the
Environment at any API Facility or at any geologically or hydrologically
adjoining property, including any Hazardous Materials contained in barrels,
aboveground or underground storage tanks, landfills, land deposits, dumps,
equipment (whether movable or fixed) or other containers, either temporary or
permanent, and deposited or located in land, water, sumps, or any other part of
the API Facility or such adjoining property, or incorporated into any structure
therein or thereon. API has not permitted or conducted, and is not aware of,
any Hazardous Activity conducted with respect to any API Facility or any other
property or assets (whether real, personal or mixed) in which API has or had an
interest except in compliance with all applicable Environmental Laws.

 

(f)                                    To
the Knowledge of Amarin, there has been no Release or Threat of Release of any
Hazardous Materials at or from any API Facility or at any other location where any
Hazardous Materials were generated, manufactured, refined, transferred,
produced, imported, used, or processed from or by any API Facility, or from any
other property or asset (whether real, personal or mixed) in which API has or
had an interest, or to the Knowledge of Amarin any geologically or hydrologically adjoining
property, whether by API or any other Person.

 

(g)                                 Amarin
has not conducted or caused to be conducted any reports, studies, analyses,
tests, or monitoring pertaining to Hazardous Materials or Hazardous Activities
in, on, or under any API Facility, or concerning compliance, by API or any
other Person for whose conduct it is or may be held responsible, with
Environmental Laws.

 

38

 

4.20                        EMPLOYEES

 

(a)                                  Schedule 4.20
contains a complete and accurate list of the following information for each
employee of API, including each employee on leave of absence or layoff status:
name; job title; and date of hiring or engagement. Amarin has heretofore provided
to Buyer information relating to current compensation paid or payable to each
API employee, any change in compensation since January 1, 2003, and sick
and vacation leave that is accrued but unused for API employees.

 

(b)                                 No
retired employee or director of API, nor their dependents, is receiving or
scheduled to receive in the future any pension benefits; pension option
election; retiree medical insurance coverage; retiree life insurance coverage;
or other benefits.

 

(c)                                  Schedule 4.20
contains a complete and accurate list of the following information for each API
employee who has been terminated or laid off, or whose hours of work have been
reduced by more than fifty percent (50%) by API, since January 1, 2003:
(i) the date of such termination, layoff or reduction in hours; and (ii) the
reason for such termination, layoff or reduction in hours.

 

(d)                                 API
has not violated the Worker Adjustment and Retraining Notification Act or any
similar state or local Legal Requirement. 
During the ninety (90) day period prior to the date of this Agreement,
API has not terminated any employees.

 

(e)                                  As
of the Closing Date, Amarin represents that to its Knowledge, no employee of
API to be retained by API after Closing (as identified in writing to Amarin at
least 5 business days prior to Closing) is bound by any Contract that purports
to limit the ability of such employee to engage in or continue or perform any
conduct, activity, duties or practice relating to the business of API.

 

4.21                        LABOR
RELATIONS; COMPLIANCE

 

(a)                                  API
has complied in all respects with all Legal Requirements relating to employment
practices, terms and conditions of employment, equal employment opportunity,
nondiscrimination, immigration, wages, hours, benefits, collective bargaining,
the payment of social security and similar Taxes, and occupational safety and
health.  API is not liable for the
payment of any Taxes, fines, penalties, or other amounts, however designated,
for failure to comply with any of the foregoing Legal Requirements.

 

(b)                                 API
has not been, and is not now, a party to any collective bargaining agreement or
other labor contract; (ii) since January 1, 2003, there has not been,
there is not presently pending or existing, and to Amarin’s Knowledge there is
not threatened, any strike, slowdown, picketing, work stoppage or employee
grievance process involving API; (iii) to Amarin’s Knowledge no event has
occurred or circumstance exists that could reasonably be expected to provide
the basis for any work stoppage or other labor dispute; (iv) there is not
pending or, to Amarin’s Knowledge, threatened against or affecting API any
Proceeding relating to the alleged violation of any Legal Requirement
pertaining to labor relations or employment matters, including any charge or
complaint filed with the

 

39

 

National Labor
Relations Board or any comparable Governmental Body, and, to Amarin’s
Knowledge, there is no organizational activity or other labor dispute against
or affecting API or any API Facility; (v) no application or petition for an
election of or for certification of a collective bargaining agent is pending;
(vi) no labor grievance or arbitration Proceeding exists that might have
Material Adverse Effect upon API or the conduct of its business; (vii) there is
no lockout of any employees by API, and no such action is contemplated by API;
and (viii) to Amarin’s Knowledge there has been no charge of discrimination
filed against or threatened against API with the Equal Employment Opportunity
Commission or similar Governmental Body.

 

4.22                        INTELLECTUAL
PROPERTY ASSETS

 

(a)                                  The
term “API’s Intellectual
Property Assets” means the following intellectual property owned
by or licensed to API in which API has a proprietary interest:

 

(i)                                     All
assumed fictional business names, trade names, registered and unregistered
trademarks, service marks and applications (collectively, “API Marks”);

 

(ii)                                  all
know-how, trade secrets, confidential or proprietary information, customer
lists, Software, technical information, data, process technology, plans,
drawings and blue prints (collectively, “API Trade Secrets”).

 

Notwithstanding
anything contained herein to the contrary, API’s Intellectual Property Assets
shall not be deemed to include, and API disclaims any right, title or interest
in (i) the names “Amarin,” “Amarin Pharmaceuticals Inc.,” or any variation of
such names or (ii) any internet web sites and internet domain names currently
used by API or otherwise containing the names “Amarin,” “Amarinpharma,” “Amarin
Pharmaceuticals” or any variation of such names.

 

(b)                                 Schedule 4.22
contains a complete and accurate list and summary description, including any
royalties paid or received by API, and API has delivered to Buyer accurate and
complete copies, of all Material API Contracts relating to API’s Intellectual
Property Assets, except for any license implied by the sale of a product and
perpetual, paid-up licenses for commonly available Software programs under
which API is the licensee.  There are no
outstanding and, to Amarin’s Knowledge, no threatened disputes or disagreements
with respect to any such Material API Contract.

 

(c)                                  Except
as set forth in Schedule 4.22, API is the owner of all right, title and
interest in and to each of API’s Intellectual Property Assets, free and clear
of all Encumbrances, or has a valid license to use API’s Intellectual Property
Assets, and has the right to use without payment to a Third Party (except
payments to Governmental Authorities) all of API’s Intellectual Property
Assets, other than in respect of licenses listed in Schedule 4.22.

 

(d)                                 API
does not own, and otherwise does not have any proprietary interest in, (i) any
patents, patent applications, or inventions and discoveries that may be
patentable

 

40

 

(collectively, “Patents”) or (ii) any
registered or unregistered copyrights in either published works or unpublished
works (collectively, “Copyrights”).

 

(e)                                  (i)                                     Schedule 4.22
contains a complete and accurate list and summary description                       of all API Marks;

 

(ii)                                  Except
as set forth in Schedule 4.22, All API Marks that have been registered
with the United States Patent and Trademark Office, are validly and currently
so registered;

 

(iii)                               No
API Mark has been or is now involved in any opposition, invalidation or
cancellation Proceeding during Amarin’s ownership thereof and, to Amarin’s
Knowledge, no such action is threatened with respect to any of the API Marks;
and

 

(iv)                              To
Amarin’s Knowledge, there is no trademark or trademark application of any other
Person that is potentially interfering with the API Marks.

 

(f)                                    API
has taken all reasonable precautions to protect the secrecy, confidentiality
and value of all API Trade Secrets.

 

4.23                        CERTAIN
PAYMENTS

 

Since January 1,
2003, neither API nor any other person acting for or on behalf of API, has
directly or indirectly (a) made any contribution, gift, bribe, rebate, payoff,
influence payment, kick-back, or other payment to any Person, private or
public, regardless of form, whether in money, property, or services in
violation of any Legal Requirement, or (b) established or maintained any fund
or asset for such purpose that has not been recorded in the books and records
of API .

 

4.24                        RELATIONSHIPS
WITH AFFILIATES

 

No Affiliate of Amarin
other than Amarin, APCL and API has, or since January 1, 2003 has had, any
interest in any property (whether real, personal or mixed and whether tangible
or intangible) used in API’s business. 
Neither Amarin nor APCL nor any Affiliate of either of them owns, or
since January 1, 2003 has owned, of record or as a beneficial owner, a
material equity interest or any other material financial or profit interest in
any Person that has had business dealings or a material financial interest in
any transaction with API other than business dealings or transactions disclosed
in Schedule 4.24, each of which has been conducted in the Ordinary Course
of Business with API at substantially prevailing market prices and on
substantially prevailing market terms. 
Except as set forth in Schedule 4.24, neither Amarin nor APCL nor
any Affiliate of either of them is a party to any Material API Contract.

 

41

 

ARTICLE
5

REPRESENTATIONS AND WARRANTIES OF
BUYER

 

Buyer represents and warrants to Amarin as follows:

 

5.1                               ORGANIZATION AND GOOD
STANDING

 

Buyer is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware, with
full corporate power and authority to conduct its business as it is now
conducted.

 

5.2                               AUTHORITY; NO CONFLICT

 

(a)                                  This
Agreement constitutes the legal, valid and binding obligation of Buyer,
enforceable against Buyer in accordance with its terms.  Upon the execution and delivery by Buyer of
the Master Assignment and Assumption Agreement, and each other agreement to be
executed or delivered by Buyer at Closing (collectively, the “Buyer’s Closing Documents”),
each of the Buyer’s Closing Documents will constitute the legal, valid and
binding obligation of Buyer, enforceable against Buyer in accordance with its
respective terms.  Buyer has the
absolute and unrestricted right, power and authority to execute and deliver
this Agreement and the Buyer’s Closing Documents and to perform its obligations
under this Agreement and the Buyer’s Closing Documents, and such action has
been duly authorized by all necessary corporate action.

 

(b)                                 Neither
the execution and delivery of this Agreement by Buyer nor the consummation or
performance of any of the Contemplated Transactions by Buyer will give any
Person the right to prevent, delay or otherwise interfere with any of the
Contemplated Transactions pursuant to:

 

(i)                                     any
provision of Buyer’s Governing Documents;

 

(ii)                                  any
resolution adopted by the board of directors or the shareholders of Buyer;

 

(iii)                               any
Legal Requirement or Order to which Buyer may be subject; or

 

(iv)                              any
Contract to which Buyer is a party or by which Buyer may be bound.

 

(c)                                  Except
as set forth in Schedule 5.2, Buyer is not and will not be required to obtain
any Consent from any Person or Governmental Authority in connection with the
execution and delivery of this Agreement or the consummation or performance of
any of the Contemplated Transactions.

 

5.3                               CERTAIN
PROCEEDINGS

 

There is no pending Proceeding that has been commenced
against Buyer or any of its 

Affiliates that would be reasonably expected to prohibit any of the
Contemplated Transactions.  To Buyer’s
Knowledge, no such Proceeding has been threatened.

 

42

 

5.4                               BROKERS
OR FINDERS

 

Neither Buyer nor any of its Representatives have
incurred any obligation or liability, contingent or otherwise, for brokerage or
finders’ fees or agents’ commissions or other similar payment in connection
with the sale of the Acquired Assets or the Contemplated Transactions.

 

5.5                               INVESTMENT
REPRESENTATION

 

Buyer is acquiring the API Shares for investment only
for its own account and not with a view to, or for resale in connection with,
any distribution thereof in violation of the Securities Act.

 

ARTICLE
6

COVENANTS OF AMARIN PRIOR TO CLOSING

 

6.1                               ACCESS AND INVESTIGATION

 

Between the date of this Agreement and the Closing
Date, and upon reasonable advance notice received from Buyer, Amarin shall (a)
furnish Buyer and its representatives (collectively, the “Buyer’s Group”) with copies of all such
Contracts, Governmental Authorizations, books and Records and other existing
documents and data as Buyer may reasonably request relative to Amarin (but only
to the extent such documents and data relate to the Acquired Assets), APCL, API
and the Acquired Assets; (b) furnish the Buyer’s Group with such additional
financial, operating and other relevant data and information relating to the
Acquired Assets as Buyer may reasonably request; and (c) otherwise cooperate
and assist, to the extent reasonably requested by Buyer, with Buyer’s
investigation of API and the Acquired Assets.

 

6.2                               CONDUCT OF AMARIN’S
BUSINESS

 

Between the date of this Agreement and the Closing,
Amarin and APCL covenant that they will not, without the prior written consent
of Buyer, (i) enter into or amend any material agreement with respect to the
Acquired Assets, provided that Amarin shall not be restricted in any manner
from amending any of its agreements with Elan Corporation plc or its Affiliates
other than the Elan/Amarin Option Agreement, (ii)  amend or change in
any material respect its distribution practices or terms with respect to any of
the Amarin Products, (iii) cause or effect any increase outside the
Ordinary Course of Business in API’s Inventory at the wholesale, chain,
institutional or retail levels, or (v) enter into or amend any Contract
which would effect any of the foregoing matters.

 

6.3                               OPERATION OF API’S
BUSINESS

 

Between the date of this Agreement and the Closing,
Amarin shall:

 

(a)                                  conduct
API’s business consistent with the manner in which the business has been
operated since January 1, 2004, subject to adjustments reasonably related to
changes in business and/or market conditions;

 

43

 

(b)                                 except
as otherwise consented to by Buyer in writing (which consent shall not be
unreasonably withheld or delayed), and without making any commitment on Buyer’s
behalf, use its Best Efforts to preserve intact API’s current business
organization, keep available the services of its officers, employees and agents
and maintain its relations and good will with suppliers, customers, landlords,
creditors, employees, agents and others having business relationships with it;

 

(c)                                  confer
with Buyer prior to implementing operational decisions of a material nature
relative to API’s business;

 

(d)                                 report
periodically to Buyer concerning the status of API’s business, operations and
finances, and discuss with Buyer any plans to sell Amarin Products to
wholesalers or other customers;

 

(e)                                  make
no material changes in API’s management personnel without prior consultation
with Buyer;

 

(f)                                    use
its Best efforts to maintain API’s assets in a state of repair and condition
that complies with Legal Requirements and is consistent with the requirements
and normal conduct of API’s business;

 

(g)                                 use
its Best Efforts to keep in full force and effect, without amendment, all
material rights relating to API’s business;

 

(h)                                 comply
with all Legal Requirements and contractual obligations applicable to the
operations of API’s business;

 

(i)                                     continue
in full force and effect the insurance coverage under the policies set forth in
Schedule 4.18 or substantially equivalent policies;

 

(j)                                     except
as required to comply with ERISA or to maintain qualification under Section
401(a) of the Code, not amend, modify or terminate any Employee Plan without
the express written consent of Buyer, and except as required under the
provisions of any Employee Plan, not make any contributions to or with respect
to any Employee Plan without the express written consent of Buyer, provided
that Amarin shall contribute or cause API to contribute that amount of cash to
each Employee Plan necessary to fully fund all of the benefit liabilities of
such Employee Plan on a plan-termination basis as of the Closing Date;

 

(k)                                  reasonably
cooperate with Buyer and assist Buyer in identifying the Governmental
Authorizations required by Buyer to operate the business of API from and after
the Closing Date and either transferring existing Governmental Authorizations
of API to Buyer, where permissible, or obtaining new Governmental
Authorizations for Buyer;

 

(l)                                     upon
reasonable request from time to time, execute and deliver all documents, make
all truthful oaths, testify in any Proceedings involving API and do all other
acts that may be

 

44

 

reasonably necessary or
desirable in the opinion of Buyer to consummate the Contemplated Transactions,
all without further consideration; and

 

(m)                               maintain
all books and Records of API relating to API’s business in the Ordinary Course
of Business.

 

6.4                               NEGATIVE
COVENANT

 

Except as otherwise expressly permitted herein or as
required under Legal Requirements, between the date of this Agreement and the
Closing Date, Amarin shall not, without the prior written Consent of Buyer, (a)
take any affirmative action, or fail to take any reasonable action within its
control, as a result of which any of the changes or events listed in Sections
3.6 or 4.16 would be likely to occur; (b) make any modification to any material
Contract or Governmental Authorization; (c) allow the levels of raw materials,
supplies or other materials included in API’s Inventory, other than the Permax®
inventory, to vary materially from the levels customarily maintained; or (d)
enter into any compromise or settlement of any litigation, proceeding or
governmental investigation relating to the Acquired Assets, the business of API
or the Assumed Liabilities.

 

6.5                               REQUIRED
APPROVALS

 

As promptly as practicable after the date of this
Agreement, Amarin shall make all remaining filings required by Legal
Requirements to be made by it in order to consummate the Contemplated
Transactions (including all remaining filings under the HSR Act, if any).  Amarin and APCL also shall cooperate with
Buyer and its Representatives with respect to all filings that Buyer elects to
make or, pursuant to Legal Requirements, shall be required to make in
connection with the Contemplated Transactions. 
Amarin and APCL also shall cooperate with Buyer and its Representatives
in obtaining all Material Consents (including taking all actions requested by
Buyer to cause early termination of the applicable waiting period under the HSR
Act); provided that neither Amarin nor API shall be required to dispose of or
make any change to its business, expend any material funds or incur any other
burden in order to comply with this Section 6.5.

 

6.6                               NOTIFICATION

 

Between the date of this Agreement and the Closing,
Amarin may from time to time supplement or amend the Disclosure Schedules if
Amarin becomes aware of any fact or condition that would cause or constitute a
Breach of any of Amarin’s representations and warranties made as of the date of
this Agreement, provided that either (i) such fact or condition arose or
occurred after the date on which this Agreement was executed and delivered by
the parties or (ii) Amarin first receives notification of such fact or
condition on or subsequent to the date on which this Agreement was executed and
delivered by the parties.  Should any
such fact or condition require any change to the Disclosure Schedules, Amarin
shall promptly deliver to Buyer a supplement to the Disclosure Schedules
specifying such change.  If the
matter(s) disclosed in a supplement to the Disclosure Schedules would not be
reasonably expected to have a Material Adverse Effect, then Buyer shall remain
obligated to close the Contemplated Transactions on the terms set out herein
and shall have no rights under Section 10.1 or Article 12 as a result of such
updated

 

45

 

disclosure. If any matter disclosed in a supplement to
the Disclosure Schedules would be reasonably expected to have a Material
Adverse Effect, then Buyer at its option may either (i) terminate this
Agreement, in which case such right of termination shall be Buyer’s sole remedy
relating to such disclosed matter or (ii) close the Contemplated Transactions
on the terms set out herein, in which case Buyer shall not be entitled to
exercise any rights under Section 10.1 or Article 12 as a result of such
updated disclosure.  During the period
between the date of this Agreement and the Closing, Amarin also shall promptly
notify Buyer of the occurrence of any Breach of any covenant of Amarin in this
ARTICLE 6 or of the occurrence of any event that would make the satisfaction of
the conditions in ARTICLE 8 impossible or unlikely.

 

6.7                               RESTRICTIONS ON
NEGOTIATIONS; BREAKUP FEES

 

(a)  Until such
time as this Agreement shall be terminated pursuant to Section 10.1, Amarin and
APCL shall not directly or indirectly take any action to solicit, initiate,
encourage or entertain any inquiries or proposals from, discuss or negotiate
with, or provide any nonpublic information to, any Person (other than Buyer)
relating to any transaction or arrangement involving Amarin, APCL, API or the
Acquired Assets, that would render the Contemplated Transactions incapable of
consummation (an “Alternative Transaction”), including any merger or
consolidation of Amarin or API, the transfer of any capital stock of API to a
third party by Amarin, the issuance by API to a third party of any capital
stock (or other securities convertible into capital stock of API), the sale of
all or substantially all of Amarin’s or API’s current business, or the sale or
other disposition of substantially all of the Acquired Assets. Amarin shall
notify Buyer of any such inquiry or proposal within twenty-four (24) hours of
receipt or awareness of the same by Amarin. 
Notwithstanding the foregoing, if a majority of the Board of Directors
of Amarin determines in good faith that (i) any proposal, inquiry or request is
reasonably likely to lead to an Alternative Transaction that would be
materially more favorable to the stockholders of Amarin than the terms of the
Contemplated Transactions hereunder (a “Superior Transaction”) and (ii) it
would otherwise constitute a breach of the directors’ fiduciary duties to
stockholders not to further consider such Superior Transaction, 

Amarin may furnish information with respect to Amarin and API to the Person
making such proposal, inquiry or request pursuant to a customary
confidentiality agreement, and may participate in discussions and negotiations
with the Person making such proposal, inquiry or request.  If Amarin elects to enter into the Superior Transaction and
fails to perform its obligation to sell the Acquired Assets and to take the
other actions required to be taken by it at the Closing, Buyer shall be
entitled to receive and recover as its sole remedy from Amarin, within five
business days after the termination of this Agreement, a fee in the amount of
Three Million Dollars ($3,000,000).

 

(b)  If for any
reason other than as specified in Section 10.1 below Buyer fails to perform its
obligation to purchase the Acquired Assets and to take the other actions
required to be taken by it at the Closing, Amarin shall be entitled to receive
and recover as its sole remedy from Buyer, within five Business Days after the
termination of this Agreement, a fee in the amount of Three Million Dollars
($3,000,000).

 

46

 

6.8                               BEST
EFFORTS

 

Amarin shall use its Best Efforts to cause the
conditions in ARTICLE 8 and Section 9.3 to be satisfied and to otherwise take,
or cause to be taken, all actions, and to do, or cause to be done and cooperate
with Buyer in order to do, all things necessary, proper or advisable to
consummate the Closing and the Contemplated Transactions as promptly as
practicable.

 

6.9                               PAYMENT OF API
LIABILITIES

 

Except as disclosed on Schedule 6.9, between the date
of this Agreement and the Closing Date Amarin shall cause API to pay or
otherwise satisfy its Liabilities in the Ordinary Course of Business, except
those being contested in good faith.

 

ARTICLE
7

COVENANTS OF BUYER PRIOR TO CLOSING

 

7.1                               REQUIRED
APPROVALS

 

As promptly as practicable after the date of this
Agreement, Buyer shall make all remaining filings required by Legal
Requirements to be made by it to consummate the Contemplated Transactions
(including all remaining filings under the HSR Act, if any).  Buyer also shall cooperate with Amarin (a)
with respect to all filings Amarin shall be required by Legal Requirements to
make and (b) in obtaining all Material Consents (including taking all actions
requested by Amarin to cause early termination of the applicable waiting period
under the HSR Act).

 

7.2                               BEST
EFFORTS

 

Buyer shall use its Best Efforts to cause the
conditions in ARTICLE 9 and Section 8.3 to be satisfied and to otherwise take,
or cause to be taken, all actions, and to do, or cause to be done and cooperate
with Sellers in order to do, all things necessary, proper or advisable to
consummate the Closing and the Contemplated Transactions as promptly as
practicable.

 

ARTICLE
8

CONDITIONS PRECEDENT TO BUYER’S
OBLIGATION TO CLOSE

 

Buyer’s obligation to purchase the Acquired Assets and
to take the other actions required to be taken by Buyer at the Closing is
subject to the satisfaction, at or prior to the Closing, of each of the
following conditions (any of which may be waived by Buyer, in whole or in
part):

 

8.1                               ACCURACY OF
REPRESENTATIONS

 

(a)                                  All
of Amarin’s representations and warranties in this Agreement (considered
collectively), and each of these representations and warranties (considered
individually), shall have been accurate in all material respects as of the date
of this Agreement, and shall be accurate in all material respects as of the
time of the Closing as if then made, without giving effect to any supplement to
the Disclosure Schedules.

 

47

 

(b)                                 Each
of the representations and warranties in Sections 4.2(a) and 4.4, and each of
the representations and warranties in this Agreement that contains an express
materiality qualification, shall have been accurate in all respects as of the
date of this Agreement, and shall be accurate in all respects as of the time of
the Closing as if then made, without giving effect to any supplement to the
Disclosure Schedules.

 

8.2                               AMARIN’S
PERFORMANCE

 

All of the covenants and obligations that Amarin is
required to perform or to comply with pursuant to this Agreement at or prior to
the Closing (considered collectively), and each of these covenants and
obligations (considered individually), shall have been duly performed and
complied with in all material respects.

 

8.3                               MATERIAL CONSENTS AND
APPROVALS

 

Each of the Material Consents identified in Schedules
3.2, 4.2, and 5.2 and each of the required approvals under Section 6.5 shall
have been obtained and shall be in full force and effect.

 

8.4                               EXERCISE OF ELAN OPTION

 

Amarin shall have timely and properly exercised its
option under Section 3 of the Elan/Amarin Option Agreement, and Amarin shall
have received and delivered to Buyer written confirmation from Elan as to (i)
Amarin’s timely and proper exercise of such option, and (ii) Amarin’s
having fully satisfied all other conditions precedent to the effective exercise
of the option.

 

8.5                               ELAN ASSIGNMENT
AGREEMENT

 

Unless otherwise waived in writing by Buyer, Amarin
shall have negotiated and executed, and delivered to Buyer a copy of, the
Assignment Agreement between Elan and Amarin (the “Elan Assignment Agreement”) referenced in
Section 3.1(b) of the Elan/Amarin Option Agreement.

 

8.6                               ADDITIONAL DOCUMENTS

 

Amarin shall have caused the documents and instruments
required by Section 2.6(a) and the following documents to be delivered (or
tendered subject only to Closing) to Buyer:

 

(a)                                  a
certificate of the secretary of Amarin certifying, as complete and accurate as
of the Closing, attached copies of the Governing Documents of API;

 

(b)                                 releases
of all Encumbrances on the Acquired Assets, other than Permitted Encumbrances;

 

(c)                                  certificates
dated as of a date not earlier than the fifth Business Day prior to the Closing
as to the good standing of API and, to the extent available, payment of all
applicable state Taxes by API, executed by the appropriate officials of the
State of Delaware and each

 

48

 

jurisdiction in which
Amarin is licensed or qualified to do business as a foreign corporation as
specified in Schedule 4.1(a); and

 

(d)                                 such
other documents as Buyer may reasonably request for the purpose of:

 

(i)                                     evidencing
the accuracy of any of Amarin’s representations and warranties;

 

(ii)                                  evidencing
the performance by Amarin of, or the compliance by Amarin with, any covenant or
obligation required to be performed or complied with by Amarin;

 

(iii)                               evidencing
the satisfaction of any condition referred to in this ARTICLE 8; or

 

(iv)                              otherwise
facilitating the consummation or performance of any of the Contemplated
Transactions.

 

8.7                               NO
PROCEEDINGS

 

Since the date of this Agreement, there shall not have
been commenced or threatened against Buyer any Proceeding that would be
reasonably likely to have the effect of prohibiting any of the Contemplated
Transactions.

 

ARTICLE
9

CONDITIONS PRECEDENT TO SELLERS’
OBLIGATIONS TO CLOSE

 

Amarin’s and APCL’s obligation to sell the Acquired
Assets and to take the other actions required to be taken by Amarin and APCL at
the Closing is subject to the satisfaction, at or prior to the Closing, of each
of the following conditions (any of which may be waived by Amarin in whole or
in part):

 

9.1                               ACCURACY OF
REPRESENTATIONS

 

All of Buyer’s representations and warranties in this
Agreement (considered collectively), and each of these representations and
warranties (considered individually), shall have been accurate in all material
respects as of the date of this Agreement and shall be accurate in all material
respects as of the time of the Closing as if then made.

 

9.2                               BUYER’S
PERFORMANCE

 

All of the covenants and obligations that Buyer is
required to perform or to comply with pursuant to this Agreement at or prior to
the Closing (considered collectively), and each of these covenants and
obligations (considered individually), shall have been performed and complied
with in all material respects.

 

9.3                               MATERIAL CONSENTS AND
APPROVALS

 

Each of the Material Consents identified in Schedule
5.2 and each of the required approvals under Section 7.1 shall have been
obtained and shall be in full force and effect.

 

49

 

9.4                               ADDITIONAL DOCUMENTS

 

Buyer shall have caused the documents and instruments
required by Section 2.6(c) to be delivered (or tendered subject only to
Closing) to Amarin, together with such other documents as Amarin may reasonably
request for the purpose of:

 

(i)                                     evidencing
the accuracy of any representation or warranty of Buyer;

 

(ii)                                  evidencing
the performance by Buyer of, or the compliance by Buyer with, any covenant or
obligation required to be performed or complied with by Buyer; or

 

(iii)                               evidencing
the satisfaction of any condition referred to in this ARTICLE 9.

 

9.5                               NO
PROCEEDING

 

Since the date of this Agreement, there shall not have
been commenced or threatened against Seller any Proceeding that would be
reasonably likely to have the effect of prohibiting any of the Contemplated
Transactions.

 

9.6                               DEED
OF TERMINATION

 

Amarin and API shall have entered into a Deed of
Termination substantially in the form agreed between Amarin and Buyer.

 

ARTICLE
10

TERMINATION

 

10.1                        TERMINATION
EVENTS

 

By notice given prior to or at the Closing, subject to
Section 10.2, this Agreement may be terminated as follows:

 

(a)                                  by
Buyer if a material Breach of any provision of this Agreement has been
committed by Amarin and such Breach has not been waived by Buyer;

 

(b)                                 by
Amarin if a material Breach of any provision of this Agreement has been
committed by Buyer and such Breach has not been waived by Amarin;

 

(c)                                  by
Buyer if any condition in ARTICLE 8 has not been satisfied as of the date
specified for Closing in Section 2.5 or if satisfaction of such a condition by
such date is or becomes impossible (other than through the failure of Buyer to
comply with its obligations under this Agreement), and Buyer has not waived
such condition on or before such date;

 

(d)                                 by
Amarin if any condition in ARTICLE 9 has not been satisfied as of the date
specified for Closing in Section 2.5 or if satisfaction of such a condition by
such date is or becomes impossible (other than through the failure of Amarin or
APCL to comply with their obligations under this Agreement), and Amarin has not
waived such condition on or before such date;

 

50

 

(e)                                  by
mutual consent of Buyer and Amarin;

 

(f)                                    by
Buyer if the Closing has not occurred on or before March 31, 2004, or such
later date as the parties may agree upon, unless Buyer is in material Breach of
this Agreement; or

 

(g)                                 by
Amarin if the Closing has not occurred on or before March 31, 2004, or such
later date as the parties may agree upon, unless Amarin is in material Breach
of this Agreement.

 

10.2                        EFFECT OF TERMINATION

 

EACH PARTY’S RIGHT
OF TERMINATION UNDER SECTION 10.1 IS IN ADDITION TO ANY OTHER RIGHTS IT MAY
HAVE UNDER THIS AGREEMENT OR OTHERWISE, AND THE EXERCISE OF SUCH RIGHT OF
TERMINATION WILL NOT BE AN ELECTION OF REMEDIES.  IF THIS AGREEMENT IS TERMINATED PURSUANT TO SECTION 10.1, ALL
OBLIGATIONS OF THE PARTIES UNDER THIS AGREEMENT WILL TERMINATE, EXCEPT THAT THE
OBLIGATIONS OF THE PARTIES IN THIS SECTION 10.2, ARTICLE 13, AND SECTION 14.1
WILL SURVIVE.

 

ARTICLE
11

ADDITIONAL COVENANTS

 

11.1                        PAYMENT OF TAXES RESULTING FROM
SALE OF ACQUIRED ASSETS

 

Seller shall pay in a timely manner all Taxes other
than VAT resulting from or payable in connection with the sale of the Acquired
Assets pursuant to this Agreement, regardless of the Person on whom such Taxes
are imposed by Legal Requirements. Buyer shall be responsible for paying all
VAT resulting from or payable in connection with the sale of the Acquired
Assets pursuant to this Agreement.

 

11.2                        REGULATORY
MATTERS

 

(a)                                  Regulatory
Responsibility for Zelapar, Permax® and the PCP Products.  From and after the Closing Date, the
following parties shall retain or assume, as the case may be, the regulatory
responsibilities under all applicable laws and regulations with respect to the
ownership, use, sale or distribution of Zelapar, Permax® and the PCP Products
in the Territory:

 

(i)                                     Zelapar.  Buyer and Amarin shall enter into the
Zelapar Development Agreement substantially in the form attached hereto as
Exhibit B at Closing.  Pursuant thereto,
effective as of the Closing Date, Amarin shall be responsible for the
implementation of the Zelapar R&D Studies as more particularly provided
therein.  Amarin shall pay up to a
maximum of Two Million Five Hundred Thousand U.S. Dollars
(U.S. $2,500,000) of actual out-of-pocket costs incurred by it in
connection with conducting the Zelapar R&D Studies, and Buyer shall be
responsible for paying all such costs incurred by Amarin in excess of
$2,500,000 all as more particularly prescribed in the Zelapar Development
Agreement.

 

51

 

(ii)                                  Permax®.  From and after the Closing Date, all
regulatory responsibilities relative to the ownership, use, sale and
distribution of Permax® in the Territory shall be discharged either by Eli
Lilly or Buyer, as the case may be, under the Eli Lilly/Amarin License
Agreement, or any successor agreement thereto.

 

(iii)                               PCP Products.  From and after the Closing Date, Buyer shall
assume all regulatory responsibilities with respect to the ownership, use, sale
and distribution of the PCP Products in the Territory.

 

(b)                                 Transfer of
Product Registrations.  As
soon as reasonably practicable following the Closing Date, Buyer shall file
with the FDA the NDA/ANDA Transfer Letter in order to effect the transfer of
the Product Registrations listed on Schedule 3.9 from Amarin to Buyer.  Amarin shall use reasonable effort and take
any and all actions otherwise reasonably required by the FDA or by any other
Governmental Body to effect the transfer of the Product Registrations from
Amarin to Buyer.

 

(c)                                  Communications
with Governmental Bodies. 
From and after the Closing Date, Amarin shall upon request provide Buyer
with copies of all correspondence between Amarin and the FDA or any other
Governmental Body relating to the Amarin Products in the Territory.

 

(d)                                 Governmental
Inquiries.  From and after
the Closing Date, Amarin shall advise Buyer in writing of any inquiries
received or other contact from the FDA or any other Governmental Body relative
to the Amarin Products including the manufacture, storage, handling, marketing,
selling, promotion or distribution of Zelapar, Permax® or the PCP
Products.  Amarin shall promptly furnish
to Buyer any report, correspondence, warning letter and other documents issued
by or provided to the FDA or any other Governmental Body in connection with any
such inquiries.

 

11.3                        REDUCTION OF INVENTORY

 

(a)  As promptly as reasonably practicable after
the execution and delivery of this Agreement, Amarin shall use Best Efforts to
enter into inventory repurchase agreements (the “Repurchase Agreements”) with
each of Quality King Health Care, Cardinal Distribution, Amerisource Bergen and
McKesson Drug Company (collectively, the “Key Wholesalers”) providing for the repurchase
by Amarin at its own cost of certain inventory held by such distributors.  The Repurchase Agreements shall be
reasonably acceptable to Buyer.  Under
the Repurchase Agreements, Amarin shall seek to repurchase the quantities of
inventory set forth in Schedule 11.3 hereto (the “Designated Inventory”) at the
prices indicated therein; provided, however, that in Amarin’s
sole discretion it may repurchase any portion of the Designated Inventory at
prices exceeding those set forth in Schedule 11.3, up to a maximum of 5% above
the scheduled prices. [].  To the extent
Amarin effects any repurchases at a price higher than that set forth in
Schedule 11.3, the quantity of Designated Inventory that Amarin shall seek to
repurchase from the relevant Key Wholesaler(s) (as set forth on Schedule 11.3)
will be proportionately reduced. Each of the Repurchase Agreements, and the
obligations thereunder of Amarin and the respective Key Wholesalers, shall be
subject to and conditioned upon the consummation of the Closing under this
Agreement (except to the extent any Repurchase Agreements are entered into

 

52

 

after the Closing as
contemplated in Section 11.3(b) below). 
The Repurchase Agreements shall provide that (i) Amarin’s obligation to
pay for repurchased inventory shall be subject to confirmation of the receipt
and authenticity of the applicable inventory to Amarin’s reasonable
satisfaction and (ii) Amarin shall use its Best Efforts to cause any or all
repurchased inventory to be destroyed. The Repurchase Agreements shall give
Amarin the option of using repurchasing agents or other third parties
reasonably acceptable to Buyer to perform any of Amarin’s obligations under
this Section 11.3.  Notwithstanding
anything herein to the contrary, in no event shall Amarin be required to pay
more than Eight Million Eight Hundred Thousand Dollars ($8,800,000) in
performing its obligations under this Section 11.3, which limitation shall
apply to all costs and expenses incurred by Amarin in effecting the repurchase
of Designated Inventory including the costs of repurchase and any
administrative fees, third party costs including fees and expenses of any
repurchasing agent, and costs of destroying repurchased inventory.

 

(b)  Amarin and
Buyer acknowledge and agree that the Closing hereunder shall not be contingent
on Amarin’s ability to enter into any Repurchase Agreements and the execution
of Repurchase Agreements shall not constitute a condition to the obligation of
either party to consummate the Closing. 
In the event that, within 30 Business Days after the execution and
delivery of this Agreement (i) any of the Key Wholesalers has not entered into
a Repurchase Agreement providing for the repurchase of Designated Inventory on
the terms contemplated herein or (ii) Amarin is otherwise unable to obtain
Repurchase Agreements for the repurchase of all or any portion of the
Designated Inventory within the price range specified herein, then the parties
shall proceed with the Closing (subject to the satisfaction of all applicable
conditions set forth in this Agreement), and for a period of 30 days after the
Closing Date Amarin shall continue to use its Best Efforts to enter into
Repurchase Agreements with respect to any Designated Inventory not then covered
by a Repurchase Agreement, provided that the maximum price payable by
Amarin as specified in Section 11.3(a) above shall be increased to ten percent
(10%) above the prices indicated on Schedule 11.3 (and the quantity of
Designated Inventory that Amarin shall seek to repurchase from the relevant Key
Wholesaler(s) will be proportionately reduced).  Upon the expiration of such 30-day period, this Section 11.3
shall automatically terminate and Amarin shall have no further obligations
whatsoever hereunder (other than its obligations under any Repurchase
Agreements then in effect), provided that within twenty (20) Business
Days thereafter Amarin shall pay to Buyer an amount equal to the difference
between (i) Eight Million Eight Hundred Thousand Dollars ($8,800,000) and (ii)
the aggregate amount of costs and expenses incurred by Amarin as of such date
in performing its obligations under this Section 11.3.

 

(c)  In
addition to the foregoing, within thirty (30) days of Closing, Amarin shall pay
a total of $1.2 million to certain of the Key Wholesalers to reduce or
eliminate the credit balances claimed to be due to such Key Wholesalers, as
shown on Schedule 4.8, provided that if Amarin does not pay the full
$1.2 million to the Key Wholesalers in accordance herewith wihin such thirty
(30) day period, then Amarin shall immediately pay the unexpended portion of
such $1.2 million to Buyer.

 

11.4                        REPORTS
AND RETURNS

 

(a)                                  After
the Closing, Amarin shall prepare and file on a timely basis all reports and
returns required by Legal Requirements relating to its ownership and use of the
Acquired Assets

 

53

 

through and including the
Closing Date and shall prepare the Tax Returns and computations of API for all
accounting periods, VAT prescribed accounting periods or other relevant periods
ending on or before the Closing Date. Amarin shall prepare such returns and
reports based on the normal and historical methods of accounting used to
calculate and prepare such information.

 

(b)                                 Amarin
or its duly authorized agents shall prepare all documentation and shall conduct
all matters (including correspondence) relating to the agreement of the Tax
Returns and computations of API for all accounting periods, VAT prescribed
accounting periods, or other relevant periods ending on or prior to the Closing
Date with the appropriate Tax Authority; provided, however, that any agreement
with a taxing authority relating to the foregoing shall be subject to approval
by Buyer if the results of such agreement could materially adversely impact or
affect the tax liability or tax attributes of API for any period after the
Closing Date.

 

(c)                                  Buyer
or its duly authorized agents shall prepare the Tax Returns and computations of
API for the accounting period, VAT prescribed accounting period, or other
relevant period after which Closing occurs. Buyer shall be responsible for
agreeing with the Tax Authority regarding such Tax Returns, but where the
matter to be agreed may affect Amarin’s liability under this Agreement Buyer
shall inform Amarin thereof prior to agreeing the same and shall take proper
notice of all reasonable representations which Amarin may make with respect
thereto.

 

(d)                                 Buyer
shall provide or procure to be provided to Amarin such access to books,
accounts and records (during normal business hours upon prior written notice)
and copies of all information, documents and evidence in its possession or in
the possession of its agents or API in respect of any accounting period or
prescribed accounting period of API ending on or before the Closing Date which
may reasonably be requested by Amarin for the purposes of this Section 11.4.

 

11.5                        ASSISTANCE IN PROCEEDINGS

 

Amarin and APCL will cooperate with Buyer and its
counsel in the contest or defense of, and make reasonably available their
personnel and provide any testimony and reasonable access to their books and
Records in connection with, any Proceeding involving or relating to (a) any
Contemplated Transaction or (b) any action, activity, circumstance, condition,
conduct, event, fact, failure to act, incident, occurrence, plan, practice,
situation, status or transaction on or before the Closing Date involving
Amarin, APCL, API or the Acquired Assets.

 

11.6                        NONCOMPETITION,
NONSOLICITATION AND NONDISPARAGEMENT

 

(a)                                  Noncompetition.  For a period of four (4) years after the
Closing Date, Amarin shall not, anywhere in the Territory, directly or
indirectly (including by or through any of its affiliates or Subsidiaries)
invest in, own, manage, operate, finance, control, advise, render services to
or guarantee the obligations of any Person engaged in or planning to become
engaged in any business that develops, manufactures, sells, or otherwise
distributes in the Territory any pharmaceutical products containing any of the
active pharmaceutical

 

54

 

ingredients contained in
any of the Amarin Products (a “Competing Business”); provided, however, that
Amarin may purchase or otherwise acquire up to (but not more than) five percent
(5%) of any class of the securities of any Person engaged in or planning to
become engaged in a Competing Business (but may not otherwise participate in
the activities of such Person) if such securities are listed on any national or
regional securities exchange or have been registered under Section 12(g) of the
Exchange Act.

 

(b)                                 Nonsolicitation.  For a period of three (3) years after the
Closing Date, Amarin, on the one hand, and Buyer and API on the other hand,
shall not, directly or indirectly:

 

(i)                                     Disparage
the other party by making an untrue statement intended to cause or induce any
customer, supplier, licensee, licensor, franchisee, employee, consultant or
other business relation of such party to cease doing business with such party,
to deal with any competitor of such party or in any way interfere with its
relationship with such party;

 

(ii)                                  Disparage
the other party by making an untrue statement intended to cause or induce any
customer, supplier, licensee, licensor, franchisee, employee, consultant or
other business relation of such party on the Closing Date or within the year
preceding the Closing Date to cease doing business with such party, to deal
with any competitor of such party or in any way interfere with its relationship
with such party; or

 

(iii)                               hire,
retain or attempt to hire or retain any employee of such party or in any way
interfere with the relationship between such party and any of its employees;
provided that the foregoing shall not restrict Amarin in any manner from hiring
or offering employment to any former employees of API who are note retained by
API or Buyer after the Closing..

 

(c)                                  Modification
of Covenant.  If a final
judgment of a court or tribunal of competent jurisdiction determines that any
term or provision contained in Sections 11.6(a) through (b) is invalid or
unenforceable, then the parties agree that the court or tribunal will have the
power to reduce the scope, duration or geographic area of the term or
provision, to delete specific words or phrases or to replace any invalid or
unenforceable term or provision with a term or provision that is valid and
enforceable and that comes closest to expressing the intention of the invalid
or unenforceable term or provision.  This
Section 11.6 will be enforceable as so modified after the expiration of the
time within which the judgment may be appealed.  This Section 11.6 is reasonable and necessary to protect and
preserve Buyer’s legitimate business interests and the value of the Acquired
Assets and to prevent any unfair advantage conferred on Amarin.

 

11.7                        CUSTOMER AND OTHER BUSINESS
RELATIONSHIPS

 

After the Closing, Amarin will reasonably cooperate
with Buyer in its efforts to continue and maintain for the benefit of Buyer
those business relationships of Amarin relative to the Acquired Assets that
existed prior to the Closing, including relationships with lessors,

 

55

 

employees,
regulatory authorities, licensors, customers, suppliers and others.  Amarin will refer to Buyer all inquiries
relating to such business.

 

11.8                        RETENTION OF AND ACCESS TO
RECORDS

 

After the Closing Date, Buyer shall retain for a
period consistent with Buyer’s record-retention policies and practices those
Records of Amarin delivered to Buyer. 
Buyer also shall provide Amarin and their Representatives reasonable
access thereto, during normal business hours and on reasonable prior written
notice, to enable them to prepare financial statements or tax returns or deal
with tax audits.

 

11.9                        FURTHER
ASSURANCES

 

Subject to the proviso in Section 7.1, the parties
shall cooperate reasonably with each other and with their respective
Representatives in connection with any steps required to be taken as part of
their respective obligations under this Agreement, and shall (a) furnish upon
request to each other such further information; (b) execute and deliver to each
other such other documents; and (c) do such other acts and things, all as the
other party may reasonably request for the purpose of carrying out the intent
of this Agreement and the Contemplated Transactions.

 

11.10                 CHANGE
OF API NAME

 

After a reasonable transition period following the
Closing, but in any event not later than 180 days after the Closing, Buyer
shall take all actions required to cause the name of API to be changed such
that it no longer contains the words “Amarin Pharmaceuticals,” “Amarin” or any
variation thereof.

 

11.11                 INVENTORY IDENTIFICATION AND PACKAGING

 

After Closing, Buyer and API shall be entitled to take
delivery of and distribute, sell or otherwise dispose of all Prepackaged
Products (as hereinafter defined) without being required to reidentify, remark
or otherwise repackage any of the Prepackaged Products to remove or obscure any
API or Amarin marks or identifying information.  For purposes hereof, “Prepackaged  Products” means collectively (i) all of API’s Inventory
as of Closing, (ii) any Amarin Products reacquired after Closing by API or
Buyer from wholesalers or other participants in the distribution network, and
(iii) any Amarin Products delivered to API or Buyer by the manufacturers after
Closing based on purchase orders submitted by API or Amarin prior to Closing.

 

11.12                 LEASES

 

(a)  Buyer
shall pay to Amarin the full amount of rent, additional rent and like amounts
payable by Amarin for the six-month period following the Closing under the
lease between Amarin and LB Strawberry LLC dated August 6, 2001 (as amended)
relating to the Mill Valley Facility (the “Mill Valley Lease”). Payment shall
be made on or prior to the dates on which Amarin’s monthly payment obligations
under the Mill Valley Lease come due. If Amarin is able

 

56

 

to sublease or assign the Mill
Valley Lease to a third party or terminate the Mill Valley Lease prior to the
expiration of such six-month period, Buyer’s payment obligations under this
Section 11.12(a) shall either (i) be reduced to the extent of the payments
actually received by Amarin from, or actually made on behalf of Amarin by, any
sub-lessee or assignee or (ii) terminate in the event the lease is terminated.

 

(b)  On or
before Closing, Amarin shall pay, or provide funds to API to pay, the full
amount of rent, additional rent and like amounts payable by API through the end
of the current lease term ending August, 2005 under the lease relating to the
New Jersey Facility (the “New Jersey Lease”). Payment shall be made on or prior
to the dates on which API’s monthly payment obligations under the New Jersey
Lease come due. If API is able to sublease or assign the New Jersey Lease to a
third party or terminate the New Jersey Lease prior to the expiration of the
term thereof, Amarin’s payment obligations under this Section 11.12(b) shall
either (i) be reduced to the extent of the payments actually received by API
from, or actually made on behalf of API by, any sub-lessee or assignee or (ii)
terminate in the event the lease is terminated.

 

11.13                 POST CLOSING ACCESS AND COOPERATION

 

For a period of three months after the Closing Date,
API shall give Amarin and its representatives, without cost to Amarin,
reasonable access during normal business hours to the employees retained by API
after the Closing, for the purpose of assisting and advising Amarin in
connection with its ongoing business. Similarly, during the same period of
time, Amarin shall upon request provide Buyer with such advice and consultation
as Buyer may reasonably request in connection with facilitating the transition
of API to Buyer.

 

11.14                 API
EMPLOYEES

 

Amarin shall pay directly, and indemnify Buyer under
Section 12.2 against any Third Party Claims related to, all API employee
bonuses relative to employment periods ending on or before the Closing Date.
API shall pay, and shall retain all Liabilities with respect to, employee
bonuses relative to employment periods after the Closing Date.

 

11.15                 SEVERANCE PAYMENTS

 

Buyer shall pay directly or cause API to pay, and
shall indemnify Amarin under Section 12.3 against, all severance obligations
due to the persons listed on Schedule 11.15 hereto. Buyer shall directly, or
cause API to, carry out any severance program strictly in accordance with any
applicable terms.

 

57

 

ARTICLE
12

INDEMNIFICATION; REMEDIES

 

12.1                        SURVIVAL

 

All representations, warranties, covenants and
obligations in this Agreement, the Disclosure Schedules, the supplements to the
Disclosure Schedules, the certificates delivered pursuant to Section 2.6 and
any other certificate or document delivered pursuant to this Agreement shall
survive the Closing and the consummation of the Contemplated Transactions,
subject to Section 12.6.  The right to
indemnification, reimbursement or other remedy based upon such representations,
warranties, covenants and obligations shall not be affected by any investigation
(including any environmental investigation or assessment) conducted with
respect to, or any Knowledge acquired (or capable of being acquired) at any
time, whether before or after the execution and delivery of this Agreement or
the Closing Date, with respect to the accuracy or inaccuracy of or compliance
with any such representation, warranty, covenant or obligation; provided,
however, that no party shall be entitled to indemnification under
this Article 12 with respect to the breach of a representation or warranty to
the extent such party had actual Knowledge that such representation or warranty
was not true and correct when made.

 

12.2                        INDEMNIFICATION AND
REIMBURSEMENT BY SELLERS

 

Amarin and APCL will each indemnify and hold harmless
Buyer, and its officers, directors, employees and Affiliates (collectively, the
“Buyer Indemnified Persons”),
and will reimburse the Buyer Indemnified Persons for any loss, liability,
claim, damage, expense (including costs of investigation and defense and
reasonable attorneys’ fees and expenses) whether or not involving a Third-Party
Claim (collectively, “Damages”), arising from or in connection with:

 

(a)                                  any
Breach of any representation or warranty made by Amarin or APCL in (i) this
Agreement, (ii) the Disclosure Schedules (other than the Pro Forma Balance
Sheet), (iii) the supplements to the Disclosure Schedules, (iv) the
certificates delivered pursuant to Section 2.6 (for this purpose, each such
certificate will be deemed to have stated that Amarin’s representations and warranties
in this Agreement fulfill the requirements of Section 8.1 as of the Closing
Date as if made on the Closing Date, (v) any transfer instrument, or (vi) any
other certificate, document, writing or instrument delivered by Amarin or APCL
pursuant to this Agreement except for the Zelapar Development Agreement, the
CRO Agreement (as defined in the Zelapar Development Agreement) and the
Repurchase Agreements (collectively, the “Excluded Agreements”), and subject to
the further limitation that none of items (ii) through (vi) above shall be
deemed to include the API Closing Balance Sheet;

 

(b)                                 any
Breach of any covenant or obligation of Amarin or APCL in this Agreement or in
any other certificate, document, writing or instrument delivered by Amarin or
APCL pursuant to this Agreement except for the Excluded Agreements;

 

58

 

(c)                                  any
Liability arising out of the ownership, operation, or use of the PCP Product
Assets or Amarin Product Rights prior to the Closing Date, other than the
Liabilities of API (described in Section 2.3(b) hereof) and the Assumed
Liabilities;

 

(d)                                 any
brokerage or finder’s fees or commissions or similar payments based upon any
agreement or understanding made, or alleged to have been made, by any Person
with Amarin or APCL (or any Person acting on their behalf) in connection with
any of the Contemplated Transactions;

 

(e)                                  any
noncompliance with any fraudulent transfer law in respect of the Contemplated
Transactions;

 

(f)                                    any
Employee Plan established or maintained by Amarin and only if the Damages are a direct
result of action or inaction by API that occurred prior to the Closing Date;
or

 

(g)                                 any
Breach of any covenant
or obligation of Amarin in any of the Excluded Agreements, but only to the extent
that such Breach is a result of the gross negligence or willful misconduct of
Amarin.

 

12.3                        INDEMNIFICATION AND
REIMBURSEMENT BY BUYER

 

Buyer will indemnify and hold harmless Amarin and its
officers, directors, employees and Affiliates (collectively, the “Seller Indemnified Persons”),
and will reimburse Amarin, for any Damages arising from or in connection with:

 

(a)                                  any
Breach of any representation or warranty made by Buyer in this Agreement or in
any certificate, document, writing or instrument delivered by Buyer pursuant to
this Agreement;

 

(b)                                 any
Breach of any covenant or obligation of Buyer in this Agreement or in any other
certificate, document, writing or instrument delivered by Buyer pursuant to
this Agreement;

 

(c)                                  any
claim by any Person for brokerage or finder’s fees or commissions or similar
payments based upon any agreement or understanding alleged to have been made by
such Person with Buyer (or any Person acting on Buyer’s behalf) in connection
with any of the Contemplated Transactions;

 

(d)                                 any
Assumed Liability;

 

(e)                                  any
severance payments, or severance payment obligations, to the persons listed on
Schedule 11.15 hereto; or

 

59

 

(f)                                    any
Liability arising out of the ownership, operation, or use of the Acquired
Assets after the Closing Date.

 

12.4                        LIMITATIONS ON AMOUNT—SELLERS

 

Sellers shall have no liability (for indemnification
or otherwise) with respect to claims under Section 12.2(a) until the total of
all Damages with respect to such matters exceeds Two Hundred Fifty Thousand
U.S. Dollars (U.S. $250,000). 
Thereafter, Sellers shall be liable for all Damages in excess of Two
Hundred Fifty Thousand U.S. Dollars (U.S. $250,000) of Damages.  However, this Section 12.4 will not apply to
claims under Section 12.2(b) through (g) or to matters arising in respect of
Sections 3.3, 4.6, 4.11, or 4.13 or to any Breach of any of Sellers’
representations and warranties of which either Seller had Knowledge at any time
prior to the date on which such representation and warranty is made or any
intentional Breach by either Seller of any covenant or obligation, and Sellers
will be liable for all Damages with respect to such Breaches.  Notwithstanding anything to the contrary in
this Agreement, the aggregate Liability of Sellers to the Buyer Indemnified
Parties for indemnification under this Article 12 shall be limited to Seven
Million U.S. Dollars (U.S. $7,000,000).

 

12.5                        LIMITATIONS ON AMOUNT—BUYER

 

Buyer will have no liability (for indemnification or
otherwise) with respect to claims under Section 12.3(a) until the total of all
Damages with respect to such matters exceeds Two Hundred Fifty Thousand U.S.
Dollars (U.S. $250,000). Thereafter, Buyer shall be liable for all Damages in
excess of Two Hundred Fifty Thousand_U.S. Dollars (U.S. $250,000) of Damages.
However, this Section 12.5 will not apply to claims under Section 12.3(b)
through (d) or to any Breach of any of Buyer’s representations and warranties
of which Buyer had Knowledge at any time prior to the date on which such
representation and warranty is made or any intentional Breach by Buyer of any
covenant or obligation, and Buyer will be liable for all Damages with respect
to such Breaches. Notwithstanding anything to the contrary in this Agreement, the
aggregate Liability of Buyer to the Seller Indemnified Parties for
indemnification under this Article 12 shall be limited to Seven Million U.S.
Dollars (U.S. $7,000,000).

 

12.6                        TIME
LIMITATIONS

 

(a)                                  If
the Closing occurs, Amarin and APCL will have no liability (for indemnification
or otherwise) with respect to any Breach of (i) a covenant or obligation to be
performed or complied with prior to the Closing Date or (ii) a representation
or warranty (other than those in Sections 3.3, 4.6, 4.11, 4.13, and 4.19, as to
which a claim may be made at any time prior to the expiration of the applicable
statute of limitations), unless on or before April 1, 2005 , Buyer notifies
Amarin of a claim specifying the factual basis of the claim in reasonable
detail to the extent then known by Buyer.

 

(b)                                 If
the Closing occurs, Buyer will have no liability (for indemnification or
otherwise) with respect to any Breach of (i) a covenant or obligation to be
performed or complied with prior to the Closing or (ii) a representation or
warranty, unless on or before April 1, 2005,

 

60

 

Amarin notifies Buyer of
a claim specifying the factual basis of the claim in reasonable detail to the
extent then known by Amarin.

 

12.7                        RIGHT
OF SETOFF

 

Buyer may set off against amounts otherwise payable to
Amarin hereunder, including but not limited to the amounts specified in
Sections 2.2(a)(ii) and 2.2(a)(iii), (i) any amount which is due and payable by
Amarin under the Zelapar Development Agreement or any Repurchase Agreement,
subject to any applicable cure periods set forth in such agreements and
excluding any such amounts that Amarin is contesting in good faith, provided
that if Buyer exercises its right of set off under this clause (i), the entire amount
withheld from Amarin shall be applied toward the payment of the amount then due
and payable by Amarin under the Development Agreement or Repurchase
Agreemet(s), as the case may be, and (ii) any amount to which Buyer may be
entitled under this ARTICLE 12 and which amount has been reduced to a final
non-appealable judgment.   Neither the
exercise of nor the failure to exercise such right of setoff will constitute an
election of remedies or limit Buyer in any manner in the enforcement of any
other remedies that may be available to it.

 

12.8                        THIRD-PARTY
CLAIMS

 

(a)                                  Promptly
after receipt by a Person entitled to indemnity under Section 12.2 or 12.3 (an
“Indemnified Person”)
of notice of the assertion of a Third-Party Claim against it, such Indemnified
Person shall give notice to the Person obligated to indemnify under such
Section (an “Indemnifying Person”)
of the assertion of such Third-Party Claim, provided that the failure to notify
the Indemnifying Person will not relieve the Indemnifying Person of any liability
that it may have to any Indemnified Person, except to the extent that the
Indemnifying Person demonstrates that the defense of such Third-Party Claim is
actually and materially prejudiced by the Indemnified Person’s failure to give
such notice.

 

(b)                                 If
an Indemnified Person gives notice to the Indemnifying Person pursuant to
Section 12.8(a) of the assertion of a Third-Party Claim, the Indemnifying
Person shall be entitled to participate in the defense of such Third-Party
Claim and, to the extent that it wishes (unless (i) the Indemnifying Person is
also a Person against whom the Third-Party Claim is made and in the opinion of
counsel to the Indemnified Person there is a reasonable likelihood of a
conflict of interest between the Indemnifying Person and the Indemnified Person
or (ii) the Indemnifying Person fails to provide reasonable assurance to the
Indemnified Person of its financial capacity to defend such Third-Party Claim
and provide indemnification with respect to such Third-Party Claim), to assume
the defense of such Third-Party Claim with counsel reasonably satisfactory to
the Indemnified Person.  After notice
from the Indemnifying Person to the Indemnified Person of its election to
assume the defense of such Third-Party Claim, the Indemnifying Person shall
not, so long as it diligently conducts such defense, be liable to the
Indemnified Person under this ARTICLE 12 for any fees of other counsel or any
other expenses with respect to the defense of such Third-Party Claim, in each
case subsequently incurred by the Indemnified Person in connection with the
defense of such Third-Party Claim, other than reasonable costs of
investigation.  If the Indemnifying
Person assumes the defense of a Third-Party Claim, the Indemnifying Person
shall have full control of such defense and

 

61

 

proceedings, including
any compromise of settlement thereof, provided that no compromise or settlement
of such Third-Party Claims may be effected by the Indemnifying Person without
the Indemnified Person’s Consent, which shall not be unreasonably withheld or
delayed; provided further that the Indemnified Person’s Consent shall not be
required if (A) there is no finding or admission of any violation of Legal
Requirement or any violation of the rights of any Person; (B) the sole relief
provided is monetary damages that are paid in full by the Indemnifying Person;
and (C) the Indemnified Person shall have no liability with respect to any
compromise or settlement of such Third-Party Claims effected without its
Consent.  If requested by the
Indemnifying Person, the Indemnified Person agrees, at its own cost and
expense, to cooperate with the Indemnifying Person and its counsel in
contesting any Third Party Claim which the Indemnifying Person elects to
contest, including the making of any related counterclaim against the Person
asserting the Third Party Claim or any cross complaint against any Person.  If notice is given to an Indemnifying Person
of the assertion of any Third-Party Claim and the Indemnifying Person does not,
within sixty (60) days after the Indemnified Person’s notice is given, give
notice to the Indemnified Person of its election to assume the defense of such
Third-Party Claim, the Indemnified Party shall have full control of such
defense and proceedings, including any compromise of settlement thereof,
provided that no compromise or settlement of such Third-Party Claims may be
effected by the Indemnified Party without the Indemnifying Person’s consent,
which shall not be unreasonably withheld or delayed.

 

(c)                                  Notwithstanding
the foregoing, if an Indemnified Person determines in good faith that there is
a reasonable probability that a Third-Party Claim may materially and adversely
affect it or its Affiliates other than as a result of monetary damages for
which it would be entitled to indemnification under this Agreement, the
Indemnified Person may, by notice to the Indemnifying Person, assume the
exclusive right to defend, compromise or settle such Third-Party Claim, but the
Indemnifying Person will not be bound by any determination of any Third-Party
Claim so defended for the purposes of this Agreement or any compromise or
settlement effected without its Consent (which may not be unreasonably
withheld).

 

(d)                                 With
respect to any Third-Party Claim subject to indemnification under this ARTICLE
12: (i) both the Indemnified Person and the Indemnifying Person, as the case
may be, shall keep the other Person fully informed of the status of such
Third-Party Claim and any related Proceedings at all stages thereof where such
Person is not represented by its own counsel, and (ii) the parties agree (each
at its own expense) to render to each other such assistance as they may
reasonably require of each other and to cooperate in good faith with each other
in order to ensure the proper and adequate defense of any Third-Party Claim.

 

(e)                                  With
respect to any Third-Party Claim subject to indemnification under this ARTICLE
12, the parties agree to cooperate in such a manner as to preserve in full (to
the extent possible) the confidentiality of all Confidential Information and
the attorney-client and work-product privileges.  In connection therewith, each party agrees that: (i) it will use
its Best Efforts, in respect of any Third-Party Claim in which it has assumed
or participated in the defense, to avoid production of Confidential Information
(consistent with

 

62

 

applicable law and rules
of procedure), and (ii) all communications between any party hereto and counsel
responsible for or participating in the defense of any Third-Party Claim shall,
to the extent possible, be made so as to preserve any applicable
attorney-client or work-product privilege.

 

12.9                        OTHER
CLAIMS

 

A claim for indemnification for any matter not
involving a Third-Party Claim may be asserted by notice to the party from whom
indemnification is sought and shall be paid promptly after such notice.

 

12.10                 INDEMNIFICATION IN CASE OF STRICT
LIABILITY OR INDEMNITEE NEGLIGENCE

 

THE INDEMNIFICATION PROVISIONS IN THIS ARTICLE 12
SHALL BE ENFORCEABLE REGARDLESS OF WHETHER THE LIABILITY IS BASED UPON PAST,
PRESENT OR FUTURE ACTS, CLAIMS OR LEGAL REQUIREMENTS (INCLUDING ANY PAST,
PRESENT OR FUTURE BULK SALES LAW, ENVIRONMENTAL LAW, FRAUDULENT TRANSFER ACT,
OCCUPATIONAL SAFETY AND HEALTH LAW OR PRODUCTS LIABILITY, SECURITIES OR OTHER
LEGAL REQUIREMENT) AND REGARDLESS OF WHETHER ANY PERSON (INCLUDING THE PERSON
FROM WHOM INDEMNIFICATION IS SOUGHT) ALLEGES OR PROVES THE SOLE OR CONCURRENT
STRICT LIABILITY IMPOSED UPON THE PERSON SEEKING INDEMNIFICATION.

 

ARTICLE
13

CONFIDENTIALITY

 

13.1                        DEFINITION OF CONFIDENTIAL
INFORMATION

 

(a)                                  As
used in this ARTICLE 13 the term “Confidential Information” includes any and all of the
following information of Amarin or Buyer that has been or may hereafter be
disclosed in any form, whether in writing, orally, electronically or otherwise,
or otherwise made available by observation, inspection or otherwise by either
party (Buyer on the one hand or Amarin on the other hand) or its
Representatives (collectively, a “Disclosing Party”) to the other party or its
Representatives (collectively, a “Receiving Party”):

 

(i)                                     all
information that is a trade secret under applicable trade secret or other law;

 

(ii)                                  all
information concerning product specifications, data, know-how, formulae,
compositions, processes, designs, sketches, photographs, graphs, drawings,
samples, inventions and ideas, past, current and planned research and
development, current and planned manufacturing or distribution methods and
processes, customer lists, current and anticipated customer requirements, price
lists, market studies, business plans, computer hardware, Software and computer
software and database technologies, systems, structures and architectures;

 

(iii)                               all
information concerning the business and affairs of the Disclosing Party (which
includes historical and current financial statements, financial projections and
budgets, tax returns and accountants’ materials, historical, current and
projected

 

63

 

sales, capital spending
budgets and plans, business plans, strategic plans, marketing and advertising
plans, publications, client and customer lists and files, contracts, the names
and backgrounds of key personnel and personnel training techniques and
materials, however documented), and all information of any nature obtained from
review of the Disclosing Party’s documents or property or discussions with the
Disclosing Party regardless of the form of the communication; and

 

(iv)                              all
notes, analyses, compilations, studies, summaries and other material prepared
by the Receiving Party to the extent containing or based, in whole or in part,
upon any information included in the foregoing.

 

(b)                                 Any
trade secrets of a Disclosing Party shall also be entitled to all of the
protections and benefits under applicable trade secret law and any other
applicable law.  If any information that
a Disclosing Party deems to be a trade secret is found by a court of competent
jurisdiction not to be a trade secret for purposes of this ARTICLE 13, such
information shall still be considered Confidential Information of that
Disclosing Party for purposes of this ARTICLE 13 to the extent included within
the definition.  In the case of trade
secrets, each of Buyer and Amarin hereby waives any requirement that the other
party submit proof of the economic value of any trade secret or post a bond or
other security.

 

13.2                        RESTRICTED USE OF CONFIDENTIAL
INFORMATION

 

(a)                                  Each
Receiving Party acknowledges the confidential and proprietary nature of the
Confidential Information of the Disclosing Party and agrees that such
Confidential Information (i) shall be kept confidential by the Receiving Party
using at least the same degree of care that the Receiving Party uses to protect
its own proprietary information; (ii) shall not be used for any reason or
purpose other than to evaluate and consummate the Contemplated Transactions;
and (iii) without limiting the foregoing, shall not be disclosed by the Receiving
Party to any Person, except in each case as otherwise expressly permitted by
the terms of this Agreement or with the prior written consent of an authorized
officer of Amarin with respect to Confidential Information of Amarin (each, a “Amarin Contact”) or
an authorized representative of Buyer with respect to Confidential Information
of Buyer (each, a “Buyer Contact”).  Each of Buyer and Amarin shall disclose the
Confidential Information of the other party only to its Representatives who
reasonably require such material for the purpose of evaluating the Contemplated
Transactions and are informed by Buyer or Amarin, as the case may be, of the
obligations of this ARTICLE 13 with respect to such information.  Each of Buyer, Amarin and Shareholders shall
(i) enforce the terms of this ARTICLE 13 as to its respective Representatives;
(ii) take such action to the extent necessary to cause its Representatives to
comply with the terms and conditions of this ARTICLE 13 and (iii) be
responsible and liable for any breach of the provisions of this ARTICLE 13 by
it or its Representatives.

 

64

 

(b)                                 From
and after the Closing, the provisions of Section 13.2(a) above shall not apply
to or restrict in any manner Buyer’s use of any Confidential Information of
Amarin relating to any of the Acquired Assets or the Assumed Liabilities.

 

13.3                        EXCEPTIONS

 

Section 13.2(a) does not apply to that part of the
Confidential Information of a Disclosing Party that a Receiving Party demonstrates
(a) was, is or becomes generally available to the public other than as a result
of a breach of this ARTICLE 13 or the Confidentiality Agreement by the
Receiving Party or its Representatives; (b) was or is developed by the
Receiving Party independently of and without reference to any Confidential
Information of the Disclosing Party; or (c) was, is or becomes available to the
Receiving Party on a nonconfidential basis from a Third Party not bound by a
confidentiality agreement or any legal, fiduciary or other obligation
restricting disclosure.

 

13.4                        LEGAL
PROCEEDINGS

 

If a Receiving Party becomes compelled in any
Proceeding or is requested by a Governmental Body having regulatory
jurisdiction over the Contemplated Transactions to make any disclosure that is
prohibited or otherwise constrained by this ARTICLE 13, that Receiving Party
shall provide the Disclosing Party with prompt notice of such compulsion or
request so that it may seek an appropriate protective order or other
appropriate remedy or waive compliance with the provisions of this ARTICLE
13.  In the absence of a protective
order or other remedy, the Receiving Party may disclose that portion (and only
that portion) of the Confidential Information of the Disclosing Party that,
based upon advice of the Receiving Party’s counsel, the Receiving Party is
legally compelled to disclose or that has been requested by such Governmental
Body; provided,
however, that the Receiving Party shall use reasonable efforts to
obtain reliable assurance that confidential treatment will be accorded by any
Person to whom any Confidential Information is so disclosed.  The provisions of this Section 13.4 do not
apply to any Proceedings between the parties to this Agreement.

 

13.5                        RETURN OR DESTRUCTION OF
CONFIDENTIAL INFORMATION

 

If this Agreement is terminated, each Receiving Party
shall (a) destroy all Confidential Information of the Disclosing Party prepared
or generated by the Receiving Party without retaining a copy of any such
material; (b) promptly deliver to the Disclosing Party all other Confidential
Information of the Disclosing Party, together with all copies thereof, in the
possession, custody or control of the Receiving Party or, alternatively, with
the written consent of a Amarin Contact or a Buyer Contact (whichever
represents the Disclosing Party) destroy all such Confidential Information; and
(c) certify all such destruction in writing to the Disclosing Party; provided,
however, that the Receiving Party may retain a list that contains
general descriptions of the information it has returned or destroyed to
facilitate the resolution of any controversies after the Disclosing Party’s
Confidential Information is returned.

 

65

 

13.6                        ATTORNEY-CLIENT PRIVILEGE

 

The Disclosing Party is not waiving, and will not be
deemed to have waived or diminished, any of its attorney work product
protections, attorney-client privileges or similar protections and privileges
as a result of disclosing its Confidential Information (including Confidential
Information related to pending or threatened litigation) to the Receiving
Party, regardless of whether the Disclosing Party has asserted, or is or may be
entitled to assert, such privileges and protections.  The parties (a) share a common legal and commercial interest in
all of the Disclosing Party’s Confidential Information that is subject to such
privileges and protections; (b) are or may become joint defendants in
Proceedings to which the Disclosing Party’s Confidential Information covered by
such protections and privileges relates; (c) intend that such privileges and
protections remain intact should either party become subject to any actual or
threatened Proceeding to which the Disclosing Party’s Confidential Information
covered by such protections and privileges relates; and (d) intend that after
the Closing the Receiving Party shall have the right to assert such protections
and privileges.  No Receiving Party
shall admit, claim or contend, in Proceedings involving either party or
otherwise, that any Disclosing Party waived any of its attorney work-product
protections, attorney-client privileges or similar protections and privileges
with respect to any information, documents or other material not disclosed to a
Receiving Party due to the Disclosing Party disclosing its Confidential
Information (including Confidential Information related to pending or
threatened litigation) to the Receiving Party.

 

ARTICLE
14

GENERAL PROVISIONS

 

14.1                        EXPENSES

 

Except as otherwise provided in this Agreement, each
party to this Agreement will bear its respective fees and expenses incurred in
connection with the preparation, negotiation, execution and performance of this
Agreement and the Contemplated Transactions, including all fees and expense of
its Representatives. Buyer will pay the HSR Act filing fee.  If this Agreement is terminated, the
obligation of each party to pay its own fees and expenses will be subject to
any rights of such party arising from a Breach of this Agreement by another
party.

 

14.2                        PUBLIC ANNOUNCEMENTS

 

Any public announcement, press release or similar
publicity with respect to this Agreement or the Contemplated Transactions will
be issued, if at all, at such time and in such manner as Buyer and Amarin
jointly determine.  Except with the prior
consent of Buyer or as permitted by this Agreement, neither Amarin, API nor any
of their Representatives shall disclose to any Person (a) the fact that any
Confidential Information of Amarin has been disclosed to Buyer or its
Representatives, that Buyer or its Representatives have inspected any portion
of the Confidential Information of Amarin, that any Confidential Information of
Buyer has been disclosed to Amarin, API or their Representatives or that
Amarin, API or their Representatives have inspected any portion of the
Confidential Information of Buyer or (b) any information about the Contemplated
Transactions, including the status of such discussions or negotiations, the
execution of any documents (including this Agreement) or any of the terms of the
Contemplated

 

66

 

Transactions or
the related documents (including this Agreement).  Amarin and Buyer will consult with each other concerning the
means by which Amarin’s and API’s employees, customers, suppliers and others
having dealings with Amarin and API will be informed of the Contemplated
Transactions, and Buyer will have the right to be present for and to
participate in or otherwise approve in advance any such communication.

 

14.3                        NOTICES

 

All notices, Consents, waivers and other
communications required or permitted by this Agreement shall be in writing and
shall be deemed given to a party when (a) delivered to the appropriate address
by hand or by recognized overnight courier service (costs prepaid); (b) sent by
facsimile or e-mail with confirmation of transmission by the transmitting
equipment; or (c) received or rejected by the addressee, if sent by certified
mail, return receipt requested, in each case to the following addresses,
facsimile numbers or e-mail addresses and marked to the attention of the person
(by name or title) designated below (or to such other address, facsimile
number, e-mail address or person as a party may designate by notice to the
other parties):

 

	
  Amarin and APCL:

  	
   

  	
  Amarin Corporation plc

  
	
   

  	
   

  	
  7 Curzon Street

  
	
   

  	
   

  	
  London W1J 5HG

  
	
   

  	
   

  	
  Attention: General Counsel

  
	
   

  	
   

  	
  Fax no.:

  
	
   

  	
   

  	
  E-mail address:

  
	
   

  	
   

  	
   

  
	
  with a copy to:

  	
   

  	
  Mr. Richard A.B. Stewart:

  
	
   

  	
   

  	
  7 Curzon Street

  
	
   

  	
   

  	
  London W1J 5HG

  
	
   

  	
   

  	
  Fax no.:

  
	
   

  	
   

  	
  E-mail address:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Buyer:

  	
   

  	
  Valeant Pharmaceuticals International

  
	
   

  	
   

  	
  3300 Hyland Avenue

  
	
   

  	
   

  	
  Costa Mesa, California 92626

  
	
   

  	
   

  	
  Attention: Mr. Wesley P. Wheeler

  
	
   

  	
   

  	
  Fax no.:

  
	
   

  	
   

  	
  E-mail address:

  
	
   

  	
   

  	
   

  
	
  with a copy to:

  	
   

  	
  Valeant Pharmaceuticals International

  
	
   

  	
   

  	
  3300 Hyland Avenue

  
	
   

  	
   

  	
  Costa Mesa, California 92626

  
	
   

  	
   

  	
  Attention: General Counsel

  
	
   

  	
   

  	
  Fax no.: 714/641-7274

  
	
   

  	
   

  	
  E-mail address:

  

 

67

 

14.4                        JURISDICTION; SERVICE OF
PROCESS

 

Any Proceeding arising out of or relating to this
Agreement or any Contemplated Transaction may be brought in the courts of the
State of California in Orange County, or, if it has or can acquire
jurisdiction, in the United States District Court for the Southern District of
California, and each of the parties irrevocably submits to the exclusive
jurisdiction of each such court in any such Proceeding, waives any objection it
may now or hereafter have to venue or to convenience of forum, agrees that all
claims in respect of the Proceeding shall be heard and determined only in any
such court and agrees not to bring any Proceeding arising out of or relating to
this Agreement or any Contemplated Transaction in any other court.  The parties agree that either or both of
them may file a copy of this paragraph with any court as written evidence of
the knowing, voluntary and bargained agreement between the parties irrevocably
to waive any objections to venue or to convenience of forum.  Process in any Proceeding referred to in the
first sentence of this Section may be served on any party anywhere in the world.

 

14.5                        WAIVER
OF JURY TRIAL

 

THE PARTIES HEREBY WAIVE ANY RIGHT TO TRIAL BY JURY IN
ANY PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OF THE
CONTEMPLATED TRANSACTIONS, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND
WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE.  THE PARTIES AGREE THAT ANY OF THEM MAY FILE A COPY OF THIS
PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND
BARGAINED-FOR AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE TRIAL BY JURY
AND THAT ANY PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT OR
ANY OF THE CONTEMPLATED TRANSACTIONS SHALL INSTEAD BE TRIED IN A COURT OF
COMPETENT JURISDICTION BY A JUDGE SITTING WITHOUT A JURY.

 

14.6                        ENFORCEMENT OF AGREEMENT

 

Amarin acknowledges and agrees that Buyer would be
irreparably damaged if any of the provisions of this Agreement are not
performed in accordance with their specific terms and that any Breach of this
Agreement by Amarin could not be adequately compensated in all cases by
monetary damages alone.  Accordingly, in
addition to any other right or remedy to which Buyer may be entitled, at law or
in equity, it shall be entitled to enforce any provision of this Agreement by a
decree of specific performance and to temporary, preliminary and permanent
injunctive relief to prevent Breaches or threatened Breaches of any of the
provisions of this Agreement, without posting any bond or other undertaking.

 

14.7                        WAIVER; REMEDIES CUMULATIVE

 

The rights and remedies of the parties to this
Agreement are cumulative and not alternative. 
Neither any failure nor any delay by any party in exercising any right,
power or privilege under this Agreement or any of the documents referred to in
this Agreement will operate as a waiver of such right, power or

 

68

 

privilege, and no
single or partial exercise of any such right, power or privilege will preclude
any other or further exercise of such right, power or privilege or the exercise
of any other right, power or privilege. 
To the maximum extent permitted by applicable law, (a) no claim or right
arising out of this Agreement or any of the documents referred to in this
Agreement can be discharged by one party, in whole or in part, by a waiver or
renunciation of the claim or right unless in writing signed by the other party;
(b) no waiver that may be given by a party will be applicable except in the
specific instance for which it is given; and (c) no notice to or demand on one
party will be deemed to be a waiver of any obligation of that party or of the
right of the party giving such notice or demand to take further action without
notice or demand as provided in this Agreement or the documents referred to in
this Agreement.

 

14.8                        ENTIRE AGREEMENT AND
MODIFICATION

 

This Agreement supersedes all prior agreements,
whether written or oral, between the parties with respect to its subject matter
(including any letter of intent and any confidentiality agreement between Buyer
and Amarin) and constitutes (along with the Disclosure Schedules, Exhibits and
other documents delivered pursuant to this Agreement) a complete and exclusive
statement of the terms of the agreement between the parties with respect to its
subject matter.  This Agreement may not
be amended, supplemented, or otherwise modified except by a written agreement
executed by the party to be charged with the amendment.

 

14.9                        DISCLOSURE SCHEDULES

 

Any disclosure under one Schedule of the Disclosure
Schedules shall be deemed disclosure under all Schedules of the Disclosure
Schedules and this Agreement. 
Disclosure of any matter in the Disclosure Schedules shall not
constitute an expression of a view that such matter is material or is required
to be disclosed pursuant to this Agreement.

 

14.10                 ASSIGNMENTS,
SUCCESSORS AND NO THIRD-PARTY RIGHTS

 

No party may assign any of its rights or delegate any
of its obligations under this Agreement without the prior written consent of
the other parties, except that Buyer may assign any of its rights and delegate
any of its obligations under this Agreement to any Subsidiary of Buyer.  Subject to the preceding sentence, this
Agreement will apply to, be binding in all respects upon and inure to the
benefit of the successors and permitted assigns of the parties.  Nothing expressed or referred to in this
Agreement will be construed to give any Person other than the parties to this
Agreement any legal or equitable right, remedy or claim under or with respect
to this Agreement or any provision of this Agreement, except such rights as
shall inure to a successor or permitted assignee pursuant to this Section
14.10.

 

14.11                 SEVERABILITY

 

If any provision of this Agreement is held invalid or
unenforceable by any court of competent jurisdiction, the other provisions of
this Agreement will remain in full force and effect.  Any provision of this Agreement held invalid or unenforceable
only in part or degree will remain in full force and effect to the extent not
held invalid or unenforceable.

 

69

 

14.12                 CONSTRUCTION

 

The headings of Articles and Sections in this
Agreement are provided for convenience only and will not affect its
construction or interpretation.  All
references to “Articles,” “Sections” and “Schedules” refer to the corresponding
Articles, Sections and Schedules of this Agreement and the Disclosure
Schedules.

 

14.13                 TIME
OF ESSENCE

 

With regard to all dates and time periods set forth or
referred to in this Agreement, time is of the essence.

 

14.14                 GOVERNING
LAW

 

This Agreement will be governed by and construed under
the laws of the State of California without regard to conflicts-of-laws
principles that would require the application of any other law.

 

14.15                 EXECUTION OF AGREEMENT

 

This Agreement may be executed in one or more
counterparts, each of which will be deemed to be an original copy of this
Agreement and all of which, when taken together, will be deemed to constitute
one and the same agreement.  The
exchange of copies of this Agreement and of signature pages by facsimile
transmission shall constitute effective execution and delivery of this
Agreement as to the parties and may be used in lieu of the original Agreement
for all purposes.  Signatures of the
parties transmitted by facsimile shall be deemed to be their original
signatures for all purposes.

 

70

 

IN WITNESS
WHEREOF, the parties have executed this Agreement as of the date first written
above.

 

	
   

  	
  SELLER:

  
	
   

  	
   

  
	
   

  	
  AMARIN CORPORATION PLC

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  BUYER:

  
	
   

  	
   

  
	
   

  	
  VALEANT PHARMACEUTICALS
  INTERNATIONAL

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  
										

 

71

 

EXHIBIT A

 

Purchase Price Allocation

 

	
  Amarin Products and Rights

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Zelapar Rights*

  	
   

  	
  $

  	
  16.0 million

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Permax® Rights

  	
   

  	
  $

  	
  18.4 million

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  PCP Products and Rights

  	
   

  	
  $

  	
  10.0 million

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  API Shares

  	
   

  	
  $

  	
  1.6 million

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  TOTAL

  	
   

  	
  $

  	
  46.0 million

  	
   

  

 

*     Reflects the allocation to
the Zelapar Rights of the payment in full of the deferred conditional payments
provided for under Section 2.3(a)(ii) and 2.2(a)(iii).

 

 

EXHIBIT B

 

Zelapar Development Agreement

 

 

SCHEDULES—Asset Purchase Agreement

CONFIDENTIAL

 

 

ASSET
PURCHASE AGREEMENT

 

 

VALEANT—AMARIN

 

 

SCHEDULES

 

 

ANY
CROSS-REFERENCES ARE FOR CONVENIENCE ONLY AND DO NOT AFFECT DISCLOSURE FOR ALL
PURPOSES IN A SINGLE SCHEDULE

 

1

 

SCHEDULE 2.7

 

API Pro Forma Closing Balance Sheet

 

Amarin Pharmaceuticals, Inc.

Balance Sheet

 

	
   

  	
   

  	
   

  	
   

  	
  Forecast

  	
   

  	
  NJ 

  	
   

  	
  Payroll
  tax

  	
   

  	
  Mill
  Valley

  	
   

  	
  Cash from

  	
   

  	
  Adjustsments

  Agency pre-closing

  	
   

  	
   

  	
   

  	
  Agency

  Jan + Feb 

  	
   

  	
   

  	
   

  	
  Write off

  	
   

  	
  2/29/2004

  	
   

  	
  Impact of
  Buy-

  	
   

  	
  Valeant
  fair

  	
   

  	
  After
  buy-back

  	
   

  
	
  Unaudited

  	
   

  	
  12/31/2003

  	
   

  	
  1/31/2004

  	
   

  	
  2/29/2004

  	
   

  	
  Lease

  	
   

  	
  w/off

  	
   

  	
  lease

  	
   

  	
  PLC

  	
   

  	
  Pre ‘03

  	
   

  	
  2003

  	
   

  	
  Bonus

  	
   

  	
  ‘04

  	
   

  	
  Paydown

  	
   

  	
  balance

  	
   

  	
  On closing

  	
   

  	
  Back

  	
   

  	
  value

  	
   

  	
  2/29/2004

  	
   

  
	
  ASSETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Current assets:

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Cash in Bank Chase

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Petty Cash

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Accounts Receivable

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Due from Elan

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Allowance For Doubtful Account

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Allowance For Chargebacks

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Allowance For Cash Discounts

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Provision for Sales Returns

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Inventory F/G

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Inventory R/M

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Inventory Sample

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Reserve for Inventory Loss

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Provision for Permax Returns

  	
   

  	
  [
   * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Prepayments

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Total current assets

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Fixed assets:

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Office Equipment

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Office Furnishings

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Lease Improvements

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Computer Software

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Tooling

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Less accumulated depreciation

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Other assets:

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Security Deposits

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LIABILITY AND SHAREHOLDER’S EQUITY

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Current liabilities:

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Accounts Payable

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Medicaid Rebates Payable

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  MHC Rebates Payable

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Accrued Expenses

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Accrued Payroll Taxes

  	
   

  	
  —

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Accrued Employee Benefits

  	
   

  	
  —

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  NJ Restructure

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Total current liabilities

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  NET CURRENT ASSETS

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Long term liabilities:

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Due to(from) Amarin PLC Intercompany

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Shareholder’s equity:

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Retained Earnings

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Profit (loss) for period

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Total shareholder’s equity

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

1

 

SCHEDULE 3.2

 

Enforceability; Authority; No Conflict

 

(b) 
None, provided any required consents of third parties are obtained (see
(c) below and Schedule 4.17).

 

(c) 
Consents— Eli Lilly, for the Eli Lilly/Amarin License Agreement (see
document; consent may not be required but will need to address any outstanding
items per Lilly letter of 1/30/04 and subsequent agreement in principle)

 

RP Scherer/Cardinal Health Inc., for the Scherer/Elan License Agreement

 

Elan, for the Scherer/Elan License Agreement, et al.

 

1

 

SCHEDULE 3.5

 

Material Seller Contracts

 

(a)                                  Eli
Lilly/Amarin License Agreement (Permax)

 

Scherer/Elan License Agreement (Zelapar)

 

Amended and Restated Asset Purchase Agreement between Elan
Pharmaceuticals, Inc. and Amarin Corporation, plc dated as of 9/29/99 (for PCP
Products)

 

Amended and Restated Option Agreement regarding Zelapar between Amarin
and Elan, dated August 4, 2003 as amended by the letter agreement dated 23rd
December 2003 and further amended on or about the Closing Date

 

Assignment and Assumption Agreement effective as of March 29,
2002, regarding Permax between Elan and Amarin, as amended by a Deed of
Variation dated 27 January 2003 and a Deed of Variation No. 2 dated 4
August 2003

 

Settlement Agreement among Amarin Corporation, plc, Eli Lilly and
Company and Ivax Pharmaceuticals, Inc. (for Permax patent litigation
settlement; see Schedule 3.11 below)

 

Office Lease dated as of August 6, 2001, as amended May 31, 2002,
between Bently Holdings, LLC, as successor to LB Strawberry LLC (Landlord), and
Amarin Corporation, plc (Tenant)

 

1

 

SCHEDULE 3.6

 

Absence of Certain Changes and Events

 

1.               During 2003, Amarin took steps to reduce
the buildup of inventory, an issue identified in its 20F filing for 2002, e.g.,
at pages 6-7 (Risk Factors), and pages 38-39 (—Revenue).  As a result, Amarin has reduced, throughout
the course of the year, the amount of discounts and incentives previously
offered to non-contract wholesale purchasers of Amarin products.  In early 2003, those special incentives,
which in 2002 ranged from [  *  ]% to a high of [  *  ]% off of WAC price,
were generally reduced to [  *  ]% off of WAC (not including the prompt
payment discount noted below).  By year
end 2003, even the reduced [  *  ]% discount was virtually eliminated with
respect to all Amarin products.  The
result has been to reduce sales, and therefore the amount of inventory of
Amarin Products in the wholesaler trade channel, although reduced and/or
seasonal demand and the impact of generic competition has in some cases
affected the total amount of inventory in the trade channel.  As noted, the foregoing excludes managed
care and government purchasing organizations having a written rebate,
chargeback or discount contract in place, where Amarin continues to honor
contract terms.  Amarin continues to
provide its standard prompt payment discount on [  *  ]%-net [  *  ]
terms.

 

2.               Also in 2003, Amarin took other steps to
improve its position relative to its trade risks.  For example, Amarin announced a change in its returns policy,
whereby Amarin reserves the right to replace expired product with fresh
product, rather than providing a credit to customers.  Amarin also announced that it reserves the right to replace any
such product (or, in the case of providing credit) at the customer’s actual
purchase price, rather than at full WAC. 
Not all of Amarin’s customers have agreed with those changes in policy,
and have asserted contrary policies of their own.  Negotiations are conducted ad hoc as needed to address variances
in policy between buyer and seller, with varying outcomes.

 

3.               In a further effort to gain greater
certainty over levels of Amarin Products in the trade channel, since
January 1, 2003, Amarin has not sold any product to Quality King, a
customer known as a secondary purchaser and reseller of pharmaceutical
products.

 

4.               During 2003, Amarin experienced an
out-of-stock situation for the better part of the year regarding Capital &
Codeine, due to a product recall issued by its manufacturer and the necessary
transition to a new supplier (see Schedule 3.11 below).  Back orders were cancelled and the product
was reintroduced in Q4’03.

 

5.               During 2003, Amarin experienced an
out-of-stock situation with respect to the 100 count bottle of Nolahist, due to
the manufacturer of the active pharmaceutical ingredient discontinuing that
manufacture.  The 24 count box of
Nolahist remains available.  Further
production of bulk active ingredient for future manufacture would depend on
scale-up and validation of the potential new manufacturer.  See Schedule 4.16, below.

 

6.               In 2003, Amarin took price increases on
the PCP Products effective in early 2003, in amounts that were in some cases
significant.  No further price increases
have been taken since then on the PCP Products.  In 2003, Amarin did not take a price increase on Permax in light
of the entry of generic competition and the potential impact on cost of goods
under the Eli Lilly/Amarin License Agreement.

 

7.               During 2003, following the introduction
of generic pergolide into the market, Amarin discontinued its indigent patient
assistance program.

 

1

 

SCHEDULE 3.7

 

Intellectual Property

 

(b)                       The
Ivax Settlement Agreement contains a sublicense of patent rights licensed to
Amarin by Eli Lilly under the Eli Lilly/Amarin License Agreement as a part of
settling patent litigation relating to the Ivax generic pergolide product. See
Schedule 3.11 below.

 

1

 

SCHEDULE 3.8

 

Legal Proceedings; Orders - Buyer

 

(a)(i)  As initially described
in Amarin’s 20F for 2002, e.g., at page 23 (P—ermax), certain claims have been
asserted alleging product liability or similar claims against Amarin and/or API
and other parties based on alleged valvular heart disease occurring in patients
taking Permax.  See Schedule 4.15
below for an update on the individual claims known to date.  In connection with all of the foregoing and
any additional VHD or other product liability matters pertaining to Permax,
Amarin would assert all available legal or factual defenses and
counterclaims.  In addition, under the
terms of the Eli Lilly/Amarin License Agreement, Amarin believes that it would
be entitled to indemnity or contribution from Lilly and/or Elan, depending on
the circumstances of each claim, and also would assert all available defenses,
including those available as the non-manufacturing distributor of the
product.  Amarin has previously agreed
in principle with Lilly that Lilly shall take the primary role in conducting
the defense of any VHD cases that may arise. 
Amarin and Lilly have discussed, and a first draft circulated, a Tolling
Agreement by which Amarin and Lilly would agree to hold in abeyance any claims
they may have against each other under relevant documents or principles,
pending the outcome of negotiations. 
Amarin has been represented in these discussions by separate outside
counsel, Gordon & Rees, of San Francisco. 
As a part of obtaining Lilly’s consent to the assignment of the Permax
license agreement, Amarin, Lilly and Valeant have agreed in principle on an
amendment to that agreement which provides for, among other things, an
apportionment between Lilly and Valeant of any costs associated with product
liability going forward.  While Amarin
believes that it has recourse to Elan, its assignor, and/or Lilly, the
manufacturer and holder of the NDA for the product, in connection with any
ultimate liability Amarin may have to one or more plaintiffs in these matters,
there can be no assurance that Amarin will be able to recoup all or any part of
any such liability.

 

(ii)  On April 1, 2001,
Amarin entered into a copromotion agreement with TEAMM Pharmaceuticals for the
copromotion by TEAMM of Motofen and Bontril. 
TEAMM’s obligations were never fulfilled and, over the course of the
second half of 2002, communications took place regarding the parties’
respective obligations, with each party alleging nonperformance by the other
and claiming certain amounts to be due from the other.  Those communications culminated in Amarin’s
notice of termination dated October 4, 2002, to TEAMM terminating the
agreement for good cause, effective on or about January 5, 2003.  The agreement contains provisions for
arbitration in the event of a dispute. 
No further communication has been received from TEAMM since that letter
was sent, well over one year ago.  While
it appears unlikely that TEAMM would now assert any claims associated with the
agreement, there can be no assurance that TEAMM would not do so, or that if
such claims would not be successful if asserted.

 

1

 

SCHEDULE 3.9

 

PRODUCT REGISTRATIONS

 

	
  Product

  	
   

  	
  Indication

  	
   

  	
  ANDA/NDA
  (held by

  Amarin unless indicated

  otherwise)

  	
   

  	
  Manufacturer

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril® SR

  	
   

  	
  Anti-obesity

  	
   

  	
  ANDA– [  *  ]

  	
   

  	
  [  *  ]

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril® PDM

  	
   

  	
  Anti-obesity

  	
   

  	
  ANDA

  	
   

  	
  [  *  ]

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin®

  	
   

  	
  Tension Headache

  	
   

  	
  ANDA

  	
   

  	
  [  *  ]

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin® Forte

  	
   

  	
  Tension Headache

  	
   

  	
  ANDA

  	
   

  	
  [  *  ]

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin® with Caffeine and
  Codeine

  	
   

  	
  Tension Headache

  	
   

  	
  ANDA

  	
   

  	
  [  *  ]

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen®

  	
   

  	
  Anti-diarrheal

  	
   

  	
  NDA

  	
   

  	
  [  *  ]

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  CapitalTM & Codeine

  	
   

  	
  Mild to moderate pain

  	
   

  	
  ANDA

  	
   

  	
  [  *  ]

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist®

  	
   

  	
  Allergy

  	
   

  	
  OTC

  	
   

  	
  [  *  ]

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  DISCONTINUED
  PRODUCTS

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet®

  	
   

  	
  Mild to moderate pain

  	
   

  	
  ANDA– [  * 
  ]

  	
   

  	
  (Discontinued – 2002)

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Salflex®

  	
   

  	
  Arthritic pain

  	
   

  	
  Pre-1962 product

  	
   

  	
  (Discontinued – 2001)

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Theo-XTM

  	
   

  	
  Asthma

  	
   

  	
  ANDA – [  * 
  ]

  	
   

  	
  (Discontinued – 1999)

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Amen®

  	
   

  	
  Secondary amenorrhea

  	
   

  	
  ANDA

  	
   

  	
  (Discontinued – 1998)

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  NolamineTM

  	
   

  	
  Nasal congestion

  	
   

  	
  Withdrawn

  	
   

  	
  (Discontinued2—2001)

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  PropagestTM

  	
   

  	
  Nasal congestion

  	
   

  	
  Withdrawn

  	
   

  	
  (Discontinued2—2001)

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  ExgestTM

  	
   

  	
  Nasal congestion

  	
   

  	
  Withdrawn

  	
   

  	
  (Discontinued2—2001)

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  SinulinTM

  	
   

  	
  Sinus congestion

  	
   

  	
  Withdrawn

  	
   

  	
  (Discontinued2—2001)

  

 

1

 

SCHEDULE 3.10

 

Brokers or Finders

 

SG Cowen

 

 

Madison Keats

 

1

 

SCHEDULE 4.1

 

Organization and Good Standing

 

(a)           API is incorporated in Delaware.  API is qualified to do business as a foreign
corporation in California.

 

1

 

SCHEDULE 4.2

 

Enforceability; Authority; No Conflict -
Seller

 

(b)                                                         Consents
to one or more of the Contemplated Transactions may be required from the
following:

 

a.               Elan Corporation, plc, holder of a first
security interest, floating charge and lien upon all or substantially all of
the assets of Amarin and API including the Product Rights, and grantor of
present option rights for Zelapar

 

b.              Scherer/Cardinal—Zelapar

 

c.               Eli Lilly and Company (Lilly)—Permax (in
Amarin’s view, outright consent not strictly required to assign under the
Contemplated Transactions; Lilly disagrees. 
In any event, an agreement in principle for the consent of Lilly to the
assignment has been reached, as described elsewhere in these Schedules.

 

d.              While consent to the Transactions is not
required, there are change of control provisions requiring notice and/or
treatment as a contract assignment, with consent to the particular contract or
a right of termination, in the following agreements to which API is a party:

 

i.                                          Caremark,
Inc.

 

ii.                                       New Jersey
office lease

 

iii.                                    Baker Hill/Inspired
Design

 

iv.                                   Product Liability
Insurance Policy

 

In addition, several of the government purchasing contracts at API
provide for automatic “assignment” of the agreement to the new owner in the
case of a change of control.  Copies of
all of these agreements have been provided to Buyer.

 

1

 

SCHEDULE 4.4

 

Amarin Interim Balance Sheet

 

Amarin
Pharmaceuticals, Inc.

Balance Sheet

As At
December 31, 2003 and 2002

 

Unaudited

 

	
   

  	
   

  	
  12/31/2003

  	
   

  	
  12/31/2002

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  ASSETS

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Current assets:

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Cash in Bank Chase

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Petty Cash

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Accounts Receivable

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Accounts Receivable Other

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Due from Elan

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Allowance For Doubtful Account

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Allowance For Chargebacks

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Allowance For Cash Discounts

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Provision for Sales Returns

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Inventory F/G

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Inventory R/M

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Inventory Sample

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Reserve for Inventory Loss

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Provision for Permax Returns

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Prepayments

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Total current assets

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Fixed assets:

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Office Equipment

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Office Furnishings

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Lease Improvements

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Computer Software

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Tooling

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Less accumulated depreciation

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Other assets:

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Security Deposits

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LIABILITY AND SHAREHOLDER’S EQUITY

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Current liabilities:

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Accounts Payable

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Medicaid Rebates Payable

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  MHC Rebates Payable

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Accrued Expenses

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Accrued Payroll Taxes

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Accrued Employee Benefits

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Accrued To Elan

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  A/P Clearing

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  NJ Restructure

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  PCC Write Off

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Total current liabilities

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Long term liabilities:

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Due to Amarin PLC Intercompany

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Shareholder’s equity:

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Retained Earnings

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Profit (loss) for period

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
  Total shareholder’s equity

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  *  ]

  	
   

  

 

1

 

SCHEDULE 4.6

 

Permitted Encumbrances

 

Elan Corporation, plc,  or
its affiliated entities (together, “Elan”) have a first priority security
interest, charge and encumbrance on the Purchased Assets (the “Elan Charge”)
which shall be released on or prior to the Closing Date.

 

The offices presently occupied by API and subleased from Amarin at Two
Belvedere Place, Suite 330, Mill Valley, California, are the subject of a lease
from Bently Holdings, LLC, as lessor, to Amarin, as lessee.

 

API previously occupied offices in Warren, New Jersey, at 25
Independence Boulevard.  API vacated
those offices in late 2002, following the closure of its NJ facility.  API remains obligated for the balance of
that lease term in favor of the landlord, Glenborough Fund VII, LLC.  While discussions regarding possible
subleases have occurred, there is no agreement to do so at this time.

 

API rents certain office machines in its Mill Valley location from IKON
Office Solutions, and remains subject to that rental agreement.

 

See Schedule 3.11 regarding the IVAX sublicense regarding Permax
patent rights.

 

Watson Pharmaceuticals Inc. has a floating charge over the Acquired
Assets ranking second in priority to the Elan Charge. Amarin has secured
insurance in Watson’s favor to augment Amarin’s position that the covenants in
the Watson agreement have been complied with.

 

API currently provides leased cars to its field personnel through a
fleet lease agreement with Wheels, Inc.

 

1

 

SCHEDULE 4.7

 

Condition and Sufficiency of Assets

 

Certain of Amarin’s leased cars may be at or beyond their normal
replacement mileage (typically, 60,000 miles).

 

1

 

SCHEDULE 4.8

 

Accounts Receivable

 

As reflected in API’s Interim Balance Sheet and the attached Schedule,
API has reserved certain amounts to reflect potential returns or other claims
potentially asserted by certain customers with respect to the accounts
receivable carried on the books of API.

 

1

 

SCH 4.8 Accounts Receivable

 

A/R Customer Balances

December 31,
2003

 

	
  Ref-ID

  	
   

  	
  Date

  	
   

  	
  Type

  	
   

  	
  Balance

  	
   

  	
  Current

  	
   

  	
  1-30

  	
   

  	
  31-60

  	
   

  	
  61-90

  	
   

  	
  91-120

  	
   

  	
  120+

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MAR001

  	
   

  	
   

  	
   

  	
  MARTEK
  PHARMACAL CO- AP

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MCK001

  	
   

  	
   

  	
   

  	
  MCKESSON
  DRUG CO

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  TRU001

  	
   

  	
   

  	
   

  	
  TRUXTON
  INCORPORATED

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  WAL002

  	
   

  	
   

  	
   

  	
  WALSH
  DOHMEN SOUTHEAST

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  KIN003

  	
   

  	
   

  	
   

  	
  KINRAY
  DRUG COMPANY

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  CEN001

  	
   

  	
   

  	
   

  	
  DROG
  CENTRAL

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  DRO001

  	
   

  	
   

  	
   

  	
  DROG
  BETANCES

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  SMI001

  	
   

  	
   

  	
   

  	
  SMITH
  DRUG COMPANY

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  HDS001

  	
   

  	
   

  	
   

  	
  H
  D SMITH WHOLESALE DRUG

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  NCM001

  	
   

  	
   

  	
   

  	
  NORTH
  CAROLINA MUTUAL WHOLESALE

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  AME009

  	
   

  	
   

  	
   

  	
  AMERISOURCEBERGEN
  CORP

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  CAR001

  	
   

  	
   

  	
   

  	
  CARDINAL
  DISTRIBUTION

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  MOR001

  	
   

  	
   

  	
   

  	
  MORRIS
  & DICKSON CO

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  WAL027

  	
   

  	
   

  	
   

  	
  WALGREEN
  CO

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  ROC001

  	
   

  	
   

  	
   

  	
  ROCHESTER
  DRUG

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  PRE001

  	
   

  	
   

  	
   

  	
  PRESCRIPTION
  SUPPLY INC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  FMC001

  	
   

  	
   

  	
   

  	
  FMC
  DISTRIBUTORS, INC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  MCQ001

  	
   

  	
   

  	
   

  	
  MCQUEARY
  BROTHERS DRUG

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  WAL011

  	
   

  	
   

  	
   

  	
  WALMART
  WHSE #01

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  CAB001

  	
   

  	
   

  	
   

  	
  DROGUERIA
  CABALLERO DEL CARIB

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  All Others

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

   

   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  TOTAL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
																												

 

Excludes Intercompany receivable with Amarin PLC

 

 

Accounts
Receivables

Customer
Balances

12/31/2003

 

	
   

  	
   

  	
  Our Books

  	
   

  	
  Customer’s
  Books

  	
   

  	
  Difference

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Cardinal

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  McKesson

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Amerisouce-Bergen

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  A/R
  Reserve 

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Cardinal
  

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  McKesson
  

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  AmeriSource
  Bergen 

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  General
  

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  AR
  Reserve: 

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

Note: We have ongoing discussions with cardinal
regarding several issues. We believe that they have priced returns of PCC
incorrectly.

Thye have taken credit on some [ 
*  ] units at full WAC
of $[  *  ] per unit, when
they paid $[  *  ] per unit.

There is no guarantee that we will receive a credit
for these amounts.

 

In
addition we have ongoing discussions with McKesson , Bergen and Cardinal regardin
deductions that they have taken which we do not recognize primarily relating to
partial returns and returns they sent to a third party for destruction.

Wehave no guarantee that we will get credit for all
or any of these amounts.

 

Accordingly we have provided for a reserve assuming
that we will agree to and settle the balances shown in their books of account.

 

 

SCHEDULE 4.9

 

Inventory

 

1

 

SCH
4.9a Inventory by product

 

Item Valuation by Item with Location Detail

 

For Fiscal Year/Period: 2003

 

	
  Period Ending:

  	
   

  	
  12/31/2003

  	
   

  	
  Closing

  units

  	
   

  	
  Closing

  $

  at 12-31-03

  	
   

  	
  Excess/reserve

  	
   

  	
  Net
  Inventory

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  RAWMAT

  	
   

  	
  I/C Raw Materials

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  BUTL00000

  	
   

  	
  Butalbital

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  West-Ward Pharmaceuticals

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  BUTL00000

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  DIFE00000

  	
   

  	
  Difenoxin

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  14

  	
   

  	
  Lannett Company

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  West-Ward Pharmaceuticals

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  30

  	
   

  	
  N/A

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  DIFE00000

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  INSR00000

  	
   

  	
  Phrenilin/Phrenilin Forte Outsert

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  3

  	
   

  	
  Tyco Healthcare/Mallinckrodt

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  INSR00000

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  INSR04616

  	
   

  	
  Capital & Codiene 16oz

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  15

  	
   

  	
  Hi-Tech Pharmacal Co. Inc.

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  INSR04616

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  INSR04700

  	
   

  	
  Bontril SR Insert

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  16

  	
   

  	
  Lark Fulfillment

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  25

  	
   

  	
  Pharmagistics

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  3

  	
   

  	
  Tyco Healthcare/Mallinckrodt

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  INSR04700

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  INSR04800

  	
   

  	
  Bontril PDM Insert

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  16

  	
   

  	
  Lark Fulfillment

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  3

  	
   

  	
  Tyco Healthcare/Mallinckrodt

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  INSR04800

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  INSR06100

  	
   

  	
  Phrenilin CC Insert

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  11

  	
   

  	
  West-Ward Pharmaceuticals

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  3

  	
   

  	
  Tyco Healthcare/Mallinckrodt

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  5

  	
   

  	
  Test Pak

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  INSR06100

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  INSR07400

  	
   

  	
  Motofen Insert

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  11

  	
   

  	
  West-Ward Pharmaceuticals

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  16

  	
   

  	
  Lark Fulfillment

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  INSR07400

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL04616

  	
   

  	
  Capital & Codiene 16oz

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  15

  	
   

  	
  Hi-Tech Pharmacal Co. Inc.

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL04616

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL04710

  	
   

  	
  Bontril SR 100 Label

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  3

  	
   

  	
  Tyco Healthcare/Mallinckrodt

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL04710

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL04790

  	
   

  	
  Bontril SR 1000 Label

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  3

  	
   

  	
  Tyco Healthcare/Mallinckrodt

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL04790

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL04810

  	
   

  	
  Bontril PDM 100 Label

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  3

  	
   

  	
  Tyco Healthcare/Mallinckrodt

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL04810

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL04890

  	
   

  	
  Bontril PDM 1000 Label

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  3

  	
   

  	
  Tyco Healthcare/Mallinckrodt

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL04890

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL05010

  	
   

  	
  Phrenilin 100 label

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  3

  	
   

  	
  Tyco Healthcare/Mallinckrodt

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  5

  	
   

  	
  Test Pak

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL05010

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL05050

  	
   

  	
  Phrenilin 500 label

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  3

  	
   

  	
  Tyco Healthcare/Mallinckrodt

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  5

  	
   

  	
  Test Pak

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL05050

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  

 

 

	
  LABL05210

  	
   

  	
  Nolahist 100 Label

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  3

  	
   

  	
  Tyco Healthcare/Mallinckrodt

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  5

  	
   

  	
  Test Pak

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL05210

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL05610

  	
   

  	
  Phrenilin Forte 100 Label

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  14

  	
   

  	
  Lannett Company

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  3

  	
   

  	
  Tyco Healthcare/Mallinckrodt

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL05610

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL05650

  	
   

  	
  Phrenilin Forte 500 Label

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  3

  	
   

  	
  Tyco Healthcare/Mallinckrodt

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL05650

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL06110

  	
   

  	
  Phrenilin CC Label

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  11

  	
   

  	
  West-Ward Pharmaceuticals

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL06110

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL07405

  	
   

  	
  Motofen 50 Label

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  11

  	
   

  	
  West-Ward Pharmaceuticals

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL07405

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL07410

  	
   

  	
  Motofen 100 Label

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  11

  	
   

  	
  West-Ward Pharmaceuticals

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  14

  	
   

  	
  Lannett Company

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  COM001

  	
   

  	
  Comar

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LABL07410

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  UNCA05210

  	
   

  	
  Nolahist 100 Unit Carton

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  11

  	
   

  	
  West-Ward Pharmaceuticals

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  UNCA05210

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  UNCA05224

  	
   

  	
  Nolahist 7x24 Unit Carton

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  11

  	
   

  	
  West-Ward Pharmaceuticals

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  5

  	
   

  	
  Test Pak

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  UNCA05224

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  RAWMAT

  	
   

  	
  I/C Raw Materials

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  SAMPLE

  	
   

  	
  I/C Sample Inventory

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  5907561503

  	
   

  	
  Permax 0.05mg 3x30 Sample

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  16

  	
   

  	
  Lark Fulfillment

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  5907561503

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  5907562503

  	
   

  	
  Sample Permax .25mg 2x30

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  16

  	
   

  	
  Lark Fulfillment

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  5907562503

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523404702

  	
   

  	
  Bontril SR Sample Folder/fg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  16

  	
   

  	
  Lark Fulfillment

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  30

  	
   

  	
  N/A

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523404702

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523404803

  	
   

  	
  Bontril PDM Sample Folder/fg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  16

  	
   

  	
  Lark Fulfillment

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523404803

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523405602

  	
   

  	
  Phrenilin Forte Sample Folder/fg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  16

  	
   

  	
  Lark Fulfillment

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523405602

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  SAMPLE

  	
   

  	
  I/C Sample Inventory

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  TRADE

  	
   

  	
  I/C - TRADE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  5907561530

  	
   

  	
  Permax .05mg 30

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  16

  	
   

  	
  Lark Fulfillment

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  5907561530

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  5907562510

  	
   

  	
  Permax .25mg 100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  16

  	
   

  	
  Lark Fulfillment

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  5907562510

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  5907563010

  	
   

  	
  Permax 1mg 100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  16

  	
   

  	
  Lark Fulfillment

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  5907563010

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  6523402510

  	
   

  	
  Permax .25mg 100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523402510

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523402610

  	
   

  	
  Permax 1mg 100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523402610

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523404616

  	
   

  	
  Capital and Codeine Suspension

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523404616

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523404710

  	
   

  	
  Bontril SR 100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523404710

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523404790

  	
   

  	
  Bontril SR 1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523404790

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523404810

  	
   

  	
  Bontril PDM 100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523404810

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523404890

  	
   

  	
  Bontril PDM 1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523404890

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523405010

  	
   

  	
  Phrenilin 100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523405010

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523405050

  	
   

  	
  Phrenilin 500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523405050

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523405210

  	
   

  	
  Nolahist 100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523405210

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  6523405224

  	
   

  	
  Nolahist 7x24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523405224

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523405610

  	
   

  	
  Phrenilin Forte 100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523405610

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523405650

  	
   

  	
  Phrenilin Forte 500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  6523405650

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523406110

  	
   

  	
  Phrenilin CC

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523406110

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523407405

  	
   

  	
  Motofen 50

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  16

  	
   

  	
  Lark Fulfillment

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523407405

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523407410

  	
   

  	
  Motofen 100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  16

  	
   

  	
  Lark Fulfillment

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  2

  	
   

  	
  UPS Logistics Group

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  6523407410

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  TRADE

  	
   

  	
  I/C - TRADE

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Other- general

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Other- 4,800 units of 1.00mg Permax on order

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Grand Total:

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  

 

Data from UniStockCard

 

 

Support for SCH 4.9 Inventory reserves

 

Reserve for Inventory Loss

G/L# 02-1350

 

	
  Difenoxin

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  *  ] gms at Lannet unverified.

  	
   

  
	
  Butalbital

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  *  ]% of inventory

  	
   

  
	
  PCC Inserts/Labels

  	
   

  	
  [  * 
  ]

  	
   

  	
  Inventory at Westward

  	
   

  
	
  Nolahist Inserts/cartons/labels

  	
   

  	
  [  * 
  ]

  	
   

  	
  Inventory at Testpak/Westward

  	
   

  
	
  Permax

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
  Permax samples at lark

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
  Legacy

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
  General Accrual

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  G/L Balance as of December 31,2003

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax:

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Samples:

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  .05mg

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
  .25mg

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
  Subtotal Samples

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Obsolete 59075 NDC Code:

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  .05mg

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
  1.0mg

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
  Subtotal Obsolete

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Potentially short dated reserve .05mg

  	
   

  	
  [ 
  *  ]

  	
   

  	
   

  	
   

  
	
  Potentially short dated reserve .25mg

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
  Potentially short dated reserve1.00mg

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  1mg 4,800 units on order from Lilly

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
  Other

  	
   

  	
  [ 
  *  ]

  	
   

  	
   

  	
   

  
	
  Other Permax reserve

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Total Permax

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Legacy

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist
  24s

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
  Phrenilin 100s

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
  Phrenilin 500s

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
  Forte 500s

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  

 

 

Support
for Schedule 4.9 Excess Inventory

 

	
  Product/Package

  	
   

  	
  12/31/2003

  Lot #

  	
   

  	
  Units

  	
   

  	
  Expiration
  Date

  	
   

  	
  Short Date

  	
   

  	
  Potential

  Excess Inventory

  	
   

  	
  cost

  	
   

  	
  $

  	
   

  	
  Legacy

  	
   

  	
  Permax

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM 100’s

  	
   

  	
  GB263A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Jan-06

  	
   

  	
  31-Jan-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GB264A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-May-08

  	
   

  	
  01-Jun-07

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GB265A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-May-08

  	
   

  	
  01-Jun-07

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM 100’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM 1000’s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GB267B

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-May-08

  	
   

  	
  01-Jun-07

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM 1000’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR 100’s

  	
   

  	
  GSR186A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Jul-06

  	
   

  	
  31-Jul-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GSR189A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Jul-08

  	
   

  	
  01-Aug-07

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GSR190A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Jul-08

  	
   

  	
  01-Aug-07

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GSR191A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Aug-08

  	
   

  	
  01-Sep-07

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR 100’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR 1000’s

  	
   

  	
  GSR187B

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-May-05

  	
   

  	
  31-Mar-04

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GSR188B

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-May-05

  	
   

  	
  31-Mar-04

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GSR188B1

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-May-05

  	
   

  	
  31-Mar-04

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR 1000’s

  	
   

  	
  Total:

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Total:

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen 50’s

  	
   

  	
  MOTWW144H

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Nov-05

  	
   

  	
  29-Nov-04

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  MOTWW147H

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-May-06

  	
   

  	
  30-May-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  MOTWW148H

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Jun-06

  	
   

  	
  29-Jun-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen 50’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen 100’s

  	
   

  	
  MOTWW145A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-May-08

  	
   

  	
  31-May-07

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  MOTWW146A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-May-08

  	
   

  	
  31-May-07

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  MOTWW147A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-May-08

  	
   

  	
  31-May-07

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  MOTWW148A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Jul-08

  	
   

  	
  31-Jul-07

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  MOTWW149A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Jul-08

  	
   

  	
  31-Jul-07

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  MOTWW150A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Jul-08

  	
   

  	
  31-Jul-07

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen 100’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist 100’s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist 100’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist 24’s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  NLHWW129

  	
   

  	
  [  * 
  ]

  	
   

  	
  10-May-05

  	
   

  	
  10-May-04

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist 24’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax 0.05mg 30’s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  5MU85M

  	
   

  	
  [  * 
  ]

  	
   

  	
  01-Nov-04

  	
   

  	
  01-May-03

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax 0.05mg 30’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  *  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax 0.25mg 100’s

  	
   

  	
  6MA70M

  	
   

  	
  [  * 
  ]

  	
   

  	
  01-Apr-05

  	
   

  	
  01-Oct-03

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  6MA72M

  	
   

  	
  [  * 
  ]

  	
   

  	
  01-Apr-05

  	
   

  	
  01-Oct-03

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  6MA73M

  	
   

  	
  [  * 
  ]

  	
   

  	
  01-Apr-05

  	
   

  	
  01-Oct-03

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  6RN14M

  	
   

  	
  [  * 
  ]

  	
   

  	
  01-Nov-05

  	
   

  	
  03-May-04

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax 0.25mg 100’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  Permax 1.0mg 100’s

  	
   

  	
  5MS44M

  	
   

  	
  [  * 
  ]

  	
   

  	
  01-Oct-04

  	
   

  	
  03-Apr-03

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  OLD NDC

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax 1.0mg 100’s

  	
   

  	
  6RK42M

  	
   

  	
  [  * 
  ]

  	
   

  	
  01-Nov-05

  	
   

  	
  03-May-04

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  6RN15M

  	
   

  	
  [  * 
  ]

  	
   

  	
  01-Nov-05

  	
   

  	
  03-May-04

  	
   

  	
  [
   * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  6RN16M

  	
   

  	
  [  * 
  ]

  	
   

  	
  01-Nov-05

  	
   

  	
  03-May-04

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  6RK43M

  	
   

  	
  [  * 
  ]

  	
   

  	
  01-Nov-05

  	
   

  	
  03-May-04

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax 1.0mg 100’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin 100’s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GPN316A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Mar-07

  	
   

  	
  31-Mar-06

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GPN317A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Mar-07

  	
   

  	
  31-Mar-06

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PHRWW101AT

  	
   

  	
  [  * 
  ]

  	
   

  	
  28-Feb-07

  	
   

  	
  28-Feb-06

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PHRWW102AT

  	
   

  	
  [  * 
  ]

  	
   

  	
  28-Feb-07

  	
   

  	
  28-Feb-06

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GPN318A

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Jun-07

  	
   

  	
  30-Jun-06

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin 100’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin 500’s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GPN311F

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Jan-05

  	
   

  	
  01-Feb-04

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GPN313F

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-May-05

  	
   

  	
  31-May-04

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GPN314F

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Jun-05

  	
   

  	
  30-Jun-04

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GPN314F1

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Jun-05

  	
   

  	
  30-Jun-04

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  GPN315F

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Jun-05

  	
   

  	
  30-Jun-04

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PHRWW101FT

  	
   

  	
  [  * 
  ]

  	
   

  	
  28-Feb-07

  	
   

  	
  28-Feb-06

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PHRWW102FT

  	
   

  	
  [  * 
  ]

  	
   

  	
  28-Feb-07

  	
   

  	
  28-Feb-06

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin 500’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin CC 100’s

  	
   

  	
  PCCWW108

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Nov-03

  	
   

  	
  30-Nov-02

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PCCWW109

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Nov-03

  	
   

  	
  30-Nov-02

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PCCWW110A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Dec-03

  	
   

  	
  31-Dec-02

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PCCWW111A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Dec-03

  	
   

  	
  31-Dec-02

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PCCWW111-1

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Dec-03

  	
   

  	
  31-Dec-02

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PCCMK101A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Aug-03

  	
   

  	
  31-Aug-02

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PCCMK102A

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Sep-03

  	
   

  	
  30-Sep-02

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PCCMK103A

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Sep-03

  	
   

  	
  30-Sep-02

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PCCWW101AT

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Oct-03

  	
   

  	
  31-Oct-02

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PCCWW102AT

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Oct-03

  	
   

  	
  31-Oct-02

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PCCWW103AT

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Oct-03

  	
   

  	
  31-Oct-02

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin CC 100’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte 100’s

  	
   

  	
  PF466A

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Nov-06

  	
   

  	
  30-Nov-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF468A

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Nov-06

  	
   

  	
  30-Nov-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF469A

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Nov-06

  	
   

  	
  30-Nov-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF470A

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Nov-06

  	
   

  	
  30-Nov-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF471A

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Nov-06

  	
   

  	
  30-Nov-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF472A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Dec-06

  	
   

  	
  31-Dec-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF473A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Dec-06

  	
   

  	
  31-Dec-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF474A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Dec-06

  	
   

  	
  31-Dec-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF475A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Dec-06

  	
   

  	
  31-Dec-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF477A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Dec-06

  	
   

  	
  31-Dec-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF478A

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Dec-06

  	
   

  	
  31-Dec-05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF479A

  	
   

  	
  [  * 
  ]

  	
   

  	
  28-Feb-07

  	
   

  	
  28-Feb-06

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF480A

  	
   

  	
  [  * 
  ]

  	
   

  	
  28-Feb-07

  	
   

  	
  28-Feb-06

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF481A

  	
   

  	
  [  * 
  ]

  	
   

  	
  28-Feb-07

  	
   

  	
  28-Feb-06

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF482A

  	
   

  	
  [
   * 
  ]

  	
   

  	
  28-Feb-07

  	
   

  	
  28-Feb-06

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF483A

  	
   

  	
  [  * 
  ]

  	
   

  	
  28-Feb-07

  	
   

  	
  28-Feb-06

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF484A

  	
   

  	
  [  * 
  ]

  	
   

  	
  28-Feb-07

  	
   

  	
  28-Feb-06

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte 100’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  Phrenilin Forte 500’s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF444F

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Jul-05

  	
   

  	
  31-Jul-04

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF451F

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Aug-05

  	
   

  	
  31-Aug-04

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF452F

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Aug-05

  	
   

  	
  31-Aug-04

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF453F

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Aug-05

  	
   

  	
  31-Aug-04

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF454F

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Aug-05

  	
   

  	
  31-Aug-04

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF467F

  	
   

  	
  [  * 
  ]

  	
   

  	
  30-Nov-05

  	
   

  	
  30-Nov-04

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  PF485F

  	
   

  	
  [  * 
  ]

  	
   

  	
  31-Aug-07

  	
   

  	
  31-Aug-06

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte 500’s

  	
   

  	
  Total:

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  
	
  Samples at Lark- Permax .25

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Samples at Lark Permax .05

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Permax 1mg on order from Lilly

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  

 

 

SCHEDULE 4.10

 

No Undisclosed Liabilities

 

SEVERANCE PROGRAM—On or about November 13, 2003, API distributed a
severance program to its employees, as a retention tool.  This program applies to all API employees
who did not previously have an agreement in place providing for severance in
the event of certain triggering events. 
(Four employees have severance benefits included in their employment
letters.)  The program generally
provides for two months’ salary and benefits continuation if a triggering event
occurs; four months in the case of Senior Directors, and six months for Vice
Presidents not having a prior contractual agreement.  Copies of the severance memos distributed to affected employees,
along with copies of the employment agreements containing severance provisions,
have been provided to Buyer.

 

BONUSES—(a)  Management by
Objective bonus program.  API
administers an annual bonus program for employees at the Manager level or
higher, consisting of a given percentage of base salary bonus opportunity,
based on the attainment of predetermined API and individual objectives.  Program review and awards are conducted on a
calendar year basis, as measured initially by supervisors, then senior API and
Amarin management and approved by Amarin senior management.  (b)  Sales
Force bonus program.  The API sales
force, including regional managers, have a bonus opportunity described in
advance for each calendar quarter, based on metrics which can vary from quarter
to quarter.  A copy of the bonus program
for Q4’03 has been provided to Buyer.

 

See the attached schedule of open purchase orders and stability
purchase orders.

 

1

 

SCH
4.10 Open Purchase Orders

 

	
  PO #

  	
   

  	
  Supplier

  	
   

  	
  Commitment

  	
   

  	
  Description

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Open Orders - still open at Closing Date

  	
   

  	
   

  	
   

  	
   

  
	
  738

  	
   

  	
  Berg

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Phenindamine
  Tartrate - To be paid over 3 years. Problems with manufacturing process

  
	
  799

  	
   

  	
  SST

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Difenoxin-
  [  * 
  ] gms @ [  * 
  ]/gm. For deliver 01-04. We will probably store it at JM for a while.

  
	
  800

  	
   

  	
  HiTech
  Pharmacal

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Capital
  and Codeine - PO for [  * 
  ] lots totalling [  * 
  ] units. [  * 
  ] received 01-04 already. [  * 
  ] outstanding - delivery Q1 04 ?

  
	
  805

  	
   

  	
  Mallinckrodt

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Bontril
  PDM for 03-04 delivery

  
	
  804

  	
   

  	
  Mallinckrodt

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Bontril
  SR for 3-04 delivery

  
	
  688

  	
   

  	
  Westward

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Nolahist-
  manufacture [  * 
  ] tabs. Awaiting API

  
	
  724

  	
   

  	
  Westward

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Nolahist-
  manufacture [  * 
  ] tabs. Awaiting API

  
	
  688

  	
   

  	
  TestPak

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Nolahist-
  package [  * 
  ] tabs. Awaiting API

  
	
  724

  	
   

  	
  TestPak

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Nolahist-
  package [  * 
  ] tabs. Awaiting API

  
	
  527

  	
   

  	
  Scott
  Levin

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Permax
  Audit data - 2004 is the third year of a three year contract

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Various

  	
   

  	
  Mallinck/Westward/HiTech

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Various
  stability PO’s—For 5 year annual stability testing–required each year and
  prices are those in force at the time.

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Open orders at 12-31-03, but subsequent delivery of goods

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  729

  	
   

  	
  Lilly

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Permax
  .05 - [  * 
  ] units delivered into inventory 01-23-04

  
	
  729

  	
   

  	
  Lilly

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Permax
  .05 - [  * 
  ] units delivered 02-10-04

  
	
  730

  	
   

  	
  Lilly

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Permax
  .25 - [  * 
  ] units delivered 02-10-04

  
	
  692

  	
   

  	
  Lilly

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  Permax
  1.00mg - [  * 
  ] units delivered 2-10-04. Lilly sold the rest of the batch to another
  country for use there.

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  

 

 

Support
for SCH 4.10- Open Stability Purchase Orders

 

Open Stability Purchase Orders

 

	
  Current Stability test costs

  	
   

  	
  Per test

  	
   

  
	
  Mallinckrodt

  	
   

  	
   

  	
   

  
	
  Bontril SR 100s

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Bontril SR 1000s

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Bontril PDM 100s

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Bontril PDM 1000s

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Forte

  	
   

  	
  [  * 
  ]

  	
   

  
	
  PCC

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Westward

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  [  * 
  ]

  	
   

  
	
  Nolahist

  	
   

  	
  [  * 
  ]

  	
   

  
	
  PCC

  	
   

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Hitech

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  [  *  ]

  	
   

  

 

	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Monthly
  Interval - $ Commitment

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Po #

  	
   

  	
  Date

  	
   

  	
  Mfr

  	
   

  	
   

  	
   

  	
  6

  	
   

  	
  12

  	
   

  	
  18

  	
   

  	
  24

  	
   

  	
  36

  	
   

  	
  48

  	
   

  	
  60

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  50

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  Forte

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  Forte

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  52

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  Forte

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  various

  	
   

  	
   

  	
   

  	
  [  *  ]

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Probably
  Closed- status uncertain

  	
   

  	
   

  	
   

  
	
  106

  	
   

  	
  3/16/2001

  	
   

  	
  [  *  ]

  	
   

  	
  Phrenilin

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  125

  	
   

  	
  3/16/2001

  	
   

  	
  [  *  ]

  	
   

  	
  Phrenilin

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN300FT
  packed by testpak

  	
   

  	
  Status:uncertain
  if closed

  	
   

  
	
  130

  	
   

  	
  3/16/2001

  	
   

  	
  [  *  ]

  	
   

  	
  Phrenilin

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN300FT
  packed by testpak

  	
   

  	
  Status:uncertain
  if closed

  	
   

  
	
  136

  	
   

  	
  3/16/2001

  	
   

  	
  [  *  ]

  	
   

  	
  Phrenilin

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN300T
  blisters packed by testpak

  	
   

  	
  Status:uncertain
  if closed

  	
   

  
	
  159

  	
   

  	
  3/16/2001

  	
   

  	
  [  *  ]

  	
   

  	
  Bontril
  SR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GSR123A

  	
   

  	
   

  	
   

  
	
  32

  	
   

  	
  2/2/2001

  	
   

  	
  [  *  ]

  	
   

  	
  BontriPDM
  1000s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB199B

  	
   

  	
   

  	
   

  
	
  33

  	
   

  	
  2/2/2001

  	
   

  	
  [  *  ]

  	
   

  	
  Bontril
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB199A

  	
   

  	
   

  	
   

  
	
  34

  	
   

  	
  2/2/2001

  	
   

  	
  [  *  ]

  	
   

  	
  Bontril
  SR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GSR149A

  	
   

  	
   

  	
   

  
	
  37

  	
   

  	
  2/2/2001

  	
   

  	
  [  *  ]

  	
   

  	
  Bontril
  SR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GSR151

  	
   

  	
   

  	
   

  
	
  091400A

  	
   

  	
  9/14/2000

  	
   

  	
  [  *  ]

  	
   

  	
  Bontril
  SR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GSR135A

  	
   

  	
   

  	
   

  
	
  091400B

  	
   

  	
  9/14/2000

  	
   

  	
  [  *  ]

  	
   

  	
  Bontril
  SR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  GSR139

  	
   

  	
   

  	
   

  
	
  091400C

  	
   

  	
  9/14/2000

  	
   

  	
  [  *  ]

  	
   

  	
  Forte
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF412A

  	
   

  	
   

  	
   

  
	
  091400D

  	
   

  	
  9/14/2000

  	
   

  	
  [  *  ]

  	
   

  	
  Forte
  500s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF412F

  	
   

  	
   

  	
   

  
	
  592

  	
   

  	
  3/8/2002

  	
   

  	
  [  *  ]

  	
   

  	
  Bontril
  SR 1000s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [
   * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GSR172B

  	
   

  	
   

  	
   

  
	
  593

  	
   

  	
  3/8/2002

  	
   

  	
  [  *  ]

  	
   

  	
  Bontril
  PDM 1000s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB212BT

  	
   

  	
   

  	
   

  
	
  594

  	
   

  	
  3/8/2002

  	
   

  	
  [  *  ]

  	
   

  	
  Bontril
  PDM 1000s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  GB211BT

  	
   

  	
   

  	
   

  
	
  604

  	
   

  	
  3/27/2002

  	
   

  	
  [  *  ]

  	
   

  	
  Forte
  Sample Folders

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF433T

  	
   

  	
   

  	
   

  
	
  753

  	
   

  	
  3/20/2003

  	
   

  	
  [  *  ]

  	
   

  	
  Phrenilin
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN272A

  	
   

  	
   

  	
   

  
	
  753

  	
   

  	
  3/20/2003

  	
   

  	
  [  *  ]

  	
   

  	
  Phrenilin

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN272F

  	
   

  	
   

  	
   

  
	
  754

  	
   

  	
  3/20/2003

  	
   

  	
  [  *  ]

  	
   

  	
  Forte
  100s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF472A

  	
   

  	
   

  	
   

  
	
  754

  	
   

  	
  3/20/2003

  	
   

  	
  [  *  ]

  	
   

  	
  Forte
  500s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF472F

  	
   

  	
   

  	
   

  
	
  781

  	
   

  	
  5/28/2003

  	
   

  	
  [  *  ]

  	
   

  	
  Bontril
  PDM 100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB251A-ST

  	
   

  	
   

  	
   

  
	
  782

  	
   

  	
  5/28/2003

  	
   

  	
  [  *  ]

  	
   

  	
  Bontril
  PDM 1000s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB251B

  	
   

  	
   

  	
   

  
	
  783

  	
   

  	
  5/28/2003

  	
   

  	
  [  *  ]

  	
   

  	
  Bontril
  samples

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GSR187S

  	
   

  	
   

  	
   

  
	
  784

  	
   

  	
  5/30/2003

  	
   

  	
  [  *  ]

  	
   

  	
  Forte
  Samples

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF483S

  	
   

  	
   

  	
   

  
	
  792

  	
   

  	
  7/21/2003

  	
   

  	
  [  *  ]

  	
   

  	
  Phrenilin
  100s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN316A

  	
   

  	
   

  	
   

  
	
  793

  	
   

  	
  7/21/2003

  	
   

  	
  [  *  ]

  	
   

  	
  Phrenilin
  500s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN316F

  	
   

  	
   

  	
   

  
	
  806

  	
   

  	
  11/13/2003

  	
   

  	
  [  *  ]

  	
   

  	
  Bontril
  SR 100s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GSR189A

  	
   

  	
   

  	
   

  

 

 

	
  807

  	
   

  	
  11/13/2003

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  PDM 100s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB262A1

  	
   

  	
   

  	
   

  
	
  808

  	
   

  	
  11/13/2003

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  PDM 1000s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB266B1

  	
   

  	
   

  	
   

  
	
  199

  	
   

  	
  4/16/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  PDM 1000s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB185B

  	
   

  	
   

  	
   

  
	
  200

  	
   

  	
  4/16/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  PDM 100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB185A

  	
   

  	
   

  	
   

  
	
  201

  	
   

  	
  4/16/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  PDM 1000s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB
  182B

  	
   

  	
   

  	
   

  
	
  203

  	
   

  	
  4/16/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  PDM 100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB181A

  	
   

  	
   

  	
   

  
	
  213

  	
   

  	
  4/18/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  PDM 100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB210AT

  	
   

  	
   

  	
   

  
	
  214

  	
   

  	
  4/18/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  PDM 1000s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB210BT

  	
   

  	
   

  	
   

  
	
  242

  	
   

  	
  4/26/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  500s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF377

  	
   

  	
   

  	
   

  
	
  243

  	
   

  	
  4/26/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  500s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF388

  	
   

  	
   

  	
   

  
	
  244

  	
   

  	
  4/26/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF388

  	
   

  	
   

  	
   

  
	
  245

  	
   

  	
  4/26/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  Blisters

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF378

  	
   

  	
   

  	
   

  
	
  246

  	
   

  	
  4/26/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF377A

  	
   

  	
   

  	
   

  
	
  250

  	
   

  	
  4/26/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF373A

  	
   

  	
   

  	
   

  
	
  252

  	
   

  	
  4/26/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF359A

  	
   

  	
   

  	
   

  
	
  253

  	
   

  	
  4/26/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  500s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF363F

  	
   

  	
   

  	
   

  
	
  254

  	
   

  	
  4/26/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  500s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF340F

  	
   

  	
   

  	
   

  
	
  255

  	
   

  	
  4/26/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF397A

  	
   

  	
   

  	
   

  
	
  256

  	
   

  	
  4/26/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Foret
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF396A

  	
   

  	
   

  	
   

  
	
  260

  	
   

  	
  4/26/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF356

  	
   

  	
   

  	
   

  
	
  340

  	
   

  	
  7/31/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Phrenilin

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN280F

  	
   

  	
   

  	
   

  
	
  341

  	
   

  	
  7/31/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Phrenilin
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  GPN280A

  	
   

  	
   

  	
   

  
	
  398

  	
   

  	
  9/18/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Phrenilin
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN299A

  	
   

  	
   

  	
   

  
	
  399

  	
   

  	
  9/18/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Phrenilin
  500s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN299F

  	
   

  	
   

  	
   

  
	
  400

  	
   

  	
  9/18/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Phrenilin
  samples

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN281

  	
   

  	
   

  	
   

  
	
  402

  	
   

  	
  9/18/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Phrenilin
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN301A

  	
   

  	
   

  	
   

  
	
  403

  	
   

  	
  9/18/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Phrenilin
  500s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN301F-ST

  	
   

  	
   

  	
   

  
	
  404

  	
   

  	
  9/18/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF418A

  	
   

  	
   

  	
   

  
	
  405

  	
   

  	
  9/18/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  500s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF418F-ST

  	
   

  	
   

  	
   

  
	
  494

  	
   

  	
  12/5/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  SR 100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GSR169A

  	
   

  	
   

  	
   

  
	
  495

  	
   

  	
  12/5/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  SR Blisters

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [
   * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GSR169T

  	
   

  	
   

  	
   

  
	
  500

  	
   

  	
  12/7/2001

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  SR 1000s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GSR168B

  	
   

  	
   

  	
   

  
	
  544

  	
   

  	
  1/24/2002

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  PDM

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  GB250T

  	
   

  	
   

  	
   

  
	
  557

  	
   

  	
  2/20/2002

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Phrenilin
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN304A

  	
   

  	
   

  	
   

  
	
  558

  	
   

  	
  2/20/2002

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Phrenilin
  500s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GPN304F

  	
   

  	
   

  	
   

  
	
  559

  	
   

  	
  2/21/2002

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  100s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF421A

  	
   

  	
   

  	
   

  
	
  565

  	
   

  	
  2/26/2002

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Forte
  500s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PF424F

  	
   

  	
   

  	
   

  
	
  588

  	
   

  	
  3/8/2002

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  PDM

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB211AT

  	
   

  	
   

  	
   

  
	
  589

  	
   

  	
  3/8/2002

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  PDM

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GB212AT

  	
   

  	
   

  	
   

  
	
  590

  	
   

  	
  3/8/2002

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  SR 1000s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GSR170B

  	
   

  	
   

  	
   

  
	
  591

  	
   

  	
  3/8/2002

  	
   

  	
  Mallinckrodt
  (MK)

  	
   

  	
  Bontril
  SR 1000s

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GSR171B

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  Westward

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  100400

  	
   

  	
  10/4/2000

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW128A

  	
   

  	
   

  	
   

  
	
  9

  	
   

  	
  11/2/2000

  	
   

  	
  Westward

  	
   

  	
  Nolahist

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  NLHWW123P

  	
   

  	
   

  	
   

  
	
  44

  	
   

  	
  2/20/2001

  	
   

  	
  Westward

  	
   

  	
  Nolahist

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  NLHWW125P

  	
   

  	
   

  	
   

  
	
  45

  	
   

  	
  2/20/2001

  	
   

  	
  Westward

  	
   

  	
  Nolahist

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  NLHWW124P

  	
   

  	
   

  	
   

  
	
  60

  	
   

  	
  3/8/2001

  	
   

  	
  Westward

  	
   

  	
  PCC

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PCCWW100

  	
   

  	
   

  	
   

  
	
  209

  	
   

  	
  4/16/2001

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW129

  	
   

  	
   

  	
   

  
	
  238

  	
   

  	
  4/26/2001

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW133A

  	
   

  	
   

  	
   

  
	
  239

  	
   

  	
  4/26/2001

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW133H

  	
   

  	
   

  	
   

  
	
  280

  	
   

  	
  5/16/2001

  	
   

  	
  Westward

  	
   

  	
  PCC

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PCCWW100
  testpak

  	
   

  	
   

  	
   

  
	
  346

  	
   

  	
  8/2/2001

  	
   

  	
  Westward

  	
   

  	
  PCC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PCCWW101AT

  	
   

  	
   

  	
   

  
	
  347

  	
   

  	
  8/2/2001

  	
   

  	
  Westward

  	
   

  	
  PCC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PCCWW102AT

  	
   

  	
   

  	
   

  
	
  348

  	
   

  	
  8/2/2001

  	
   

  	
  Westward

  	
   

  	
  PCC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PCCWW103AT

  	
   

  	
   

  	
   

  
	
  349

  	
   

  	
  8/2/2001

  	
   

  	
  Westward

  	
   

  	
  PCC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PCCWW101AT

  	
   

  	
   

  	
   

  
	
  350

  	
   

  	
  8/2/2001

  	
   

  	
  Westward

  	
   

  	
  PCC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PCCWW102AT

  	
   

  	
   

  	
   

  
	
  351

  	
   

  	
  8/2/2001

  	
   

  	
  Westward

  	
   

  	
  PCC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PCCWW103AT

  	
   

  	
   

  	
   

  
	
  372

  	
   

  	
  9/5/2001

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW115A

  	
   

  	
   

  	
   

  

 

 

	
  373

  	
   

  	
  9/5/2001

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW115H

  	
   

  	
   

  	
   

  
	
  374

  	
   

  	
  9/5/2001

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW116A

  	
   

  	
   

  	
   

  
	
  375

  	
   

  	
  9/5/2001

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW117A

  	
   

  	
   

  	
   

  
	
  376

  	
   

  	
  9/5/2001

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW117H

  	
   

  	
   

  	
   

  
	
  576

  	
   

  	
  3/8/2002

  	
   

  	
  Westward

  	
   

  	
  Phrenilin
  100s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PHRWW100

  	
   

  	
   

  	
   

  
	
  576

  	
   

  	
  3/8/2002

  	
   

  	
  Westward

  	
   

  	
  Phrenilin
  100s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PHRWW100AT

  	
   

  	
   

  	
   

  
	
  576

  	
   

  	
  3/8/2002

  	
   

  	
  Westward

  	
   

  	
  Phrenilin
  500s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PHRWW100FT

  	
   

  	
   

  	
   

  
	
  577

  	
   

  	
  3/8/2002

  	
   

  	
  Westward

  	
   

  	
  Phrenilin
  100s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PHRWW101

  	
   

  	
   

  	
   

  
	
  577

  	
   

  	
  3/8/2002

  	
   

  	
  Westward

  	
   

  	
  Phrenilin
  100s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PHRWW101T

  	
   

  	
   

  	
   

  
	
  577

  	
   

  	
  3/8/2002

  	
   

  	
  Westward

  	
   

  	
  Phrenilin
  500s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PHRWW101FT

  	
   

  	
   

  	
   

  
	
  578

  	
   

  	
  3/8/2002

  	
   

  	
  Westward

  	
   

  	
  Phrenilin
  100s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PHRWW102

  	
   

  	
   

  	
   

  
	
  578

  	
   

  	
  3/8/2002

  	
   

  	
  Westward

  	
   

  	
  Phrenilin
  100s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PHRWW102T

  	
   

  	
   

  	
   

  
	
  578

  	
   

  	
  3/8/2002

  	
   

  	
  Westward

  	
   

  	
  Phrenilin
  500s

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PHRWW102FT

  	
   

  	
   

  	
   

  
	
  612

  	
   

  	
  4/3/2002

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW110A

  	
   

  	
   

  	
   

  
	
  617

  	
   

  	
  4/3/2002

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW125A

  	
   

  	
   

  	
   

  
	
  618

  	
   

  	
  4/3/2002

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW126H

  	
   

  	
   

  	
   

  
	
  623

  	
   

  	
  4/3/2002

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW126H

  	
   

  	
   

  	
   

  
	
  650

  	
   

  	
  6/10/2002

  	
   

  	
  Westward

  	
   

  	
  Phrenilin

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PHRWW100FT

  	
   

  	
   

  	
   

  
	
  651

  	
   

  	
  6/10/2002

  	
   

  	
  Westward

  	
   

  	
  Phrenilin

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PHRWW100AT

  	
   

  	
   

  	
   

  
	
  652

  	
   

  	
  6/10/2002

  	
   

  	
  Westward

  	
   

  	
  Phrenilin

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PHRWW100T

  	
   

  	
   

  	
   

  
	
  786

  	
   

  	
  6/11/2003

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW147H

  	
   

  	
   

  	
   

  
	
  787

  	
   

  	
  6/11/2003

  	
   

  	
  Westward

  	
   

  	
  Motofen

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MOTWW145A

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  700

  	
   

  	
  10/8/2002

  	
   

  	
  HiTech
  Pharmacal

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  and
  [  *  ]

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
																																		

 

 

SCHEDULE 4.11

 

Taxes

 

The possible application of UK Stamp Duty to the Contemplated
Transactions remains under review.

 

1

 

SCHEDULE 4.12

 

No Material Adverse Change

 

1.               Since
January 1, 2003, API has experienced the resignation of a number of field sales
representatives and one of its regional managers.  Some of the representatives, and the regional manager, have since
been replaced, with the net effect that as of January 15, 2004, API had twelve
(12) active sales representatives along with the three regional managers.  While some replacement hiring has occurred
during that period, in light of the entry of generic competition to Permax and
the delay in approval of Zelapar, API chose not to return the sales force to
full strength.  Continued operation at
less than full strength can materially adversely affect the effectiveness of
the sales force in contributing to demand for API products.  Further resignations in the field force, and
particularly any of the regional managers, could have a further negative
impact.  In addition, API has operated
without filling the National Sales Director position for over a year, which has
compromised the ability of the Vice President, Sales and Marketing to focus on
more strategic activities.

 

2.               Following
the entry of generic competition to Permax in early 2003, API discontinued a
substantial amount of its marketing programs and spending in support of the
brand.  API has also continued its
practice of not directly promoting substitutable products other than Permax and
Phrenilin Forte.  Indirect marketing
program spending for the PCP Products was reduced in 2003 in light of reduced
sales.

 

3.               As
part of its requirements for the final approval of Zelapar, FDA has required
that Elan conduct two further safety studies (referred to either separately, or
in a combined study, as the Zelapar R&D Studies).  These studies are identified in the approvable letter for Zelapar
and referenced in Amarin’s press release attached to its Form 6-K filed on or
about December 4, 2003.  The studies
relate to (i) the potential for QTc interval prolongation, and (ii) a tyramine
challenge study based on the potential for nonselective inhibition of monoamine
oxidase A.  Elan and Amarin have
currently agreed in principle on a protocol which they believe would address
the issues raised by FDA.  As a part of
its most recent extension of payment terms due from Amarin, Elan has agreed to
allow Amarin to continue the development of Zelapar.  The protocol, timing and estimated costs of the Zelapar R&D
Studies have been provided to Buyer. 
There can be no assurance that the Zelapar R&D Studies will be completed
successfully or on time, or that FDA, upon reviewing the data generated by the
Zelapar R&D Studies, will not request additional information leading to
additional risk, time or cost for the approval of Zelapar.  Furthermore, it is possible that one or more
competitive products to Zelapar, including rasagiline, another MAO-B inhibitor,
could be approved before or after any final approval of Zelapar, which could
materially adversely affect its competitiveness in the marketplace.

 

4.               Amarin
and Elan have entered into a number of agreements which have extended the time
and amount of payments required to be made by Amarin to Elan, in addition to
various waivers or releases of other claims or potential claims.  Prior to entering into such waivers and
releases, Amarin and Elan each maintained a factual or legal basis for such
claims.  Amarin is presently negotiating
with Elan for a further reduction in the amount that would be paid to Elan in a
combined payment, settlement and partial restructure of all debt obligations
owed by Amarin.  Any further agreement
will likely require an updated and confirmed release of all claims between the
parties, subject to any agreed exceptions.

 

1

 

5.               PERMAX—(a)  In 2003 two changes were made to the
approved product labeling for Permax by Eli Lilly, as requested by FDA,
pertaining to valvular heart disease (VHD), and the potential for somnolence or
sudden onset of sleep.  As is typical in
such situations, Eli Lilly sent Dear Health Care Practitioner letters to an
appropriate segment of health care providers following each label change.  Pending or outstanding claims regarding the
VHD issue are described elsewhere in these schedules.  Amarin has no Knowledge of any claims pending or threatened as a
result of somnolence or sudden onset of sleep alleged to have occurred as a
result of taking Permax.  (b)  In 2003, Permax experienced competition from
two generic pergolide products, launched by Teva and Ivax, which had the effect
of substantially reducing revenues for branded Permax, as summarized in
Amarin’s quarterly financial reports filed on Form 6-K, commencing with the
first quarter of 2003.  Amarin has no
Knowledge of any further ANDA being filed or approved for a pergolide product
using Permax as the reference listed drug. 
Amarin cannot predict the impact on Permax of ongoing competition from
these or other generic competitors. 
(c)  In March, 2003, Lilly gave
Amarin notice, under the Lilly/Amarin license agreement for Permax, of Lilly’s
discontinuation of Permax manufacture and termination of Lilly’s supply obligations
under that agreement, effective three years from the date of that notice.  Amarin has entered into discussions with
Lilly about its intended outsource of supply of Permax for Lilly’s other
territories, and has also begun independent exploration of a possible source or
sources for commercial supply of Permax. 
Based on present and projected demand for Permax, potential sources for
supply of the product, the estimated time necessary to qualify and approve a
new vendor, and other relevant factors, Amarin does not believe that it will
face an interruption in its supply of Permax. 
However, there can be no assurance that Amarin will be able to identify
and qualify a new vendor prior to the termination of Lilly’s obligations
without interruption, or will be able to do so at a cost which is acceptable to
Amarin.

 

6.               IVAX
SETTLEMENT: In May, 2003, Amarin entered into a settlement of patent litigation
with Ivax Corporation concerning two U.S. patents licensed to Amarin by Lilly
upon Amarin’s acquisition from Elan of the exclusive U.S. license rights to
Permax® (pergolide mesylate) tablets. 
In return for a sublicense under those patents, Amarin will receive
royalty payments from Ivax’s sale of any pergolide products.  Under the terms of the settlement, Amarin
and Lilly granted to Ivax a non-exclusive sublicense in the U.S. under the two
patents at issue, beginning September 2, 2003, and continuing for the remaining
life of the patents.  In return, Ivax
will make royalty payments to Amarin, to be shared between Amarin and Lilly,
from the first six months’ gross profit (net sales less cost of goods sold)
from sales of any Ivax pergolide product sold during that initial six-month
period under its Abbreviated New Drug Application (ANDA) for pergolide
products. The patent litigation was initiated by Elan in 2001 upon the filing
by Ivax of its ANDA, and was assumed by Amarin as a part of its acquisition of
the U.S. license rights from Elan.  Ivax
launched its product in September, 2003, and its first royalty report is due to
Amarin 60 days following the first three months of commercial sales.

 

7.               As
described elsewhere in these Schedules, Amarin has virtually eliminated any
incentives to non-contract purchasers of Amarin Products other than its
standard [  *  ]%-net [ 
*  ] prompt payment
discount.  Given purchases in the
secondary market from some or all of Amarin’s customers, overlapping trade
relationships and the lack of reliable data generally regarding the amount of
trade product in the hands of customers, it is impossible to assure the levels
of inventory in the trade channel for any Amarin product or its remaining
dating, both generally and as to specific customers.  Amarin has obtained selected information from certain customers
and has made every effort to provide that information to Buyer, but cannot
provide assurance that such information was or will remain accurate.  Amarin cannot of course predict either the
demand for its products by ultimate consumers, or the amount of first line
sales by Amarin to its customers.

 

 

8.               In approximately November,
2002, Alpharma conducted a recall of a number of products it manufactured.  That recall pertained to a number of third
party products and included one lot of Capital & Codeine suspension.  Thereafter, Alpharma no longer manufactured
Capital & Codeine.  After a delay of
several months required for transition to an alternate supplier, HiTech
Pharmacal, Amarin has reintroduced the product.  Other than a minor amount of some product returns, Amarin
experienced no claims, Actions or Proceedings as a result of that recall, and
there are no claims or threatened claims pending.  In addition, in light of updated manufacturing information filed
with FDA, Amarin has requested and FDA has agreed that Amarin’s ANDA for
Capital & Codeine now stands alone and need no longer cross-reference
Alpharma’s ANDA.

 

9.               In
late 2001, Amarin introduced Phrenilin with Caffeine and Codeine (PCC).  Due to competition from West-ward
Pharmaceuticals with a similar product, and the lack of any competitive
advantage for Amarin’s product, regular sales and marketing of that product
were discontinued.  As a result, Amarin
discontinued its generic wholesale service agreement for PCC with Cardinal
Health.

 

10.         On
about June 4, 2001, FDA conducted a field audit of Amarin’s New Jersey
facility.  No further action was taken
following the report.  That facility has
since been closed, in late 2002.

 

11.         The Products identified
as Discontinued Products on Schedule 3.9 were discontinued on or about the
dates shown.  Other than Nolamine,
Propagest, Exgest and Sinulin, the others shown were discontinued for
commercial or strategic reasons.  On November 6, 2000, FDA issued a warning
regarding all decongestant products containing the active ingredient
phenylpropanolamine (“PPA”), and initiated steps to remove these products from
the marketplace.  The Company withdrew
those four products from the market and accepted returns of those products
through December 31, 2001, of $[  *  ]. During 2002, PPA returns were $[ 
*  ]. A decision was taken in early 2001 to
accept returns in certain circumstances even where customers did not have legal
right of return. Seller accounts for these returns as part of operating
expense.  Elan made a contribution to
the Company of US$5[  *  ] to cover PPA returns during the year ended
December 31, 2000.  This contribution
was offset against the cost of PPA product returns.  PPA product returns received in 2003 were less than $[ 
*  ].

 

 

SCHEDULE 4.13

 

Employee Benefits

 

Employee benefit programs at
API can be summarized as follows:

 

STOCK OPTIONS

 

Every full-time employee
receives a grant of stock options upon joining Amarin Pharmaceuticals.  These options are granted in ordinary shares
of our parent company, Amarin Corporation plc, adjusted for pricing at the fair
market value of the Company’s American Depository Receipts (ADRs).  The options granted are nonqualified stock
options, which means that they are not qualified for special income tax
treatment.  Vested options are currently
exercisable and converted to ADRs by our program administrator, Salomon Smith
Barney.

 

MEDICAL INSURANCE

 

Eligible full-time employees
may enroll in either a single or a family contract on the first day of
employment, with no waiting period.  The
current provider of our medical insurance is Guardian Life Insurance Company,
under a preferred provider organization (PPO) plan.  A list of current providers under the plan can be found at
www.glic.com, though you should verify participations since individual
physician participation can change frequently. 
Participating employees are also covered under our medical insurance
plan’s prescription drug program.

 

Amarin pays on your behalf 95%
of the cost of the medical insurance you select.  Your contribution is 5% of the cost for the coverage you choose:
individual employee, employee with a spouse or a dependant, or full family
coverage.  The amount of your
contribution will be provided to you along with your enrollment forms.  Employee contributions are accomplished
automatically by payroll deduction.  If
you elect not to receive health plan coverage, the Company will pay you $100
each pay period.

 

A summary of coverage, and a
booklet containing the details of the plan and eligibility requirements, may be
obtained from Jean Pineda.

 

1

 

DENTAL INSURANCE

 

Eligible full-time employees
may enroll in either a single or a family contract on the first day of
employment, without a waiting period. 
This coverage is also provided by Guardian.  Providers can also be found at the website shown above.  This coverage is provided to you at no cost.

 

As of May 1, 2002, we have
added orthodontia coverage, for both adults and children.  The benefit covers 50% of your costs in
network, with a $1500 annual and lifetime benefit cap per person.  This benefit is also paid for by Amarin.

 

A summary of coverage, and a
booklet containing the details of the plan and eligibility requirements, may be
obtained from Jean Pineda.

 

VISION CARE

 

As of May
1, 2002, full-time employees are eligible for enrollment in our vision care
plan after completing one month of service, administered by VSP, a national
provider.  The benefit provides for one
examination every 12 months, new lenses (contacts or glasses) every 12 months,
and new frames every 24 months, with a $25 co-pay.  Discounts on elective services such as LASIK may apply.  A list of providers can be found at www.vsp.com.  The company pays the cost of
this benefit.

 

LIFE INSURANCE

 

Eligible full-time employees
are automatically enrolled in this plan on the first day of employment, again
without waiting period, at no cost to the employee.  The life/accidental death coverage is currently provided by Unum
Insurance Company.  The benefit is two
times the employee’s annual salary, up to a maximum of $550,000.  Coverage in excess of $300,000 requires
evidence of insurability, i.e., an application process.

 

LONG TERM DISABILITY

 

As of October 1, 2001, full
time employees are also eligible for long-term disability coverage through
Unum, at no charge and with no waiting period upon employment.

 

SECTION 125 PLAN

 

Amarin offers a pre-tax
contribution option for employees.  This
employee benefit is known as a Section 125 plan.  Eligible full-time employees may enroll in this plan after
completing one month of employment.

 

A Section 125 plan is a benefit
plan that allows you to make contributions toward out-of-pocket medical
expenses, such as deductibles under the medical plan, and dependent care
expenses on a “before tax” rather than an “after tax” basis.  This means your qualified expenses are
deducted from your gross pay before income taxes and Social Security is
calculated.

 

401K      QUALIFIED
RETIREMENT PLAN

 

Amarin Pharmaceuticals provides
full time employees with the opportunity to set aside a portion of pre-tax
earnings in our Merrill Lynch 401(k) Qualified Retirement plan, which is an
excellent means of long-term savings for your retirement and provides income
tax benefits as well.

 

 

Administrative costs of the
plan are paid by Amarin.  You will
receive an enrollment packet as a part of your orientation upon employment.

 

EMPLOYEE ASSISTANCE PROGRAM

 

Our employee assistance program (EAP) helps
eligible employees and their immediate families with a wide range of
problems.  Situations addressed by the
EAP include marriage and family problems, emotional problems, alcoholism and
alcohol abuse, drug abuse and dependency, financial problems, compulsive
gambling and eating disorders.  Your
conversations and all records are strictly confidential.  The administrative cost of this program is
fully paid by Amarin.  You can obtain
information to the EAP by calling (800)EAP-CALL or (800)327-2255.

 

REFERRAL BONUS

 

Amarin will pay a referral bonus to any
employee who refers an applicant to our company who is ultimately hired to a
full-time position.  The bonus is 10% of
the referred employee’s base pay, up to a maximum of $15,000.  The bonus will be paid in two increments,
50% on start date and 50% at six months thereafter.  The referring employee must still be employed with the company at
the time the bonus is to be given.  Positions must be approved for bonus in
advance by the President and Executive Vice President.

 

HOLIDAYS

 

Beginning in calendar 2003, we
will observe the following holidays:

 

	
  New
  Year’s Day

  	
   

  	
  Wednesday,
  January 1st

  
	
  Memorial Day

  	
   

  	
  Monday, May 26th

  
	
  Independence
  Day

  	
   

  	
  Friday, July 4th

  
	
  Labor Day

  	
   

  	
  Monday, September 1st

  
	
  Thanksgiving
  Day

  	
   

  	
  Thursday, November 27th

  
	
  The Day
  after Thanksgiving

  	
   

  	
  Friday, November 28th

  
	
  Christmas
  Eve Day

  	
   

  	
  Wednesday, December 24th

  
	
  Christmas
  Day

  	
   

  	
  Thursday, December 25th

  

 

In
addition to the above holidays, a floating holiday will be designated by
management each year.  In 2004, the
floating holiday will be Friday, January 2.

 

Full-time
employees are eligible for paid holidays immediately upon hire.

 

VACATION

 

Full-time employees are
eligible to earn three weeks of paid vacation time per year.  After five years of service with the
company, you will be entitled to an additional week’s vacation.

 

SICK DAYS

 

Full-time
employees are eligible, immediately upon hire, for six (6) paid sick days each
year, prorated for partial years.  Sick
days are calculated according to the calendar year.  During your

 

 

initial
year of employment, you receive sick days as of your start date for the balance
of the calendar year.  Your supervisor
will inform you of the number of days and the date on which you become
eligible.

 

Unused
sick days are converted, at the end of the calendar year, to vacation days, at
the rate of 2:1, i.e., for every two sick days not taken, you will be entitled
to an additional vacation day in the following year.

 

In addition, Amarin provides a
short-term disability benefit summarized as follows:

 

 

SHORT-TERM DISABILITY
BENEFIT

SUMMARY

 

This is to provide a brief summary of the primary
aspects of Amarin Pharmaceuticals’ short-term disability income benefit.  There may be other aspects of the program
that may apply in a specific situation. 
The STD program provides income during a period of medical leave.  During a period of medical disability, you
will also need to arrange for an approved leave of absence under our
policies.  Contact Don Joseph or Jean
Pineda for more information.

 

•                  Short-term disability income (STD) begins on
the date your medical disability begins, as certified by your doctor (i.e. no
waiting period), after using any sick days you have

 

•                  Your doctor’s certification of medical
disability is required to qualify for STD (you must be unable to perform your
regular job duties)

 

•                  Benefit Amount consists of continued pay at
two-thirds of your then-current salary, less standard deductions, regardless of
salary amount (i.e., no cap or limit on salary rate)

 

•                  Benefit continues for actual length of
disability, up to a maximum of 90 days. 
If disability is ongoing, you will transition to our Long Term
Disability insurance (LTD) (separate LTD requirements may apply)

 

•                  Return to work requires doctor’s
certification

 

IF YOU LIVE IN  CALIFORNIA:  the above is a summary of the California
state disability income program, which you would participate in.  Amarin will make up the difference between
the capped salary amount, if applicable, and your Benefit Amount.

 

IF YOU LIVE IN  DELAWARE,
HAWAII, NEW JERSEY, NEW YORK OR RHODE ISLAND:  you would participate in the state
disability income program administered by your state, which

 

 

may
differ in some respects from the above summary.  Amarin will make up the difference between the capped salary
amount, if applicable, and your Benefit Amount.

 

IF YOU LIVE IN ANY OTHER STATE NOT LISTED
ABOVE:  you would receive the above summarized
benefit directly from Amarin, intended to be the equivalent of the California
program as in effect from time to time, except that Amarin will make up the
difference between the capped salary amount, if applicable, and your Benefit
Amount.

 

10/02

 

API
has also adopted a severance program for the benefit of its employees.  See Schedule 4.10.

 

 

SCHEDULE 4.14

 

Compliance with Legal Requirements; Governmental Authorizations

 

 

A list of applicable registered
trademarks is contained in Schedule 4.22.

 

API has both federal and state
of California tax identification numbers. 
See also Schedule 4.1.

 

See the list of Product
Registrations at Schedule 3.9 for products marketed by API.

 

1

 

SCHEDULE 4.15

 

Legal Proceedings; Orders

 

As described elsewhere in these
Schedules, certain claims have been asserted alleging product liability or
similar claims against Amarin and/or API and other parties based on alleged
valvular heart disease occurring in patients taking Permax.  The following summarizes the status of
claims known to Amarin as of the date of the Agreement and updates disclosures
made to Buyer dated November 11, 2003:

 

(a)                                  [  *  ] and [  *  ]—these
claims have now been settled through mediation in Minnesota, with the
settlement paid by [  *  ]
on behalf of potential defendants including [  *  ]. 
Binding settlement agreements have been executed and delivered, which
release [  *  ] from any liability.  To [  *  ]
Knowledge, no right of appeal or challenge has been asserted with respect to
the settled claims.  [ 
*  ] product liability
insurance carrier was timely notified of the claims and of the settlement.  An agreement in principle has been reached
with [ 
*  ] to release [ 
*  ] from any claims for
costs incurred in these matters.

 

(b)                                 [ 
*  ] v. [ 
*  ] et al.—[ 
*  ]—case pending;
discovery stage.  Plaintiff alleges
physical injury and emotional distress resulting from cardiac valvulopathy
allegedly caused by taking Permax.  [ 
*  ] and [ 
*  ] have entered into a
joint representation agreement with local Texas counsel, [ 
*  ].  Amarin’s product liability insurance carrier
was timely notified of the case filing. 
An agreement in principle has been reached with [  *  ] to release [  *  ]
from any claims for costs incurred to date in this matter.

 

(c)                                  [ 
*  ] has received a letter
dated October 16, 2003, from an attorney representing [  *  ], as “next friend” of [  *  ], who died allegedly as a result of taking Permax.  No further correspondence or communication
has been received in this matter.  [ 
*  ] product liability
insurance carrier was timely notified of the receipt of the letter, and [ 
*  ] local counsel in the [ 
*  ] matter described
above has undertaken preliminary inquiries with potential plaintiff’s counsel
in the matter.

 

(d)                                 Amarin
has received notice through [  *  ] of a potential claim by [  *  ]
and by an unnamed woman from Georgia, each of whom is represented by the
same attorney who brought the [  *  ] and [ 
*  ] claims described above.  Some information has been exchanged with
[  * 
], but to our Knowledge no formal claim or proceeding has been
initiated.  [  *  ] product liability
insurance carrier was timely notified of the receipt of this information.

 

(e)                                  As noted in
disclosure material dated November 11, 2003, previously provided to Buyer, one
of [  * 
] sales representatives was terminated from employment on August 15,
2003, for failure to perform the essential functions of her job after having
returned from an approved Family/Medical leave in April, 2003.  Following her return in April, there had
been instances of significant friction between the employee and her manager, at
which time the employee’s reporting role was immediately transferred to direct
report to the VP-Sales and Marketing. 
The employee alleged, among other things, discrimination based on her
medical condition.  An internal
investigation was conducted in which it was concluded that the employee’s allegations
were without merit.  Following her
termination, the employee sought and obtained a “right to sue” letter from the
Equal Employment Opportunity Commission. 
No further contact, and no threat of a claim or litigation, has

 

1

 

been
received by Amarin from the employee or any attorney or other representative
claiming to act on her behalf.  If such
a claim or proceeding were to be initiated, Amarin would defend itself
vigorously, although there can be no assurances of the outcome of any such
claim or litigation.

 

(f)                                    Florida
AG notice—In late December, 2003, Amarin received a notice from the Florida
Attorney General regarding an investigation being conducted by the State of
Florida into Best Price/Average Manufacturer’s Price for pharmaceuticals being
purchased by the state.  The notice
simply requests that the manufacturer receiving the notice retain all records
pertaining to Best Price/AMP calculations. 
The notice does not identify Amarin or any Amarin product by name.  Amarin intends to comply with the request to
maintain records.

 

 

SCHEDULE 4.16

 

Absence of Certain Changes and Events 

 

(i) Amarin has
previously sourced phenindamine, the active ingredient in Nolahist, from a
third party manufacturer, Ganes Chemical. 
Amarin is in the process of changing sources for that material to
Berg.  The scale-up process for that
change has not yet been completed.  At
current sales levels, the cost of that change could be prohibitive.

 

(ii) API has
distributed its products through UPS Supply Chain Services, fka Livingston
Healthcare Services Inc.  The UPS
agreement expired on August 31, 2003 and has been under discussion for
renewal.  API has not yet entered into
that renewal, based on business considerations in light of the Contemplated
Transactions and certain terms that could be considered unfavorable.  At present, API is not aware of any material
disruption to its business from the continued “handshake” operation of its
distribution and the lack of renewal.  There
can be no assurance that UPS will continue to distribute without a signed
agreement in place.

 

(iii) As
described elsewhere in these Schedules, Amarin and Lilly have reached an
agreement in principle by which Lilly will consent to the assignment to Buyer
of the Lilly license agreement.  That
agreement in principle includes payment in full to Lilly of outstanding
purchase orders by API for Permax, and certain other costs, in the total amount
of $945, 109.43.

 

1

 

SCHEDULE 4.17

 

API Contracts; No Defaults

 

In addition to those listed in
Schedule 3.5, API is a party to the following Material Contracts:

 

See Schedule
4.18 for insurance policies in place at API

 

See attached
Excel spreadsheet with summary of active and inactive managed care and
government purchase contracts

 

Adoption
Agreement for 401(k) Plan

 

Guardian Life
Insurance Company (health and dental insurance)

 

Unum Life
Insurance (Life/AD&D insurance, and long term disability insurance)

 

VSP, Inc.  (vision plan)

 

Wheels,
Inc.  (sales force fleet lease
agreement)

 

Gelco (sales
force expense administration)

 

Pharmagistics,
LLC (sample fulfillment and compliance)

 

Paychex
(payroll and 401(k), employee assistance plan and Sec.125 plan administration)

 

ProClaim
(third party administrator of product liability insurance)

 

Inspired
Design/Baker Hill (sales force automation software)

 

NDC Health
(market research data)

 

Verispan
(market research data)

 

Elan/MediCal
(facilitating agreement for Permax sold under Elan’s NDC)

 

Certain of the API contracts
contain provisions addressing the effect of a change of control of API.  Following is a chart summarizing that
impact.  Copies of all pertinent contracts
have been provided to Buyer.

 

1

 

1/14/04

 

	
  API CONTRACTS—CHANGE OF CONTROL CLAUSE 

  	
   

  	
  Y/N

  	
   

  	
  Comment

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  A.

  	
   

  	
  SUPPLY AGREEMENTS

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  1.

  	
   

  	
  Mallinckrodt

  	
   

  	
  No

  	
   

  	
   

  
	
  2.

  	
   

  	
  West-Ward

  	
   

  	
  No

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  B.

  	
   

  	
  DISTRIBUTION
  AGREEMENTS

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  3.

  	
   

  	
  Livingston
  Healthcare Services Inc.

  	
   

  	
  No

  	
   

  	
  Predecessor
  to UPS; renewal contract on hold

  
	
  4.

  	
   

  	
  Pharmagistics
  Sampling Services

  	
   

  	
  No

  	
   

  	
  Assignable
  w/o consent on sale of business-see sec. 9

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  C.

  	
   

  	
  REBATE AND CHARGEBACK AGREEMENTS

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  5.

  	
   

  	
  Cardinal
  Health (Generic Whlsl Service Agmt)

  	
   

  	
  No

  	
   

  	
   

  
	
  6.

  	
   

  	
  Caremark,
  Inc.

  	
   

  	
  Yes

  	
   

  	
  Mfr
  to give notice; Caremark can terminate. 
  Sec. 9(e)

  
	
  7.

  	
   

  	
  Allscripts,
  Inc.

  	
   

  	
  No

  	
   

  	
  Expired
  12/31/03; renewal underway

  
	
  8.

  	
   

  	
  Merck-Medco
  Managed Care, LLC

  	
   

  	
  No

  	
   

  	
   

  
	
  9.

  	
   

  	
  Kaiser
  Permanente

  	
   

  	
  No

  	
   

  	
   

  
	
  10.

  	
   

  	
  Carolina
  Allied Pharm.

  	
   

  	
  No

  	
   

  	
   

  
	
  11.

  	
   

  	
  PDM
  Healthcare

  	
   

  	
  No

  	
   

  	
  Renewed
  through 12/31/04

  
	
  12.

  	
   

  	
  PPSE
  Pharmacy Select

  	
   

  	
  No

  	
   

  	
  Renewal
  effective 1/1/04

  
	
  13.

  	
   

  	
  Pharmacy
  Bus. Assoc. (Truecare)

  	
   

  	
  No

  	
   

  	
  Expired
  12/31/03—renewal underway

  
	
  14.

  	
   

  	
  ServAll

  	
   

  	
  No

  	
   

  	
  Renewed
  via Pharmacy Select—jointly administered

  
	
  15.

  	
   

  	
  PACE
  Alliance

  	
   

  	
  No

  	
   

  	
  Renewed
  via Pharmacy Select—jointly administered

  
	
  16.

  	
   

  	
  Aetna
  Health Management Inc.

  	
   

  	
  No

  	
   

  	
   

  
	
  17.

  	
   

  	
  Prime
  Therapeutics, Inc.

  	
   

  	
  No

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  D.

  	
   

  	
  GOVERNMENT PURCHASE AGREEMENTS

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  18.

  	
   

  	
  Department
  of Veterans Affairs

  	
   

  	
  ?

  	
   

  	
  Amendments
  effective as of 1-1-04

  
	
  19.

  	
   

  	
  CMS
  (Medicaid) Master Rebate Agreement

  	
   

  	
  Yes

  	
   

  	
  Automatically
  assigned to new owner—Sec. IX(b)

  
	
  20.

  	
   

  	
  Public
  Health Service

  	
   

  	
  Yes

  	
   

  	
  Automatically
  assigned to new owner—Sec. VII(d)

  
	
  21.

  	
   

  	
  Minnesota
  Senior Rx

  	
   

  	
  No

  	
   

  	
  Amendment
  effective 1/5/04

  
	
  22.

  	
   

  	
  Missouri
  Senior Rx

  	
   

  	
  Yes

  	
   

  	
  Automatically
  assigned to new owner—Sec. VII(b)

  
	
  23.

  	
   

  	
  New
  Jersey PAAD

  	
   

  	
  Yes

  	
   

  	
  Automatically
  assigned to new owner—Sec. VII(b)

  
	
  24.

  	
   

  	
  New
  Jersey Senior Gold

  	
   

  	
  Yes

  	
   

  	
  Automatically
  assigned to new owner—Sec. VII(b)

  
	
  25.

  	
   

  	
  New
  York EPIC

  	
   

  	
  Yes

  	
   

  	
  Automatically
  assigned to new owner—Sec. IX(b)

  

 

 

	
  26.

  	
   

  	
  Pennsylvania
  PACE—updated/renewed

  	
   

  	
  Yes

  	
   

  	
  Automatically
  assigned to new owner—Sec. 32

  
	
  27.

  	
   

  	
  Vermont
  PATH

  	
   

  	
  No

  	
   

  	
   

  
	
  28.

  	
   

  	
  Wisconsin
  Senior Care

  	
   

  	
  No

  	
   

  	
   

  
	
  29.

  	
   

  	
  Delaware
  DHSS

  	
   

  	
  No

  	
   

  	
   

  
	
  30.

  	
   

  	
  Louisiana
  Dept of Health

  	
   

  	
  No

  	
   

  	
   

  
	
  31.

  	
   

  	
  California—MediCal

  	
   

  	
  No

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  E.

  	
   

  	
  OTHER
  MATERIAL AGREEMENTS AT API

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  32.

  	
   

  	
  Office
  Lease—New Jersey

  	
   

  	
  Yes

  	
   

  	
  Treated
  as assignment; consent not unreas. withheld

  
	
  33.

  	
   

  	
  Wheels,
  Inc.

  	
   

  	
  No

  	
   

  	
  Leased
  cars for sales force

  
	
  34.

  	
   

  	
  Gelco

  	
   

  	
  No

  	
   

  	
  Expense
  management system for sales force

  
	
  35.

  	
   

  	
  Inspired
  Design/Baker Hill

  	
   

  	
  Yes

  	
   

  	
  Software
  for sales force; Sec 23-consent on sale of business

  
	
  36.

  	
   

  	
  Elan—MediCal
  Agreement

  	
   

  	
  No

  	
   

  	
  For
  continuity with MediCal sales under Elan’s NDC no.

  
	
  37.

  	
   

  	
  Pharmagistics, LLC

  	
   

  	
  Yes

  	
   

  	
  Transfer on sale of business OK

  
	
  38.

  	
   

  	
  Paychex

  	
   

  	
  No

  	
   

  	
  Payroll/401(k) administration

  
	
  39.

  	
   

  	
  ProClaim

  	
   

  	
  No

  	
   

  	
  Third party administrator for product liability insurance

  
	
  40.

  	
   

  	
  NDC Health

  	
   

  	
  No

  	
   

  	
  Market research data

  
	
  41.

  	
   

  	
  Verispan

  	
   

  	
  No

  	
   

  	
  Market research data

  
	
  42.

  	
   

  	
  Lexington

  	
   

  	
  No

  	
   

  	
  Product liability insurance

  

 

 

(Terminated or Inactive)

AMARIN PHARMACEUTICALS CONTRACTS

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Mediserv

  Columbus, OH

  	
   

  	
  Product
  Price

  Less WAC

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Chargeback #CH000200

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/2001

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2002

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
  [  * 
  ]%off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  No response to extension letter assumed terminated

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Albertsons

  Scttsdale AZ

  	
   

  	
   

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  terminated
  10-31-03

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Allscrips

  Libertyville, IL

  (Accepted)

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  #CH001100

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/2001

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2003

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  ternminated
  wef 12-31-03

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Carolina
  Allied Pharm.

  Durham, NC

  (Accepted)

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Chargeback #CH000100

  	
   

  	
  #REF!

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/2001

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2003

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [
   * 
  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  * 
  ]% off WAC

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Contract not extended therefor terminated 1-1-04

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Scott & White

  Temple, TX

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Chargeback #CH000800

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/2001

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2002

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin HCL/Atropine
  Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  No
  response to extension letter assumed terminated

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Scott & White

  Temple, TX

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Rebate # RB000300

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/2001

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2002

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  No
  response to extension letter assumed terminated

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Harvard Pilgrim

  Boston, MA

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  CH001800

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/2001

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2002

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin HCL/Atropine
  Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  No
  response to extension letter assumed terminated

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Harvard Pilgrim

  Boston, MA

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Rebate

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/1/1997

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  No
  response to extension letter assumed terminated

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Health Alliance

  Plan of Michigan

  Detroit, MI

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Rebate

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  9/1/1993

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  No
  response to extension letter assumed terminated

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Health Services Corp.

  of America

  Bridgeton, MO

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  CH002100

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/2001

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2002

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  No
  response to extension letter assumed terminated

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Cigna

  (Connecticut general)

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  term 6-30-03

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergren

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  6/30/2003

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Dropped
  off formulary contract termed 6-30-03

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Humana

  Louisville, KY

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  CH002200

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/2000

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2002

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  No
  response to extension letter assumed terminated

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Humana

  Louisville, KY

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Rebate

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/1/1997

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin HCL/Atropine
  Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  No
  response to extension letter assumed terminated

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Integrated Pharmaceutical

  Services

  Rancho Cordova, Ca

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Rebate

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  7/1/1997

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Inactive

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  NPA

  East Hanover, NJ

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Rebate

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  4/1/1999

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Inactive
  Co does not exist

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Pharmaceutical

  Buyers, Inc

  Boulder, Co

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  #CH001600

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  11/1/2000

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2002

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  No
  response to extension letter assumed terminated

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Pharmacy

  Associates, Inc.

  Little Rock, AR

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Rebate

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  7/1/1998

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  *  ]%

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Inactive

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Pro-Vantage

  Brookfield, WI

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Rebate

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/1999

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  (2% Admin
  Fee-Quarterly)

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  59075-0625-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  59075-0630-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% Stand Form/[  *  ]%
  AdVantage

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  *  ]% Stand Form/[  *  ]%
  AdVantage

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% Stand Form/[  *  ]%
  AdVantage

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  *  ]% Stand Form/[  *  ]%
  AdVantage

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Inactive

  	
   

  	
   

  	
   

  

 

 

Active Government Contracts

AMARIN PHARMACEUTICALS INC

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Delaware

  Pharm. Assistance

  Program

  Newark, DE

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  7/1/2003

  	
   

  	
  Fixed Price

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  All prices calculated quarterly based on
  medicaid

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  EPIC

  Albany NY

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  4/1/2002

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  All prices calculated quarterly based on
  medicaid

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  LA Medicaid

  Supplemental

  Rebate

  Baton Rouge LA

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  3/6/2003

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
  [  *  ]% minus nat’l medicaid rebate

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
  [  *  ]% minus nat’l medicaid rebate

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
  [  *  ]% minus nat’l medicaid rebate

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  All prices calculated quarterly based on
  medicaid

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Medicaid (CMS) 

  National Drug

  Rebate program

  Baltimore MD

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  2/6/2001

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  All prices calculated quarterly based on
  medicaid

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Medi-Cal

  Supplemental

  Rebate

  Sacramento CA

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  6/26/2003

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  3/31/2006

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
  [  *  ]% supplemental

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
  [  *  ]% supplemental

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
  [  *  ]% supplemental

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  All prices calculated quarterly based on
  medicaid

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Minnesota

  Senior RX

  St Paul MN

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  7/1/2002

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2005

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  All prices calculated quarterly based on
  medicaid

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Missouri

  Senior RX

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/1/2002

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  All prices calculated quarterly based on
  medicaid

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  New Jersey

  PAAD

  trenton NJ

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  6/1/2003

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  All prices calculated quarterly based on
  medicaid

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  New Jersey

  Senior Gold

  Trenton NJ

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  6/1/2003

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  All prices calculated quarterly based on
  medicaid

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  PACE

  Harrisburg PA

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/2003

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  All prices calculated quarterly based on
  medicaid

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  PHS

  Bethesda, MD

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  5/1/2003

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Prices
  calculated qtrly 340B calc

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Vermont PATH

  Waterburg VT

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/2003

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  All
  prices calculated quarterly based on medicaid

  	
   

  	
   

  	
   

  

 

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Wisconsin

  Senior Care

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  9/1/2003

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  All
  prices calculated quarterly based on medicaid

  	
   

  	
   

  	
   

  

 

 

(Current)

AMARIN PHARMACEUTICALS CONTRACTS

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Aetna

  Atlanta GA

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  4/1/2002

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2004

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

1

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Cardinal

  Preferred

  Program

  GWSA

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  9/1/2002

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  evergreen

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
  [  *  ]% off WAC plus contract
  price of [  *  ]

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  plus additional [  *  ]% discount for K Mart & [  *  ]% to Medicine Shoppe, Kerr drugs, Winn Dixie and Cigna

  	
   

  

 

2

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Kaiser Permanante

  Added 1/29/02

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  EC2052

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  7/1/2002

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  9/30/2004

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine
  w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Fixed price contract

  	
   

  	
   

  	
   

  

 

3

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Caremark

  Chicago IL

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  0

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  4/1/2003

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  3/31/2005

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

4

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  PharmaCare (PDM)

  Cleveland, OH

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Chargeback #CH000300

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  11/4/2003

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2004

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  (3% Admin Fee-Quarterly)

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

5

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  PPSC

  Pharmacy Select

  Talahassee FL

  	
   

  	
   

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Chargeback #CH002400

  	
   

  	
   

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/2004

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2004

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  (2% Admin Fee-Quarterly)

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Pharmacy
  select includes PPSC, PACE and Servall

  	
   

  

 

6

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Pharmacy Bus.Assoc.

  Kansas City, MO

  (Truecare)

  (Accepted)

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Chargeback #CH001500

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/2004

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2004

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  (3% Admin
  Fee-Quarterly)

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

7

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  ServAll

  Gahanna, OH

  (Accepted)

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Chargeback #CH001200

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/2004

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2004

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  (2% Admin
  Fee-Quarterly)

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Contract
  now falls under Phamacy Select 

  	
   

  	
   

  	
   

  

 

8

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Medco

  Franklin Lakes NJ

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Rebate

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/1/2000

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2006

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
  up
  to[  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
  up
  to[  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
  up
  to[  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Permax
  discount dependent on market share

  	
   

  	
   

  	
   

  

 

9

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  PACE Alliance

  Lawrence, KS

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  CH001900

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  1/1/2004

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/31/2004

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Contract
  now falls under Phamacy Select 

  	
   

  	
   

  	
   

  

 

10

 

	
   

  	
   

  	
  Form

  	
   

  	
  Size

  	
   

  	
  Generic

  	
   

  	
  Strength

  	
   

  	
  NDC#

  	
   

  	
  Prime

  Therapeutics

  St Paul MN

  	
   

  	
  Product Price

  Less WAC

  	
   

  
	
  Contract Type

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Revised 01-01-03

  	
   

  
	
  Contracted with

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Amarin

  	
   

  	
   

  	
   

  
	
  Begin Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  4/1/2002

  	
   

  	
   

  	
   

  
	
  End Date

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  3/31/2005

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  35mg

  	
   

  	
  65234-048-10

  	
   

  	
  [  *  ]% Admin Fee Plus:

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril PDM

  	
   

  	
  Tablet

  	
   

  	
  1000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-048-90

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bontril SR (slow release)

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Phendimetrazine
  Tartrate

  	
   

  	
  105mg

  	
   

  	
  65234-047-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Capital & Codeine

  	
   

  	
  Susp

  	
   

  	
  473ml

  	
   

  	
  Acetaminophen and
  Codeine Phosphate

  	
   

  	
  120mg/12mg

  	
   

  	
  65234-046-16

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hydrocet

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Hydrocodone
  Bitartrate/Acetaminophen

  	
   

  	
  5mg/500mg

  	
   

  	
  0086-0057-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  50

  	
   

  	
  Difenoxin
  HCL/Atropine Sulfate

  	
   

  	
  1mg/0.025mg

  	
   

  	
  65234-074-05

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Motofen

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-074-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Phenindamine
  Tartrate

  	
   

  	
  25mg

  	
   

  	
  65234-052-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Nolahist

  	
   

  	
  Tablet

  	
   

  	
  24

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-052-24

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  30

  	
   

  	
   

  	
   

  	
  0.05

  	
   

  	
  59075-0615-30

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  0.25

  	
   

  	
  65234-025-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
  Permax

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
   

  	
   

  	
  1

  	
   

  	
  65234-026-10

  	
   

  	
  [  *  ]% off WAC

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-050-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin

  	
   

  	
  Tablet

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-050-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/650mg

  	
   

  	
  65234-056-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Forte

  	
   

  	
  Capsule

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  65234-056-50

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Phrenilin Caffeine w/Codeine

  	
   

  	
  Tablet

  	
   

  	
  100

  	
   

  	
  Butalbital/Acetaminophen

  	
   

  	
  50mg/325mg

  	
   

  	
  65234-061-10

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Caffeine/Codeine

  	
   

  	
  40mg/30mg

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

11

 

SCHEDULE 4.18

 

Insurance

 

Amarin Corporation, plc is an
additional named insured under the products liability insurance policy shown on
the attached schedule.

 

1

SCH
4.18 Insurance Coverage of Amarin Pharmaceuticals Inc.

 

	
  Policy Detail

  	
   

  	
  Coverage

  	
   

  	
  Period

  covered

  	
   

  	
  Company

  	
   

  	
  Annual

  Premium

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Property & General Liability Coverage

  	
   

  	
  Property
  $625K. Electronic Eqpt $300K General Aggregate $2M. Personal Injury $1M
  Damage to rented property $1M

  	
   

  	
  10/1/03-10/1/04

  	
   

  	
  The Chubb
  Group

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Automobile Insurance

  	
   

  	
  Liability
  and Uninsured motorist $1M

  	
   

  	
  5/15/03-5/15-04

  	
   

  	
  Hartford
  Insurance

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Umbrella Liability Insurance

  	
   

  	
  $3M
  Each Ocurrence

  	
   

  	
  10/1/03-10/1/04

  	
   

  	
  The Chubb
  Group

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Workers Compensation

  	
   

  	
  $1M
  Employers Liability all states excl OH WA WY WV ND

  	
   

  	
  10/1/03-10/1/04

  	
   

  	
  The Chubb
  Group

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Earthquake Insurance

  	
   

  	
  $475K
  on Belvedere Place

  	
   

  	
  12/3/02-12/3/03

  	
   

  	
  Essex
  Insurance Company

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Products Liability

  	
   

  	
  $10M
  each occurrence/$10M aggregate Retention $250K.
  Claims Made basis

  	
   

  	
  12/22/03-12/22/04

  	
   

  	
  Lexington
  Insurance Company

  	
   

  	
  $

  	
  [  *  ]

  	
   

  

 

 

SCHEDULE 4.19

 

Environmental Matters

 

API has normal office
solvents/computer supplies at the Mill Valley facility, and did so during its
occupancy of the New Jersey Facility.

 

1

 

SCHEDULE 4.20

 

Employees

 

(a)                                  See
attached and updated employee census as of the date of this Agreement.

 

(b)                                 None

 

(c)                                  2003
terminations by API (not including voluntary resignations):

 

a.               Eric
Short—General Ledger Accountant—January, 2003—performance related; release
obtained

 

b.              Michael
Wess—VP, Scientific and Medical Affairs—July, 2003—performance related; release
obtained

 

c.               Anne
Lagano—Sales Representative—August, 2003—performance related; no release
obtained (see Schedule 4.15, above)

 

1

 

 

PHARMACEUTICALS, INC.

Employee Census as of 1/26/03

 

 

	
   

  	
   

  	
  Employee
  Name

  (last, first, middle initial)

  	
   

  	
  Occupation/Job
  Title

  	
   

  	
  Employee

  Location

  	
   

  	
  Date of
  Hire

  (mm/dd/yyyy)

  	
   

  	
  Sex

  	
   

  	
  Severance

  Benefit(1)

  	
   

  	
  Basic
  Monthly

  Earnings

  	
   

  	
  State/

  Zip Code

  	
   

  	
  Supervisor

  	
   

  	
  Department

  	
   

  	
  Health

  Insurance

  Enrolled?

  	
   

  	
  Coverage(2)

  	
   

  
	
  1

  	
   

  	
  [  *  ]

  	
   

  	
  Neurology Sales Specialist

  	
   

  	
  Field

  	
   

  	
  10/8/2001

  	
   

  	
  F

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA  92692

  	
   

  	
  Katie Hanstad

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  E

  	
   

  
	
  2

  	
   

  	
  [  *  ]

  	
   

  	
  Senior Regional Manager,
  Sales

  	
   

  	
  Field

  	
   

  	
  10/12/2001

  	
   

  	
  M

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  MA  02052

  	
   

  	
  Steve Guillen

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  F

  	
   

  
	
  3

  	
   

  	
  [  *  ]

  	
   

  	
  Neurology Sales Specialist

  	
   

  	
  Field

  	
   

  	
  10/8/2001

  	
   

  	
  M

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  FL  33176

  	
   

  	
  Stephen Ornella

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  E

  	
   

  
	
  4

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  MV

  	
   

  	
  1/2/2002

  	
   

  	
  M

  	
   

  	
  See
  note (3)

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA,
  94920

  	
   

  	
  Rick Stewart

  	
   

  	
  G&A

  	
   

  	
  Y

  	
   

  	
  F

  	
   

  
	
  5

  	
   

  	
  [  *  ]

  	
   

  	
  Vice President, Regulatory

  	
   

  	
  MV

  	
   

  	
  7/9/2002

  	
   

  	
  F

  	
   

  	
  6
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA,
  94920

  	
   

  	
  Michael Coffee

  	
   

  	
  Regulatory

  	
   

  	
  Y

  	
   

  	
  ES

  	
   

  
	
  6

  	
   

  	
  [  *  ]

  	
   

  	
  Neurology Sales Specialist

  	
   

  	
  Field

  	
   

  	
  11/4/2002

  	
   

  	
  M

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [
   * 
  ]

  	
   

  	
  MA,
  02108

  	
   

  	
  Eric Baker

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  E

  	
   

  
	
  7

  	
   

  	
  [  *  ]

  	
   

  	
  Neurology Sales Specialist

  	
   

  	
  Field

  	
   

  	
  8/25/2003

  	
   

  	
  M

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PA  15650

  	
   

  	
  Eric Baker

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  E

  	
   

  
	
  8

  	
   

  	
  [  *  ]

  	
   

  	
  Neurology Sales Specialist

  	
   

  	
  Field

  	
   

  	
  9/2/2003

  	
   

  	
  F

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  MO  63141

  	
   

  	
  Katie Hanstad

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  E

  	
   

  
	
  9

  	
   

  	
  [  *  ]

  	
   

  	
  Senior Director of
  Marketing

  	
   

  	
  MV

  	
   

  	
  2/18/2002

  	
   

  	
  F

  	
   

  	
  4
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA  94015

  	
   

  	
  Steve Guillen

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  ES

  	
   

  
	
  10

  	
   

  	
  [  *  ]

  	
   

  	
  Accounts Payable Assistant

  	
   

  	
  MV

  	
   

  	
  10/23/2002

  	
   

  	
  F

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA
  94945

  	
   

  	
  Christine Hergenrother

  	
   

  	
  Finance

  	
   

  	
  Y

  	
   

  	
  EC

  	
   

  
	
  11

  	
   

  	
  [  *  ]

  	
   

  	
  Director of Trade &
  Customer Dev

  	
   

  	
  MV

  	
   

  	
  2/4/2002

  	
   

  	
  M

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA  94112

  	
   

  	
  Steve Guillen

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  EC

  	
   

  
	
  12

  	
   

  	
  [  *  ]

  	
   

  	
  Vice President, Sales &
  Marketing

  	
   

  	
  MV

  	
   

  	
  7/9/2001

  	
   

  	
  M

  	
   

  	
  See
  note (4)

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA  94920

  	
   

  	
  Mike Coffee

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  F

  	
   

  
	
  13

  	
   

  	
  [  *  ]

  	
   

  	
  Director, Managed Care

  	
   

  	
  MV

  	
   

  	
  3/4/2002

  	
   

  	
  M

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA  94957

  	
   

  	
  Steve Guillen

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  EC

  	
   

  
	
  14

  	
   

  	
  [  *  ]

  	
   

  	
  Regional Manager, Sales

  	
   

  	
  Field

  	
   

  	
  2/3/2003

  	
   

  	
  F

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA
  94115

  	
   

  	
  Steve Guillen

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  E

  	
   

  
	
  15

  	
   

  	
  [  *  ]

  	
   

  	
  Controller

  	
   

  	
  MV

  	
   

  	
  9/30/2002

  	
   

  	
  F

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA
  94952

  	
   

  	
  Michael Winsor

  	
   

  	
  Finance

  	
   

  	
  Y

  	
   

  	
  EC

  	
   

  
	
  16

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  MV

  	
   

  	
  7/2/2001

  	
   

  	
  M

  	
   

  	
  See
  note (3)

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA  94920

  	
   

  	
  Mike Coffee

  	
   

  	
  G&A

  	
   

  	
  Y

  	
   

  	
  F

  	
   

  
	
  17

  	
   

  	
  [  *  ]

  	
   

  	
  Associate Director, Info
  Systems

  	
   

  	
  MV

  	
   

  	
  9/24/2001

  	
   

  	
  M

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA
  94030

  	
   

  	
  Steve Guillen

  	
   

  	
  S&M

  	
   

  	
  N

  	
   

  	
  W

  	
   

  
	
  18

  	
   

  	
  [  *  ]

  	
   

  	
  Marketing Manager

  	
   

  	
  MV

  	
   

  	
  10/21/2002

  	
   

  	
  F

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA
  94556

  	
   

  	
  Gretchen Fieschko

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  E

  	
   

  
	
  19

  	
   

  	
  [  *  ]

  	
   

  	
  Director, Technical Affairs

  	
   

  	
  MV

  	
   

  	
  3/31/2003

  	
   

  	
  F

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA
  94002

  	
   

  	
  Margie Nemcik-Cruz

  	
   

  	
  Regulatory

  	
   

  	
  Y

  	
   

  	
  F

  	
   

  
	
  20

  	
   

  	
  [  *  ]

  	
   

  	
  Director of Training

  	
   

  	
  MV

  	
   

  	
  4/1/2002

  	
   

  	
  F

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA  94010

  	
   

  	
  Steve Guillen

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  F

  	
   

  
	
  21

  	
   

  	
  [  *  ]

  	
   

  	
  Neurology Sales Specialist

  	
   

  	
  Field

  	
   

  	
  10/8/2001

  	
   

  	
  M

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  NY  14094

  	
   

  	
  Eric Baker

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  F

  	
   

  
	
  22

  	
   

  	
  [  *  ]

  	
   

  	
  Neurology Sales Specialist

  	
   

  	
  Field

  	
   

  	
  10/8/2001

  	
   

  	
  M

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  AZ
  85044

  	
   

  	
  Katie Hanstad

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  E

  	
   

  
	
  23

  	
   

  	
  [  *  ]

  	
   

  	
  Neurology Sales Specialist

  	
   

  	
  Field

  	
   

  	
  10/8/2001

  	
   

  	
  M

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  NJ  07643

  	
   

  	
  Eric Baker

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  F

  	
   

  
	
  24

  	
   

  	
  [  *  ]

  	
   

  	
  Senior Executive Assistant

  	
   

  	
  MV

  	
   

  	
  10/1/2001

  	
   

  	
  F

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA,
  94014

  	
   

  	
  Mike Coffee

  	
   

  	
  G&A

  	
   

  	
  N

  	
   

  	
  W

  	
   

  
	
  25

  	
   

  	
  [  *  ]

  	
   

  	
  Assoc. Manager, Mktg.
  Operations

  	
   

  	
  MV

  	
   

  	
  4/29/2002

  	
   

  	
  F

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA  94118

  	
   

  	
  Gretchen Fieschko

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  E

  	
   

  
	
  26

  	
   

  	
  [  *  ]

  	
   

  	
  Neurology Sales Specialist

  	
   

  	
  Field

  	
   

  	
  10/8/2001

  	
   

  	
  F

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  RI
  02840

  	
   

  	
  Eric Baker

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  E

  	
   

  
	
  27

  	
   

  	
  [  *  ]

  	
   

  	
  Neurology Sales Specialist

  	
   

  	
  Field

  	
   

  	
  10/8/2001

  	
   

  	
  M

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  KS  66062

  	
   

  	
  Katie Hanstad

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  F

  	
   

  
	
  28

  	
   

  	
  [  *  ]

  	
   

  	
  Senior Director, Medical
  Affairs

  	
   

  	
  MV

  	
   

  	
  2/11/2002

  	
   

  	
  F

  	
   

  	
  4
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA  94404

  	
   

  	
  Bimmie Strausser

  	
   

  	
  Medical

  	
   

  	
  Y

  	
   

  	
  EC

  	
   

  
	
  29

  	
   

  	
  [  *  ]

  	
   

  	
  Neurology Sales Specialist

  	
   

  	
  Field

  	
   

  	
  10/8/2001

  	
   

  	
  F

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  PA  19382

  	
   

  	
  Eric Baker

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  F

  	
   

  
	
  30

  	
   

  	
  [  *  ]

  	
   

  	
  VP, Clinical and Medical
  Affairs

  	
   

  	
  MV

  	
   

  	
  8/1/2003

  	
   

  	
  M

  	
   

  	
  See
  note (4)

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA  94127

  	
   

  	
  Mike Coffee

  	
   

  	
  Medical

  	
   

  	
  Y

  	
   

  	
  E

  	
   

  
	
  31

  	
   

  	
  [  *  ]

  	
   

  	
  Neurology Sales Specialist

  	
   

  	
  Field

  	
   

  	
  8/25/2003

  	
   

  	
  F

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  GA  30305

  	
   

  	
  Stephen Ornella

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  E

  	
   

  
	
  32

  	
   

  	
  [  *  ]

  	
   

  	
  Neurology Sales Specialist

  	
   

  	
  Field

  	
   

  	
  12/9/2002

  	
   

  	
  F

  	
   

  	
  2
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  LA
  70119

  	
   

  	
  Stephen Ornella

  	
   

  	
  S&M

  	
   

  	
  Y

  	
   

  	
  E

  	
   

  
	
  33

  	
   

  	
  [  *  ]

  	
   

  	
  VP Finance

  	
   

  	
  MV

  	
   

  	
  1/2/2002

  	
   

  	
  M

  	
   

  	
  6
  months

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  CA  94927

  	
   

  	
  Mike Coffee

  	
   

  	
  Finance

  	
   

  	
  Y

  	
   

  	
  E

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

(1)               “Months” means
salary and benefits continuation for that period from date of job elimination,
reduction or relocation.

(2)               E - Employee only

EC - Employee + child

ES -Employee + Spouse

F - Family

W - Waived Coverage

(3)               See contract.  Generally provides for 12 months’ salary and
benefits continuation, plus one additional month for each year or part year of
service (max. 18 mo. total); outplacement; stock option treatment.

(4)               See contract.  Generally provides for 6 months’ salary and
benefits continuation, plus one additional month for each year or part year of
service (max. 12 mo. total); outplacement; stock option treatment.

 

TEMPORARY
EMPLOYEES

 

	
   

  	
   

  	
  Pickrel,
  Michele

  	
   

  	
  Marketing
  Coordinator

  	
   

  	
  MV

  	
   

  	
   

  	
   

  	
  F

  	
   

  	
  none

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Steve
  Guillen

  	
   

  	
  S&M

  	
   

  	
  N/A

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Yankey,
  Jeannie

  	
   

  	
  Regulatory
  Assistant

  	
   

  	
  MV

  	
   

  	
   

  	
   

  	
  F

  	
   

  	
  none

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Margie
  Nemcik-Cruz

  	
   

  	
  Regulatory

  	
   

  	
  N/A

  	
   

  	
   

  	
   

  

 

 

SCHEDULE 4.22

 

Intellectual Property Assets

 

(e) Trademarks:  The following are
the trademarks relevant to the API Products (owned by API unless otherwise
noted):

 

 

Currently
marketed products:

 

Bontril® (trademark renewed January 6, 2004) (owned by Seller; to be conveyed to Buyer or
designee at Closing)

Motofen®

Nolahist®

CapitalTM & Codeine Suspension (trademark
lapsed; renewal application in process; filed on October 17, 2003) (owned by Seller; to be conveyed to Buyer or
designee at Closing)

Phrenilin®

Permax® (owned by Eli Lilly and
licensed to Seller under the Eli Lilly/Amarin Agreement)

 

Discontinued products:

Amen®

Hydrocet®

Salflex®

Trademarks have lapsed for the following
discontinued products; Amarin does not intend to renew these marks: Theo-XTM,
PropagestTM, ExgestTM, SinulinTM and NolamineTM

 

Development
product:

ZelaparTM (owned by Elan, to be
conveyed to Seller or its designee at Closing)

 

Copyrights—none,
except for any common law copyright rights associated with marketing and other
materials used in promotion of the Products

 

Patents—none, except for licensed patents through
Lilly and Scherer agreements

 

(e)(iv)        With
respect to Hydrocet, API has entered into an agreement with Xanodyne not to
contest or sue over the proposed use by Xanodyne of a particular trademark
contemplated for use by Xanodyne which could be considered as infringing on the
Hydrocet mark.

 

1

 

SCHEDULE 5.2

 

Authority; No Conflict

 

 

See the references made in
Schedule 3.2, above.

 

1

 

SCHEDULE 6.9

 

API Liabilities

 

1

 

SCHEDULE 11.3

 

Designated Inventory

 

	
  Wholesaler

  	
   

  	
   

  	
   

  	
  Units

  	
   

  	
  WAC /

  Purchase

  Price

  	
   

  	
  Acquisition
  cost

  	
   

  	
  Service
  fee

  	
   

  	
  Total Cost

  	
   

  
	
  QK

  	
   

  	
  Phrenilin
  100’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  QK

  	
   

  	
  Phrenilin
  500’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  QK

  	
   

  	
  Phrenilin
  Forte 100’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  QK

  	
   

  	
  Phrenilin
  Forte 500’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  QK

  	
   

  	
  Permax
  0.05mg 30’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  QK

  	
   

  	
  Permax
  0.25mg 100’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  QK

  	
   

  	
  Permax
  0.25mg 100’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  QK

  	
   

  	
  Permax 1mg
  100’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  QK

  	
   

  	
  Bontril PDM
  100’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  QK

  	
   

  	
  Bontril PDM
  1000’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  QK

  	
   

  	
  Bontril SR
  100’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  QK

  	
   

  	
  Nolahist
  24’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  McKesson 1-4-04

  	
   

  	
  Permax
  0.05mg 30’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  McKesson 1-4-04

  	
   

  	
  Permax
  0.25mg 100’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  McKesson 1-4-04

  	
   

  	
  Permax 1.0mg
  100’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  Bergen 12/23/03

  	
   

  	
  Permax
  0.05mg 30’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  Bergen 12/23/03

  	
   

  	
  Permax
  0.25mg 100’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  Bergen 12/23/03

  	
   

  	
  Permax 1.0mg
  100’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  Cardinal

  	
   

  	
  Permax
  0.05mg 30’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  Cardinal

  	
   

  	
  Permax
  0.25mg 100’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
  Cardinal

  	
   

  	
  Permax 1.0mg
  100’s

  	
   

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
   

  	
  $

  	
  [  *  ]

  	
   

  	
  [  *  ]

  	
  %

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Total
  Acquisition Cost

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Freight

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Total
  Disposal Cost

  	
   

  	
  $

  	
  [  *  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Total Cost

  	
   

  	
  $

  	
  [  *  ]

  	
   

  

 

Note:  The total quantity purchased will vary as a function of the
available product and negotiated price within individual accounts

 

1Exhibit
4.25

 

AMENDMENT
NO. 1

TO

ASSET PURCHASE AGREEMENT

 

This Amendment No.
1 to the Asset Purchase Agreement (the “Amendment”) is made and entered into this 25th day of
February, 2004, by and between Valeant Pharmaceuticals International, a
Delaware corporation (“Buyer”), and Amarin Corporation plc, a public limited
company incorporated in England and Wales (“Amarin”) and Amarin Pharmaceuticals Company
Limited, a limited company incorporated in England and Wales (“APCL”) (Amarin and
APCL being hereinafter from time to time referred to collectively as the “Sellers”).

 

WITNESSETH:

 

WHEREAS, Buyer and
Sellers have previously entered into that certain Asset Purchase Agreement,
dated February 11, 2004 (the “Asset Purchase Agreement”);

 

WHEREAS, Buyer and
Sellers desire to amend the Asset Purchase Agreement to provide for a
re-distribution of certain portions of the Purchase Price to be paid by Buyer
under the Asset Purchase Agreement;

 

NOW, THEREFORE, in
consideration of the premises, the mutual covenants herein contained, and other
good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows:

 

ARTICLE 1

DEFINITIONS AND USAGE

 

1.1                               DEFINITIONS

 

For purposes of
this Amendment, capitalized terms used but not otherwise defined in this
Amendment will have the meaning ascribed to such terms

 

1.2                               USAGE

 

(a)                                  Interpretation.  In this Amendment, unless a clear
contrary intention appears:

 

(i)                                     the
singular number includes the plural number and vice versa;

 

(ii)                                  reference
to any Person includes such Person’s successors and assigns but, if applicable,
only if such successors and assigns are not prohibited by this Agreement, and
reference to a Person in a particular capacity excludes such Person in any
other capacity or individually;

 

(iii)                               reference
to any gender includes each other gender;

 

(iv)                              reference
to any agreement, document or instrument means such agreement, document or
instrument as amended or modified and in effect from time to time in accordance
with the terms thereof;

 

 

(v)                                 reference
to any Legal Requirement means such Legal Requirement as amended, modified,
codified, replaced or reenacted, in whole or in part, and in effect from time
to time, including rules and regulations promulgated thereunder, and reference
to any section or other provision of any Legal Requirement means that
provision of such Legal Requirement from time to time in effect and
constituting the substantive amendment, modification, codification, replacement
or reenactment of such section or other provision;

 

(vi)                              “hereunder,”
“hereof,” “hereto,”  and words of
similar import shall be deemed references to this Agreement as a whole and not
to any particular Article, Section or other provision hereof;

 

(vii)                           “including”
(and with correlative meaning “include”) means including without limiting the
generality of any description preceding such term;

 

(viii)                        “or”
is used in the inclusive sense of “and/or”;

 

(ix)                                with
respect to the determination of any period of time, “from” means “from and
including” and “to” means “to but excluding”; and

 

(x)                                   references
to documents, instruments or agreements shall be deemed to refer as well to all
addenda, exhibits, schedules or amendments thereto.

 

(b)                                 Accounting
Terms and Determinations.  Unless
otherwise specified herein, all accounting terms used herein shall be
interpreted and all accounting determinations hereunder shall be made in
accordance with UK GAAP.

 

(c)                                  Legal
Representation of the Parties.  This
Amendment was negotiated by the parties with the benefit of legal
representation, and any rule of construction or interpretation otherwise
requiring this Agreement to be construed or interpreted against any party shall
not apply to any construction or interpretation hereof.

 

ARTICLE 2

AMENDMENTS

 

2.1                               AMENDMENT
TO SECTION 2.7 OF ASSET PURCHASE AGREEMENT

 

Section 2.7
of the Asset Purchase Agreement is hereby amended to read in its entirety as
follows:

 

“2.7API  ADJUSTMENT AMOUNT AND PAYMENT

 

“(a)   As promptly as reasonably practicable
following the Closing, Buyer shall prepare, and Buyer and Amarin shall jointly
agree upon, a balance sheet of API (the “API Closing Balance Sheet”) as of the Closing Date on
the same basis and applying the same accounting principles, policies and
practices as were used in preparing the Pro Forma Closing Balance Sheet (as set
out in Schedule 2.7 hereto). Each of the Buyer and Amarin shall give the
other (or procure that the other has) access, through its employees, agents and
advisers (provided that each party shall be

 

2

 

entitled, at its option,
to have its Representatives present), to all relevant files and/or working
papers (with the right to take copies) in their possession or control to the
extent that they are required in connection with the preparation and/or review
of the API Closing Balance Sheet. The Buyer shall submit the draft API Closing
Balance Sheet to Amarin for review within 30 calendar days after Closing. Once
accepted by Amarin or otherwise agreed upon by Amarin and Buyer, the API
Closing Balance Sheet shall be binding upon the parties. To avoid potential
duplication between this Section 2.7 and Section 11.3, the API
Closing Balance Sheet shall reflect the completion of the inventory repurchase
under Section 11.3 whether or not the inventory repurchase has in fact
been completed.  In addition, the API
Closing Balance Sheet shall contain the same fair value adjustments in the same
amount as contained in the Pro-Forma Closing Balance Sheet.”

 

2.2  AMENDMENT TO SECTION 11.3 OF ASSET
PURCHASE AGREEMENT

 

Section 11.3
of the Asset Purchase Agreement is hereby amended to read in its entirety as
follows:

 

“11.3                 REDUCTION OF INVENTORY

 

“(a)  As promptly as reasonably practicable after
the execution and delivery of this Agreement, Amarin shall use Best Efforts to
enter into inventory repurchase agreements (the “Repurchase Agreements”) with
each of Quality King Health Care, Cardinal Distribution, Amerisource Bergen and
McKesson Drug Company (collectively, the “Key Wholesalers”) providing for the
repurchase by Amarin at its own cost of certain inventory held by such
distributors.  The Repurchase Agreements
shall be reasonably acceptable to Buyer. 
Under the Repurchase Agreements, Amarin shall seek to repurchase the
quantities of inventory set forth in Schedule 11.3 hereto (the “Designated
Inventory”) at the prices indicated therein; provided, however,
that in Amarin’s sole discretion it may repurchase any portion of the
Designated Inventory at prices exceeding those set forth in Schedule 11.3,
up to a maximum of 10% above the scheduled prices.  To the extent Amarin effects any repurchases at a price higher
than that set forth in Schedule 11.3, the quantity of Designated Inventory
that Amarin shall seek to repurchase from the relevant Key Wholesaler(s) (as
set forth on Schedule 11.3) will be proportionately reduced. Each of the
Repurchase Agreements, and the obligations thereunder of Amarin and the
respective Key Wholesalers, shall be subject to and conditioned upon the consummation
of the Closing under this Agreement (except to the extent any Repurchase
Agreements are entered into after the Closing as contemplated in
Section 11.3(b) below).  The
Repurchase Agreements shall provide that (i) Amarin’s obligation to pay for repurchased
inventory shall be subject to confirmation of the receipt and authenticity of
the applicable inventory to Amarin’s reasonable satisfaction and (ii) Amarin
shall use its Best Efforts to cause any or all repurchased inventory to be
destroyed. The Repurchase Agreements shall give Amarin the option of using
repurchasing agents or other third parties reasonably acceptable to Buyer to
perform any of Amarin’s obligations under this Section 11.3.  Notwithstanding anything herein to the
contrary, in no event shall Amarin be required to pay more than Nine Million
Seven Hundred Fourteen Thousand

 

3

 

Dollars ($9,714,000) in
performing its obligations under this Section 11.3, which limitation shall
apply to all costs and expenses incurred by Amarin in effecting the repurchase
of Designated Inventory including the costs of repurchase and any
administrative fees, third party costs including fees and expenses of any
repurchasing agent, and costs of destroying repurchased inventory.

 

“(b)  Amarin and Buyer acknowledge and agree that
the Closing hereunder shall not be contingent on Amarin’s ability to enter into
any Repurchase Agreements and the execution of Repurchase Agreements shall not
constitute a condition to the obligation of either party to consummate the
Closing.  In the event that upon Closing
(i) any of the Key Wholesalers has not entered into a Repurchase Agreement
providing for the repurchase of Designated Inventory on the terms contemplated
herein or (ii) Amarin is otherwise unable to obtain Repurchase Agreements for
the repurchase of all or any portion of the Designated Inventory within the
price range specified herein, then the parties shall proceed with the Closing
(subject to the satisfaction of all applicable conditions set forth in this
Agreement), and for a period of 60 days after the Closing Date Amarin shall
continue to use its Best Efforts to enter into Repurchase Agreements in a total
amount not to exceed Nine Million Three Hundred Thousand Dollars ($9,300,000)
with respect to any Designated Inventory not then covered by a Repurchase
Agreement.  Upon the expiration of such
60-day period, Amarin’s obligation to effect the Repurchase Agreements under
this Section 11.3 shall automatically terminate and Amarin shall have no
further obligations whatsoever hereunder (other than its obligations under any
Repurchase Agreements then in effect), provided that thereafter Amarin
shall pay to Buyer the following amounts: 
(i) within twenty (20) days following the expiration of such 60-day
period, Amarin shall pay Buyer an amount equal to the difference between (A)
Nine Million Three Hundred Thousand Dollars ($9,300,000) and (B) the aggregate
amount of costs and expenses incurred by Amarin as of such date in performing
its obligations under this Section 11.3; and (ii) upon Successful
Completion of the Zelapar R&D Studies in accordance with
Section 2.2.(a), and only then, Amarin shall repurchase an additional Four
Hundred Fourteen Thousand Dollars ($414,000) of inventory in accordance with
Section 11.3(a).

 

“(c)  In
addition to the foregoing, within sixty (60) days of Closing, Amarin shall pay
a total of $1.2 million to certain of the Key Wholesalers to reduce or
eliminate the credit balances claimed to be due to such Key Wholesalers, as
shown on Schedule 4.8, provided that if Amarin does not pay the
full $1.2 million to the Key Wholesalers in accordance herewith within such
sixty (60) day period, then Amarin shall immediately pay the unexpended portion
of such $1.2 million to Buyer.”

 

2.3                               AMENDED
SCHEDULES

 

The following revisions are made, effective as of the date of this
Amendment, to the Schedules attached to the Asset Purchase Agreement:

 

Schedule 3.6:  an
additional item 7 is added:  During
2003, following the introduction of generic pergolide into the market, Amarin
discontinued its indigent patient assistance program.

 

4

 

Schedule 3.9:  The column
heading reference to “Amarin” owning NDA/ANDAs (unless otherwise noted) should
be to API.

 

Schedule 4.16:  The final
Lilly settlement amount is revised to $928,646.20.

 

Schedule 4.20:  The
severance benefit reference for Steve Guillen should be to Note 3.

 

Schedule 11.3:  The schedule for Designated Inventory
is amended in its entirety to read as attached to this Amendment.

 

2.4                               NO
OTHER AMENDMENTS

 

Except as amended
by this Amendment, all other provisions of the Asset Purchase Agreement remain
unmodified and in full force and effect.

 

ARTICLE 3

GENERAL PROVISIONS

 

3.1                               SEVERABILITY

 

If any provision
of this Amendment is held invalid or unenforceable by any court of competent
jurisdiction, the other provisions of this Amendment will remain in full force
and effect.  Any provision of this
Amendment held invalid or unenforceable only in part or degree will remain in
full force and effect to the extent not held invalid or unenforceable.

 

3.2                               GOVERNING
LAW

 

This Agreement
will be governed by and construed under the laws of the State of California
without regard to conflicts-of-laws principles that would require the
application of any other law.

 

3.3                               EXECUTION
OF AMENDMENT

 

This Amendment may
be executed in one or more counterparts, each of which will be deemed to be an
original copy of this Amendment and all of which, when taken together, will be
deemed to constitute one and the same agreement.  The exchange of copies of this Amendment and of signature pages
by facsimile transmission shall constitute effective execution and delivery of
this Amendment as to the parties and may be used in lieu of the original
Amendment for all purposes.  Signatures
of the parties transmitted by facsimile shall be deemed to be their original
signatures for all purposes.

 

5

 

IN WITNESS
WHEREOF, the parties have executed this Agreement as of the date first written
above.

 

	
   

  	
  SELLER:

  
	
   

  	
   

  
	
   

  	
  AMARIN
  CORPORATION PLC

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  SELLER:

  
	
   

  	
   

  
	
   

  	
  AMARIN
  PHARMACEUTICALS COMPANY

  LIMITED

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  BUYER:

  
	
   

  	
   

  
	
   

  	
  VALEANT
  PHARMACEUTICALS

  INTERNATIONAL

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  
					

 

6

 

SCHEDULE 11.3

 

Designated
Inventory

 

	
  Wholesaler

  	
   

  	
   

  	
  Units

  	
   

  	
  WAC /

  Purchase

  Price

  	
   

  	
  Acquisition
  cost

  	
   

  	
  Service
  fee

  	
   

  	
  Total Cost

  	
   

  
	
  QK

  	
  Phrenilin 100’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  QK

  	
  Phrenilin 500’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  QK

  	
  Phrenilin Forte 100’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  QK

  	
  Phrenilin Forte 500’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  QK

  	
  Permax 0.05mg 30’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  QK

  	
  Permax 0.25mg 100’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  QK

  	
  Permax 0.25mg 100’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  QK

  	
  Permax 1mg 100’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  QK

  	
  Bontril PDM 100’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  QK

  	
  Bontril PDM 1000’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  QK

  	
  Bontril SR 100’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  QK

  	
  Nolahist 24’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  McKesson
  1-4-04

  	
  Permax 0.05mg 30’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  McKesson
  1-4-04

  	
  Permax 0.25mg 100’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  McKesson
  1-4-04

  	
  Permax 1.0mg 100’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  Bergen
  12/23/03

  	
  Permax 0.05mg 30’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  Bergen
  12/23/03

  	
  Permax 0.25mg 100’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  Bergen
  12/23/03

  	
  Permax 1.0mg 100’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  Cardinal

  	
  Permax 0.05mg 30’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  Cardinal

  	
  Permax 0.25mg 100’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
  Cardinal

  	
  Permax 1.0mg 100’s

  	
   

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  	
  [  * 
  ]

  	
  %

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Total Acquisition Cost

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Freight

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Total Disposal Cost

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Total Cost

  	
   

  	
  $

  	
  [  * 
  ]

  	
   

  

 

Note:  The total quantity purchased will vary as a
function of the available product and negotiated price within individual accounts

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]